gild fasb org gaap otherassetsnoncurrent http fasb org gaap prepaidexpenseandotherassetscurrenthttp fasb org gaap otherliabilitiescurrent http fasb org gaap otherliabilitiesnoncurrenthttp fasb org gaap otherassetsnoncurrent http fasb org gaap prepaidexpenseandotherassetscurrenthttp fasb org gaap otherliabilitiescurrent http fasb org gaap fasb org gaap otherassetsnoncurrenthttp fasb org gaap otherassetsnoncurrenthttp fasb org gaap otherliabilitiescurrenthttp fasb org gaap otherliabilitiescurrenthttp fasb org gaap otherliabilitiesnoncurrenthttp fasb org gaap usdxbrli gaap gaap gaap gaap gaap gaap gaap gaap gaap retainedearningsmembersrt gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap countrygild gaap gaap machineryandequipmentmembersrt gaap machineryandequipmentmembersrt minimummemberus gaap maximummemberus gaap usgild hivproductsbiktarvymembersrt otherinternationalmembergild usgild hivproductsbiktarvymembersrt otherinternationalmembergild usgild hivproductsbiktarvymembersrt otherinternationalmembergild hivproductscompleraevipleramembercountry hivproductscompleraevipleramembersrt otherinternationalmembergild hivproductscompleraevipleramembercountry hivproductscompleraevipleramembersrt otherinternationalmembergild hivproductscompleraevipleramembercountry hivproductscompleraevipleramembersrt otherinternationalmembergild hivproductsdescovymembercountry hivproductsdescovymembersrt otherinternationalmembergild hivproductsdescovymembercountry hivproductsdescovymembersrt otherinternationalmembergild hivproductsdescovymembercountry hivproductsdescovymembersrt otherinternationalmembergild usgild hivproductsgenvoyamembersrt otherinternationalmembergild usgild hivproductsgenvoyamembersrt otherinternationalmembergild usgild hivproductsgenvoyamembersrt otherinternationalmembergild hivproductsodefseymembercountry hivproductsodefseymembersrt hivproductsodefseymembergild hivproductsodefseymembercountry hivproductsodefseymembersrt hivproductsodefseymembergild hivproductsodefseymembercountry hivproductsodefseymembersrt hivproductsodefseymembergild hivproductsstribildmembercountry hivproductsstribildmembersrt otherinternationalmembergild hivproductsstribildmembercountry hivproductsstribildmembersrt otherinternationalmembergild hivproductsstribildmembercountry hivproductsstribildmembersrt otherinternationalmembergild usgild hivproductstruvadamembersrt otherinternationalmembergild usgild hivproductstruvadamembersrt otherinternationalmembergild usgild hivproductstruvadamembersrt otherinternationalmembergild usgild productsrevenuesharesymtuzamembersrt otherinternationalmembergild usgild productsrevenuesharesymtuzamembersrt otherinternationalmembergild usgild productsrevenuesharesymtuzamembersrt otherinternationalmembergild productsotherhivmembercountry productsotherhivmembersrt otherinternationalmembergild productsotherhivmembercountry productsotherhivmembersrt otherinternationalmembergild productsotherhivmembercountry productsotherhivmembersrt otherinternationalmembergild hivproductsalesmembercountry hivproductsalesmembersrt otherinternationalmembergild hivproductsalesmembercountry hivproductsalesmembersrt otherinternationalmembergild hivproductsalesmembercountry hivproductsalesmembersrt otherinternationalmembergild veklurymembercountry veklurymembersrt veklurymembergild veklurymembercountry veklurymembersrt veklurymembergild veklurymembercountry veklurymembersrt veklurymembergild usgild hcvproductsledipasvirsofosbuvirmembersrt otherinternationalmembergild usgild hcvproductsledipasvirsofosbuvirmembersrt otherinternationalmembergild usgild hcvproductsledipasvirsofosbuvirmembersrt otherinternationalmembergild hcvproductssofosbuvirvelpatasvirmembercountry hcvproductssofosbuvirvelpatasvirmembersrt hcvproductssofosbuvirvelpatasvirmembergild hcvproductssofosbuvirvelpatasvirmembercountry hcvproductssofosbuvirvelpatasvirmembersrt hcvproductssofosbuvirvelpatasvirmembergild hcvproductssofosbuvirvelpatasvirmembercountry hcvproductssofosbuvirvelpatasvirmembersrt hcvproductssofosbuvirvelpatasvirmembergild usgild otherhcvmembersrt otherinternationalmembergild usgild otherhcvmembersrt otherinternationalmembergild usgild otherhcvmembersrt otherinternationalmembergild hcvproductsalesmembercountry hcvproductsalesmembersrt otherinternationalmembergild hcvproductsalesmembercountry hcvproductsalesmembersrt otherinternationalmembergild hcvproductsalesmembercountry hcvproductsalesmembersrt otherinternationalmembergild hepatitisbvirushepatitisdeltavirusproductvemlidymembercountry hepatitisbvirushepatitisdeltavirusproductvemlidymembersrt hepatitisbvirushepatitisdeltavirusproductvemlidymembergild hepatitisbvirushepatitisdeltavirusproductvemlidymembercountry hepatitisbvirushepatitisdeltavirusproductvemlidymembersrt hepatitisbvirushepatitisdeltavirusproductvemlidymembergild hepatitisbvirushepatitisdeltavirusproductvemlidymembercountry hepatitisbvirushepatitisdeltavirusproductvemlidymembersrt hepatitisbvirushepatitisdeltavirusproductvemlidymembergild usgild hepatitisbvirushepatitisdeltavirusproductvireadmembersrt otherinternationalmembergild usgild hepatitisbvirushepatitisdeltavirusproductvireadmembersrt otherinternationalmembergild usgild hepatitisbvirushepatitisdeltavirusproductvireadmembersrt otherinternationalmembergild hepatitisbvirushepatitisdeltavirusproductothermembercountry hepatitisbvirushepatitisdeltavirusproductothermembersrt otherinternationalmembergild hepatitisbvirushepatitisdeltavirusproductothermembercountry hepatitisbvirushepatitisdeltavirusproductothermembersrt otherinternationalmembergild hepatitisbvirushepatitisdeltavirusproductothermembercountry hepatitisbvirushepatitisdeltavirusproductothermembersrt otherinternationalmembergild usgild hepatitisbvirushepatitisdeltavirusproductmembersrt otherinternationalmembergild usgild hepatitisbvirushepatitisdeltavirusproductmembersrt otherinternationalmembergild usgild hepatitisbvirushepatitisdeltavirusproductmembersrt otherinternationalmembergild celltherapyproductstecartusmembercountry celltherapyproductstecartusmembersrt otherinternationalmembergild celltherapyproductstecartusmembercountry celltherapyproductstecartusmembersrt otherinternationalmembergild celltherapyproductstecartusmembercountry celltherapyproductstecartusmembersrt otherinternationalmembergild otherproductsyescartamembercountry otherproductsyescartamembersrt otherinternationalmembergild otherproductsyescartamembercountry otherproductsyescartamembersrt otherinternationalmembergild otherproductsyescartamembercountry otherproductsyescartamembersrt otherinternationalmembergild usgild celltherapyproductstotalcelltherapyproductsalesmembersrt otherinternationalmembergild usgild celltherapyproductstotalcelltherapyproductsalesmembersrt otherinternationalmembergild usgild celltherapyproductstotalcelltherapyproductsalesmembersrt otherinternationalmembergild usgild trodelvymembersrt otherinternationalmembergild usgild trodelvymembersrt otherinternationalmembergild usgild trodelvymembersrt otherinternationalmembergild otherproductsambisomemembercountry otherproductsambisomemembersrt otherproductsambisomemembergild otherproductsambisomemembercountry otherproductsambisomemembersrt otherproductsambisomemembergild otherproductsambisomemembercountry otherproductsambisomemembersrt otherproductsambisomemembergild otherproductsletairismembercountry otherproductsletairismembersrt otherinternationalmembergild otherproductsletairismembercountry otherproductsletairismembersrt otherinternationalmembergild otherproductsletairismembercountry otherproductsletairismembersrt otherinternationalmembergild otherproductsothermembercountry otherproductsothermembersrt otherinternationalmembergild otherproductsothermembercountry otherproductsothermembersrt otherinternationalmembergild otherproductsothermembercountry otherproductsothermembersrt otherinternationalmembergild otherproductstotalotherproductsalesmembercountry otherproductstotalotherproductsalesmembersrt otherproductstotalotherproductsalesmembergild otherproductstotalotherproductsalesmembercountry otherproductstotalotherproductsalesmembersrt otherproductstotalotherproductsalesmembergild otherproductstotalotherproductsalesmembercountry otherproductstotalotherproductsalesmembersrt otherproductstotalotherproductsalesmembergild usus gaap gaap productmembersrt otherinternationalmemberus gaap usus gaap gaap productmembersrt otherinternationalmemberus gaap usus gaap gaap productmembersrt otherinternationalmemberus gaap usgild royaltycontractandothermembersrt otherinternationalmembergild usgild royaltycontractandothermembersrt otherinternationalmembergild usgild royaltycontractandothermembersrt otherinternationalmembergild gaap customerconcentrationriskmembergild amerisourcebergencorpmemberus gaap gaap customerconcentrationriskmembergild amerisourcebergencorpmemberus gaap gaap customerconcentrationriskmembergild amerisourcebergencorpmemberus gaap gaap customerconcentrationriskmemberus gaap revenuefromcontractwithcustomermembergild gaap customerconcentrationriskmemberus gaap revenuefromcontractwithcustomermembergild gaap customerconcentrationriskmemberus gaap revenuefromcontractwithcustomermembergild mckessoncorpmemberus gaap customerconcentrationriskmemberus gaap mckessoncorpmemberus gaap customerconcentrationriskmemberus gaap mckessoncorpmemberus gaap customerconcentrationriskmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmembergild gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmembergild gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmembergild gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmembergild gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmembergild arcusbiosciencesincmemberus gaap gaap fairvaluemeasurementsrecurringmembergild arcusbiosciencesincmemberus gaap gaap fairvaluemeasurementsrecurringmembergild gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmembergild arcusbiosciencesincmemberus gaap gaap fairvaluemeasurementsrecurringmembergild arcusbiosciencesincmemberus gaap gaap fairvaluemeasurementsrecurringmembergild gaap equitysecuritiesmemberus gaap fairvaluemeasurementsrecurringmemberus gaap gaap equitysecuritiesmemberus gaap fairvaluemeasurementsrecurringmemberus gaap gaap equitysecuritiesmemberus gaap fairvaluemeasurementsrecurringmemberus gaap gaap equitysecuritiesmemberus gaap gaap equitysecuritiesmemberus gaap fairvaluemeasurementsrecurringmemberus gaap gaap equitysecuritiesmemberus gaap fairvaluemeasurementsrecurringmemberus gaap gaap equitysecuritiesmemberus gaap fairvaluemeasurementsrecurringmemberus gaap gaap equitysecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmembergild gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmembergild gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmembergild gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmembergild gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmembergild gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmembergild gaap gaap gaap gaap gaap gaap gaap gaap contingentconsiderationliabilitymembergild contingentconsiderationliabilitymembergild contingentconsiderationliabilitymembergild contingentconsiderationliabilitymembergild contingentconsiderationliabilitymembergild immunomedicsincmemberus gaap gaap fairvaluemeasurementsnonrecurringmemberus gaap immunomedicsincmemberus gaap gaap fairvaluemeasurementsnonrecurringmemberus gaap immunomedicsincmemberus gaap gaap fairvaluemeasurementsnonrecurringmemberus gaap immunomedicsincmemberus gaap gaap fairvaluemeasurementsnonrecurringmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap equitysecuritiesdonationmembergild equitysecuritiesdonationmembergild gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap othernoncurrentliabilitiesmemberus gaap gaap gaap gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap othernoncurrentliabilitiesmemberus gaap gaap gaap maximummembergild hepcludexmembergild gaap inprocessresearchanddevelopmentmembergild gaap measurementinputdiscountratemembergild hepcludexmembergild hepcludexmembergild hepcludexmembergild gaap mediumtermnotesmembergild immunomedicsincmembergild immunomedicsincmembergild gaap inprocessresearchanddevelopmentmembergild gaap licensingagreementsmembergild immunomedicsincmembergild gaap gaap licensingagreementsmembergild gaap measurementinputriskfreeinterestratemembergild gaap inprocessresearchanddevelopmentmembergild gaap gaap gaap gaap gaap measurementinputdiscountratemembergild gaap dragonflytherapeuticscollaborationagreementmembergild dragonflytherapeuticscollaborationagreementmembergild mercksharpdohmecorplicenseandcollaborationagreementmembergild oralformulationproductmembergild mercksharpdohmecorplicenseandcollaborationagreementmembergild arcusbiosciencesincmembergild arcusbiosciencesincmembergild arcusbiosciencesincmembergild arcusbiosciencesincmembergild arcusbiosciencesincmembergild arcusstockpurchaseagreementmembergild arcusbiosciencesincmembergild arcusbiosciencesincmembergild arcusbiosciencesincmembergild arcuscollaborationagreementmembergild arcusbiosciencesincmembergild arcuscollaborationagreementmembergild pionyrimmunotherapeuticsincmembergild pionyrimmunotherapeuticsincmembergild pionyrimmunotherapeuticsincmembergild pionyrimmunotherapeuticsincmembergild pionyrimmunotherapeuticsincmembergild researchanddevelopmentserviceagreementmembergild researchanddevelopmentserviceagreementmembergild tizonamergerandoptionagreementsmembergild tizonamergerandoptionagreementsmembergild tizonamergerandoptionagreementsmembergild tizonamergerandoptionagreementsmembergild tizonamergerandoptionagreementsmembergild maximummembergild tizonamergerandoptionagreementsmembergild developmentagreementmembergild amendedandrestatedresearchcollaborationandlicenseagreementandstockpurchaseagreementmembergild amendedandrestatedresearchcollaborationandlicenseagreementandstockpurchaseagreementmembergild tangotherapeuticsincmembersrt jouncetherapeuticsincmembergild jouncetherapeuticsincmembergild jouncetherapeuticsincmembergild galapagosmembergild galapagosmembergild galapagosmembergild galapagosmembergild galapagossubscriptionagreementmembergild galapagossubscriptionagreementmembergild galapagossubscriptionagreementmembergild gaap licensingagreementsmembergild everestmedicinesandimmunomedicsagreementmembergild everestmedicinesandimmunomedicsagreementmembergild gaap licensingagreementsmembergild gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap seniornotesmembergild gaap seniornotesmembergild gaap gaap gaap gaap gaap gaap gaap seniornotesmembergild gaap seniornotesmembergild gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap minimummemberus gaap maximummemberus gaap gaap measurementinputexpectedtermmembergild gaap revolvingcreditfacilitymemberus gaap gaap revolvingcreditfacilitymemberus gaap gaap revolvingcreditfacilitymemberus gaap gaap revolvingcreditfacilitymemberus gaap gaap lawsuitgild gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap minimummemberus gaap maximummemberus gaap minimummemberus gaap maximummemberus gaap gaap minimummemberus gaap maximummemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap mirobioltdmembergild immunomedicsincmembergild fortysevenincmembergild gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap fairvaluemeasurementsrecurringmembergild deferredcompensationplanmemberus gaap gaap fairvaluemeasurementsrecurringmembergild deferredcompensationplanmemberus gaap gaap gaap globalstrategiccollaborationagreementmembergild arcellxincmemberus gaap globalstrategiccollaborationagreementmembergild arcellxincmemberus gaap globalstrategiccollaborationagreementmembergild arcellxincmembergild arcellxincmemberus gaap tmunitytherapeuticsmemberus gaap united statessecurities exchange commissionwashington form mark one annual report pursuant section security exchange act of the fiscal year ended december transition report pursuant to section or of the security exchange act of the transition period to commission file gilead science inc exact name of registrant specified charter state or jurisdiction of incorporation or organization irs employer identification no lakeside drive foster city california address of principal executive office including zip code registrant telephone number including area code security registered pursuant to section of the exchange act title of classtrading symbol name of each exchange registeredcommon stock par value per sharegildthe nasdaq global select marketsecurities registered pursuant to section of the exchange act noneindicate check mark the registrant well known seasoned issuer defined in rule of the security act yes no indicate by check mark if the registrant is required to file report pursuant to section or section of the exchange act yes no indicate by check mark whether the registrant filed report required to filed by section or of the exchange act the preceding month or for shorter period the registrant required to file such report and ha subject to such filing requirement for the past day yes no indicate by check mark whether the registrant ha submitted electronically every interactive data file required to be submitted pursuant to rule of regulation of chapter during the preceding month or for such shorter period that the registrant wa required to submit such file yes no indicate by check mark whether registrant is large accelerated filer accelerated filer non accelerated filer smaller reporting company or an emerging growth company see the definition of large accelerated filer accelerated filer smaller reporting company and emerging growth company in rule of the exchange act large accelerated filer accelerated filer non accelerated filer smaller reporting company emerging growth company if an emerging growth company indicate by check mark if the registrant ha elected not to use the extended transition period for complying new or revised financial accounting standard provided pursuant to section of the exchange act indicate by check mark whether the registrant ha filed report on and attestation to it management assessment of the effectiveness of it internal control financial reporting section of the sarbanes oxley act by the registered public accounting firm that prepared or issued it audit report if security registered pursuant to section of the act indicate by check mark whether the financial statement of the registrant included in the filing reflect the correction of an error to previously issued financial statement indicate by check mark whether any of error correction are restatement that required recovery analysis of incentive based compensation received by any of the registrant executive officer during the relevant recovery period pursuant to indicate by check mark whether the registrant is shell company defined in rule of the exchange act yes no the aggregate market value of the voting and non voting common equity held by non affiliate of the registrant based upon the closing price of it common stock on the nasdaq global select market on june wa billion the number of share outstanding of the registrant common stock on february wa incorporated by reference specified portion of the registrant proxy statement which be filed with the commission pursuant to regulation in connection with the registrant annual meeting of stockholder to be held on may are incorporated by reference part iii of this report based on closing price of per share on june excludes share of the registrant common stock held by executive officer director and any stockholder whose ownership exceeds of registrant common stock outstanding june exclusion of such share not be construed to indicate that any such person posse the power direct or indirect to direct or cause the direction of the management or policy of the registrant or that such person is controlled by or under common control with the registrant gilead science inc form annual reporttable of contentspart item staff safety ii item for registrant common equity related stockholder matter and issuer purchase of equity reserved discussion and analysis of financial condition and result of and qualitative disclosure market statement and supplementary in and disagreement with accountant on accounting and financial and regarding foreign jurisdiction that prevent iii item executive officer and corporate ownership of certain beneficial owner and management and related stockholder relationship and related transaction and director accountant fee and iv item and financial statement or right to various trademark and trade name used in business including the following gilead gilead science kite ambisome atripla biktarvy cayston complera descovy descovy for prep emtriva epclusa eviplera genvoya harvoni hepcludex hepsera jyseleca letairis odefsey ranexa sovaldi stribild sunlenca tecartus trodelvy truvada truvada for prep tybost veklury vemlidy viread vosevi yescarta and zydelig this report also refers to trademark service mark and trade name of other company which are the property of respective owner this annual report on form including part ii item management discussion and analysis of financial condition and result of operation contains forward looking statement regarding future event and our future result that are subject to the safe harbor created under the security act of amended the security act and the security exchange act of amended the exchange act word such expect anticipate target goal project hope intend plan believe seek estimate continue may could should might forecast and variation of such word and similar expression are intended to identify such forward looking statement in addition any statement other statement of historical fact are forward looking statement including statement regarding overall trend operating cost and revenue trend liquidity and capital need plan and expectation with respect to product product candidate corporate strategy business and operation financial projection and the use of capital collaboration and licensing arrangement patent protection and estimated loss of exclusivity for our product and product candidate ongoing litigation and investigation matter statement regarding the anticipated future impact on our business of the coronavirus disease covid and related public health measure and other statement of expectation belief future plan and strategy anticipated event or trend and similar expression have based forward looking statement on our current expectation about future event these statement are not guarantee of future performance and involve risk uncertainty and assumption that are difficult to predict our actual result may differ materially from those suggested by these forward looking statement for various reason including those identified in part item risk factor of this annual report on form given these risk and uncertainty are cautioned not to place undue reliance on forward looking statement the forward looking statement included in this report are made of the date hereof unless otherwise specified except required under federal security law and the rule and regulation of security and exchange commission sec we not undertake and specifically decline any obligation to update any of these statement or to publicly announce the result of any revision to any forward looking statement the distribution of this report whether result of new information future event change in assumption or otherwise in evaluating our business you should carefully consider the risk described under part item risk factor of this annual report on form any of the risk contained herein could materially and adversely affect our business result of operation and financial condition iitem businessgilead science inc gilead we our or is biopharmaceutical company that ha pursued and achieved breakthrough in medicine for than three decade with the goal of creating healthier world for all people we are committed to advancing innovative medicine to prevent and treat life threatening disease including hiv viral hepatitis and cancer we operate in more than country worldwide with headquarters in foster city california our businessproductswe have transformed care for people around the world by discovering developing and delivering innovative medicine to address unmet medical need in virology oncology and other therapeutic area our innovative medicine represent advancement by offering first in class therapy greater efficacy enhanced mode of delivery more convenient treatment and prevention regimen improved resistance profile and reduced side effect in our primary revenue generating product and the approved indication in the follows hiv biktarvy is an oral formulation dosed day for the treatment of hiv infection in certain patient biktarvy is single tablet regimen of fixed dose combination of our antiretroviral medication bictegravir emtricitabine ftc and tenofovir alafenamide taf genvoya is an oral formulation dosed once day for the treatment of hiv infection in certain patient genvoya is single tablet regimen of fixed dose combination of our antiretroviral medication elvitegravir cobicistat ftc and taf descovy is an oral formulation indicated in combination with other antiretroviral agent for the treatment of hiv infection in certain patient descovy is fixed dose combination of our antiretroviral medication ftc and taf descovy is also approved by food and drug administration fda for pre exposure prophylaxis prep indication to reduce the risk of sexually acquired hiv infection in certain at risk patient odefsey is an oral formulation dosed once day for the treatment of hiv infection in certain patient odefsey is single tablet regimen of fixed dose combination of our antiretroviral medication ftc and taf and rilpivirine marketed by janssen science ireland unlimited company one of the janssen pharmaceutical company of johnson johnson janssen complera eviplera is an oral formulation dosed once day for the treatment of hiv infection in certain patient the product marketed in the complera and in europe eviplera is single tablet regimen of fixed dose combination of our antiretroviral medication tenofovir disoproxil fumarate tdf and ftc and janssen rilpivirine hydrochloride truvada is an oral formulation indicated in combination with other antiretroviral agent for the treatment of hiv infection in certain patient truvada is fixed dose combination of our antiretroviral medication tdf and ftc truvada is also approved by fda for prep indication to reduce the risk of sexually acquired hiv infection in certain at risk patient stribild is an oral formulation dosed once day for the treatment of hiv infection in certain patient stribild is single tablet regimen of fixed dose combination of our antiretroviral medication elvitegravir cobicistat tdf and ftc covid veklury remdesivir an injection for intravenous use is nucleotide analog rna polymerase inhibitor indicated for the treatment of coronavirus disease covid in certain adult and pediatric patient day of age and older and weighing at least kg are hospitalized or ii not hospitalized and have mild to moderate covid and are at high risk for progression to severe covid including hospitalization or death viral hepatitis epclusa is an oral formulation of once daily single tablet regimen of sofosbuvir and velpatasvir for the treatment of chronic hepatitis virus hcv infection in adult and pediatric patient year of age and older with genotype or without cirrhosis or with compensated cirrhosis or ii with decompensated cirrhosis for use in combination with ribavirin in addition we have an authorized generic version of epclusa distributed by our separate subsidiary asegua therapeutic llc vemlidy is an oral formulation of taf dosed once day for the treatment of chronic hepatitis virus hbv infection in adult and pediatric patient year of age and older with compensated liver disease harvoni is an oral formulation of once daily single tablet regimen of ledipasvir and sofosbuvir for the treatment of chronic hcv infection in adult and pediatric patient year of age and older with genotype or without cirrhosis or with compensated cirrhosis ii genotype with decompensated cirrhosis in combination with ribavirin iii genotype or who are liver transplant recipient without cirrhosis or with compensated cirrhosis in combination with ribavirin in addition we have an authorized generic version of harvoni distributed by our separate subsidiary asegua therapeutic llc viread is an oral formulation of tdf dosed once day for the treatment of chronic hbv infection in adult and pediatric patient year of age and older and weighing at least kg oncology yescarta axicabtagene ciloleucel suspension for intravenous infusion is chimeric antigen receptor car cell therapy for the treatment of adult patient with large cell lymphoma lbcl that is refractory to first line chemoimmunotherapy or that relapse within month of first line chemoimmunotherapy ii adult patient with relapsed or refractory lbcl after two or more line of systemic therapy including diffuse lbcl dlbcl not otherwise specified primary mediastinal lbcl high grade cell lymphoma and dlbcl arising from follicular lymphoma fl and iii adult patient with relapsed or refractory fl after two or more line of systemic therapy trodelvy sacituzumab govitecan hziy an injection for intravenous use is trop directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patient with unresectable locally advanced or metastatic triple negative breast cancer tnbc who have received two or more prior systemic therapy at least one of for metastatic disease ii unresectable locally advanced or metastatic hormone receptor positive human epidermal growth factor receptor negative hr breast cancer who have received endocrine based therapy and at least two additional systemic therapy in the metastatic setting and iii locally advanced or metastatic urothelial cancer uc who have previously received platinum containing chemotherapy and either programmed death receptor pd or programmed death ligand pd inhibitor tecartus brexucabtagene autoleucel suspension for intravenous infusion is car cell therapy for the treatment of adult patient with relapsed or refractory mantle cell lymphoma mcl and ii relapsed or refractory cell precursor acute lymphoblastic leukemia all ________________________________ this indication is approved under accelerated approval by fda and continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial this indication received fda approval in february other ambisome amphotericin liposome for injection is proprietary liposomal formulation of amphotericin an antifungal agent for the treatment of serious invasive fungal infection caused by various fungal specie in adult letairis ambrisentan is an oral formulation of an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension pah who group to improve exercise capacity and delay clinical worsening or ii in combination with tadalafil to reduce the risk of disease progression and hospitalization for worsening pah and to improve exercise ability for the disaggregated revenue amount contributed by the product listed well the total product sale that include our other approved product see note revenue of the note to consolidated financial statement included in part ii item of this annual report on form in december we received fda approval for sunlenca lenacapavir hiv capsid inhibitor in tablet form for oral use and an injection for subcutaneous use sunlenca in combination with other antiretrovirals is approved twice yearly treatment option for hiv infection in heavily treatment experienced adult with multidrug resistant hiv infection revenue share and other revenueswe also generate revenue from other activity including revenue share from combination product royalty for outbound license of our intellectual property and other payment received from our collaboration with third party partner for example pursuant to our collaboration with janssen we receive revenue share from cobicistat ftc and taf that are component of symtuza darunavir cobicistat ftc taf fixed dose combination product commercialized by janssen we include our revenue share from symtuza in our product sale for description of our collaboration with janssen and other partner see note collaboration and other arrangement of the note to consolidated financial statement included in part ii item of this annual report on form and distributionwe have and international commercial sale operation with marketing subsidiary in more than country our product are marketed our commercial team and or in conjunction with third party distributor and corporate partner our commercial team promote our product through direct field contact with physician hospital clinic and other healthcare provider we generally grant our third party distributor the exclusive right to promote our product in territory for specified period of time of our agreement with these distributor provide for collaborative effort the distributor and gilead in obtaining and maintaining regulatory approval for the product in the specified territory we sell and distribute most of our product in the exclusively through the wholesale channel during the year ended december approximately of our product sale in the and approximately of our total worldwide revenue were from three large wholesaler amerisourcebergen corporation cardinal health inc and mckesson corporation we sell and distribute our product in europe and country outside the the product is approved either through our commercial team third party distributor or corporate partner competitionwe operate in highly competitive environment our product compete with other commercially available product based primarily on efficacy safety tolerability acceptance by doctor ease of patient compliance ease of use price insurance and other reimbursement coverage distribution and marketing we also face significant competition third party pursue the development of product and technology that may be competitive with our existing product or research program these third party include large pharmaceutical and biotechnology company and specialized pharmaceutical firm acting either independently or together with other such company furthermore academic institution government agency and other public and private organization conducting research may seek patent protection or may establish collaborative arrangement for competitive product or program in addition our product mature pricing pressure from private insurer and government payer often result in reduction of the net product price new branded or generic product are introduced into major market our ability to maintain pricing and market share may be affected research and developmentour research and development mission is to discover and develop transformational therapy in area of high unmet medical need our product development effort are focused primarily in viral disease oncology and inflammatory disease our team of research scientist is engaged in the discovery and development of new molecule and technology that we hope will lead to the approval of innovative medicine and therapy that will transform care for people around the world we intend to continue committing significant resource to internal opportunity and external business development activity to drive innovation and growth of our business the development of product candidate and investigational therapy in our pipeline is subject to various risk and uncertainty these risk and uncertainty include challenge in clinical trial protocol design our ability to enroll patient in clinical trial the possibility of unfavorable or inadequate trial result to support further development of our product candidate including failure to meet trial primary endpoint safety issue arising from our clinical trial and the need to modify or delay our clinical trial or to perform additional trial result we may be unable to successfully complete our clinical trial on our anticipated timeline or at all based on trial result is possible that fda and other regulatory authority do not approve our product candidate or that any market approval include significant limitation on the product use further we may make strategic decision to discontinue development of our product candidate if for example we believe commercialization will be difficult relative to other opportunity in our pipeline therefore our product candidate may never be successfully commercialized and we may be unable to recoup the significant and clinical trial expense incurred we expect to expend significant time and resource on our activity without any assurance that we will recoup our investment or that our effort will be commercially successful drug development is inherently risky and many product candidate and investigational therapy fail during the development process in we continued to invest in and advance our pipeline across our therapeutic area is summary of our product candidate that are in phase or registrational phase clinical trial or pending marketing authorization review by fda or european medicine agency ema candidate in viral diseasesproduct candidatesdescriptionregulatory filingsbulevirtidea biologics license application bla ha been filed with fda for bulevirtide for the treatment of chronic hepatitis delta virus hdv infection it ha been granted orphan drug and breakthrough therapy designation by fda for this indication approval is pending resolution of certain manufacturing and delivery concern cited in complete response letter issued by fda in october in europe hepcludex bulevirtide ha been granted conditional marketing authorization by the european commission ec and priority medicine prime scheme eligibility by the ema the first approved treatment in adult with chronic hdv infection with compensated liver disease phase is evaluated for an hiv prep indication novel oral covid nucleoside is being evaluated for the treatment of covid infection product candidate in oncologyproduct candidatesdescriptionregulatory filingssacituzumab govitecan hziya type ii variation marketing authorization application ha been filed with ema for sacituzumab govitecan hziy trop directed antibody and topoisomerase inhibitor conjugate for the treatment of adult patient with unresectable or metastatic hr breast cancer who have received endocrine based therapy and at least two additional systemic therapy in the metastatic setting this indication received fda approval in february phase ciloleucelaxicabtagene ciloleucel car cell therapy is being evaluated second line and later treatment for high risk follicular lymphoma sacituzumab govitecan hziysacituzumab govitecan hziy is being evaluated second or third line treatment for non small cell lung cancer nsclc ii first line treatment for pd negative metastatic triple negative breast cancer tnbc and iii second line treatment for metastatic urothelial cancer in collaboration with merck sharp dohme llc merck sacituzumab govitecan hziy is being evaluated in combination with merck pembrolizumab first line treatment for pd positive metastatic tnbc and ii first line treatment for nsclc sacituzumab govitecan hziy is also being evaluated in combination with pembrolizumab treatment for adjuvant tnbc magrolimabmagrolimab an anti monoclonal antibody is being evaluated in combination with azacitidine first line treatment for higher risk myelodysplastic syndrome md it ha been granted breakthrough therapy designation by fda and prime scheme eligibility for this indication magrolimab is also being evaluated in combination with azacitidine first line treatment for acute myeloid leukemia aml magrolimab is also being evaluated in combination with venetoclax and azacitidine first line treatment for unfit aml and zimberelimabin collaboration with arcus bioscience inc arcus the combination of zimberelimab an anti pd monoclonal antibody and domvanalimab an fc silent anti tigit antibody is being evaluated first line treatment for nsclc in collaboration with arcus the combination of zimberelimab and domvanalimab with chemotherapy is also being evaluated first line treatment for nsclc and ii first line treatment for upper gastrointestinal tract cancer in collaboration with arcus and astrazeneca the combination of domvanalimab and durvalumab is being evaluated for the treatment of stage nsclc registrational phase autoleucelbrexucabtagene autoleucel car cell therapy is being evaluated for the treatment of pediatric acute lymphoblastic leukemia ________________________________ for additional information regarding our collaboration with merck and arcus see note collaboration and other arrangement of the note to consolidated financial statement included in part ii item of this annual report on form in we also received regulatory approval or authorization from fda and ec for new product and expanded indication of our product including productregulatory approval or authorizationsunlencafda and ec approved sunlenca first in class long acting hiv capsid inhibitor for the treatment of hiv infection in combination with other antiretrovirals in adult with multi drug resistant hiv who are heavily treatment experienced sunlenca is new twice yearly treatment option for adult with hiv infection that is not adequately controlled by their current treatment regimen yescartafda approved yescarta for the treatment of adult patient with lbcl that is refractory to first line chemoimmunotherapy or that relapse within month of first line chemoimmunotherapy yescarta is the first fda approved car cell therapy for the initial treatment of relapsed or refractory lbcl ec approved yescarta for the treatment of adult patient with dlbcl and high grade cell lymphoma who relapse within month from completion of or are refractory to first line chemoimmunotherapy yescarta is the first car cell therapy approved for patient in europe who do not respond to first line treatment for dlbcl and high grade cell lymphoma ec also approved yescarta for the treatment of adult patient with relapsed or refractory fl after three or more line of systemic therapy tecartusec approved tecartus for the treatment of adult patient year of age and above with relapsed or refractory cell precursor all vekluryfda approved an expanded use of veklury for the treatment of non hospitalized patient who are at high risk of progression to severe covid including hospitalization and death fda also expanded the approval of veklury to include pediatric patient day of age and older and weighing at least kg biktarvyec approved low dose tablet dosage form of biktarvy and an extension of the indication for biktarvy to treat hiv infection in virologically suppressed child who are at least two year of age and weigh at least kg vemlidyfda approved an expanded use of vemlidy for the treatment of chronic hbv infection in pediatric patient year of age and older with compensated liver disease trodelvyfda approved trodelvy for the treatment of unresectable locally advanced or metastatic hr breast cancer who have received endocrine based therapy and at least two additional systemic therapy in the metastatic setting this indication received fda approval in february addition we seek to enhance our commercial portfolio and clinical pipeline across multiple therapeutic area through acquisition in licensing and strategic collaboration in we announced multiple strategic collaboration including research collaboration with dragonfly therapeutic inc to develop natural killer cell engager based immunotherapy in oncology and inflammation ii global strategic collaboration with arcellx inc to co develop and co commercialize arcellx lead late stage product candidate cart ddbcma for the treatment of relapsed or refractory multiple myeloma and iii an oncology collaboration with macrogenics inc to develop bispecific antibody including gilead exclusive option to license potential treatment for certain blood cancer we also announced the acquisition of mirobio private based biotech company focused on restoring immune balance with agonist targeting immune inhibitory receptor ii tmunity therapeutic clinical stage private biotech company focused on next generation car cell therapy and technology and iii all remaining right to an anti antibody in development potential treatment for solid tumor from jounce therapeutic inc our strategic business development activity reflects our commitment to focus on transformative science build sustainable and diverse portfolio and position for the near medium and long term growth of our business patent and proprietary rightsu and european patent expirationwe have number of and foreign patent patent application and right to patent related to our compound product and technology we not be certain that issued patent will be enforceable or provide adequate protection or that pending patent application will result in issued patent the following table show the estimated expiration date including patent term extension supplementary protection certificate and or pediatric exclusivity where granted in the and the european union eu for the primary typically compound patent for our key product candidate described above for our product candidate that are fixed dose combination of single tablet regimen the estimated patent expiration date provided corresponds to the latest expiring compound patent for one of the active ingredient in the single tablet regimen key product candidatespatent expirationu euviral disease disease axicabtagene brexucabtagene sacituzumab govitecan domvanalimab the listed expiration date do not include any potential additional exclusivity patent term extension supplementary protection certificate or pediatric exclusivity that ha not yet been granted _______________________________ the composition of matter patent ha expired in the eu in the eu and the patent application are pending relating to proprietary manufacturing process of kite gilead company kite regulatory exclusivity in the expires in in collaboration with arcus date in parenthesis reflect the estimated expiration date of patent which may issue from currently pending application following table show the actual or estimated expiration date including patent term extension supplementary protection certificate and or pediatric exclusivity where granted in the and the eu for the primary typically compound patent for our principal product for our product that are fixed dose combination or single tablet regimen the estimated patent expiration date provided correspond to the latest expiring compound patent for one of the active ingredient in the single tablet regimen productspatent expiration listed expiration date do not include any potential additional exclusivity patent term extension supplementary protection certificate or pediatric exclusivity that ha not yet been granted ______________________________ where applicable settlement and license agreement with generic manufacturer relating to the patent that protect our principal product are noted the nature and timing of loss of exclusivity for these product depends on multitude of factor and loss of exclusivity may be earlier under certain circumstance for more information see item risk factor our success depends to significant degree on our ability to obtain and defend our patent and other intellectual property right both domestically and internationally and to operate without infringing upon the patent or other proprietary right of third party in september gilead and five generic manufacturer lupin ltd apotex inc macleod pharma ltd hetero lab ltd and cipla ltd reached agreement to settle the patent litigation concerning patent that protect taf in our descovy vemlidy and odefsey product the composition of matter patent ha expired in the eu in the eu and the patent application are pending relating to proprietary manufacturing process of kite in gilead and mylan pharmaceutical reached an agreement to settle the patent litigation concerning patent that protect cobicistat in our stribild and genvoya product regulatory exclusivity in the expires in patent protection and certain challenge patent and other proprietary right are important to our business if we have properly drafted and enforceable patent it can be more difficult for our competitor to use our technology to create competitive product and more difficult for our competitor to obtain patent that prevents from using technology we create part of our business strategy we actively seek patent protection both in the and internationally and file additional patent application appropriate to cover improvement in our compound product and technology patent covering certain of the active pharmaceutical ingredient api of of our product are held by third party we acquired exclusive right to these patent in the agreement we have with these party we may obtain patent for certain product many year marketing approval is obtained result the commercial value of the patent may be limited the patent term is based on the date the patent application wa filed which may be prior to the regulatory approval and commercial sale of the related product however we may be able to apply for patent term extension or supplementary protection certificate in some country for example extension for the patent or supplementary protection certificate on many of our product have been granted in the and in number of european country compensating in part for delay in obtaining marketing approval similar patent term extension may be available for other product we are developing but we can not be certain we will obtain them in some country is also important that we do not infringe the valid patent of third party if we infringe the valid patent of third party our reputation may be harmed and we may be required to pay significant monetary damage we may be prevented from commercializing product or we may be required to obtain license from these third party we may not be able to obtain alternative technology or any required license on reasonable term or at all if we fail to obtain these license or alternative technology we may be unable to develop or commercialize some or all of our product for example we are aware of patent and patent application owned by other party that such party may claim to cover the use of our product and research activity because patent application are confidential for period of time after filing we may not know if our competitor have filed application for technology covered by our pending application or if we were the first to invent or first to file an application directed toward the technology that is the subject of our patent application competitor may have filed patent application or received patent and proprietary right that block or compete with our product in addition if competitor file patent application covering our technology we may have to participate in litigation post grant proceeding before the patent and trademark office or other proceeding to determine the right to patent or validity of any patent granted such litigation and proceeding are unpredictable and expensive and could divert management attention from other operation such that even if we are ultimately successful we may be adversely impacted patent relating to pharmaceutical biopharmaceutical and biotechnology product compound and process such those that cover our existing compound product and process and those that we will likely file in the future do not always provide complete or adequate protection filing patent application is fact intensive and complex process we may file patent application that ultimately do not result in patent or have patent that do not provide adequate protection for the related product future litigation or other proceeding regarding the enforcement or validity of our existing patent or any future patent could result in the invalidation of our patent or substantially reduce their protection from time to time certain individual or entity may challenge our patent our pending patent application and the patent application filed by our collaborative partner may not be able to prevent third party from developing compound or product that are closely related to those which we have developed or are developing in addition certain country do not provide effective enforcement of our patent and third party manufacturer may be able to sell generic version of our product in those country we may face criticism result of our legitimate use of the patent system to protect our investment in new and useful innovation in medicine further incentive and exclusivities relating to our product and product candidate may change in the future we are aware that several country are considering change to support sharing to make and use new invention that could impact the current patent system and protection for innovation any such change could also impact the voluntary licensing patent program that we establish for our product to support access to medicine for description of our significant pending legal proceeding see note commitment and contingency of the note to consolidated financial statement included in part ii item of this annual report on form see also item risk factor our success depends to significant degree on our ability to obtain and defend our patent and other intellectual property right both domestically and internationally and to operate without infringing upon the patent or other proprietary right of third party trade secretswe also rely on unpatented trade secret and improvement unpatented internal know how and technological innovation for example great deal of our liposomal manufacturing expertise which is key component of our liposomal technology is not covered by patent but is instead protected trade secret we protect these right mainly through confidentiality agreement with our corporate partner employee consultant and vendor these agreement provide that all confidential information developed or made known to an individual during the course of their relationship with will be kept confidential and will not be used or disclosed to third party except in specified circumstance in the case of employee the agreement provide that all invention made by an individual employed by will be our exclusive property we can not be certain that these party will comply with these confidentiality agreement that we have adequate remedy for any breach or that our trade secret internal know how or technological innovation will not otherwise become known or be independently discovered by our competitor under some of our agreement invention become jointly owned by and our corporate partner and in other case become the exclusive property of one party in certain circumstance it can be difficult to determine who owns particular invention and dispute could arise regarding those invention if our trade secret or confidential information become known or independently discovered by competitor or if we enter into dispute over ownership of invention our business and result of operation could be adversely affected and raw materialsour product are manufactured either at our own facility or by third party contract manufacturer we depend on third party to perform manufacturing activity for the majority of our api and drug product for most of our product including our hiv and hcv product we use multiple third party contract manufacturer that we have primary and back supplier and manufacturing site for our cell therapy product we have established clinical and commercial manufacturing facility for cell processing activity for our future product we continue to develop additional manufacturing capability and establish additional third party supplier to manufacture sufficient quantity of our product candidate to undertake clinical trial and to manufacture sufficient quantity of any product that is approved for commercial sale our manufacturing facility we own or lease manufacturing facility to manufacture and distribute certain product and api for clinical and or commercial us of the end of these facility include foster city california we conduct process chemistry research analytical method development and formulation and device development activity and manufacture api and drug product for our clinical trial san dimas and la verne california we manufacture ambisome and also package and label the majority of our commercial product for distribution to the america and the pacific rim oceanside california we utilize the facility for commercial retroviral vector manufacturing and clinical manufacturing and process development of our biologics candidate el segundo california we utilize the facility for clinical and commercial manufacturing and processing of our cell therapy product frederick maryland we utilize the facility for clinical and commercial manufacturing and processing of our cell therapy product cork and dublin ireland we utilize the cork facility for commercial manufacturing packaging and labeling of our product we also perform quality control testing labeling packaging and final release of many of our product at the cork facility which are distributed to the eu and other international market through our facility in dublin edmonton canada we conduct process chemistry research and scale up activity for our clinical development candidate manufacture api for both investigational and commercial product and conduct chemical development activity to improve existing commercial manufacturing process hoofddorp netherlands we utilize the facility for commercial manufacturing and processing of our cell therapy product third party manufacturerswe believe the technology we use to manufacture our product is proprietary for product manufactured by our third party contract manufacturer we have disclosed all necessary aspect of this technology to enable them to manufacture the product for we have agreement with these third party manufacturer that are intended to restrict them from using or revealing this technology but we can not be certain that these third party manufacturer will comply with these restriction for more information about our third party manufacturer see item risk factor we may face manufacturing difficulty delay or interruption including at our third party manufacturer and corporate partner regulation of manufacturing processthe manufacturing process for pharmaceutical product is highly regulated and regulator may shut manufacturing facility that observe are not complying with regulation we our third party manufacturer and our corporate partner are subject to current good manufacturing practice gmp which are extensive regulation governing manufacturing process stability testing record keeping and quality standard defined by fda and ema similar regulation are in effect in other jurisdiction our manufacturing operation are subject to routine inspection by regulatory agency for our cell therapy product we are required by fda to comply with the risk evaluation and mitigation strategy program which includes educating and certifying medical personnel regarding the therapy procedure and the potential side effect profile of our therapy such the potential adverse side effect related to cytokine release syndrome and neurologic toxicity additionally we are required to maintain complex chain of identity and custody with respect to patient material such material move to the manufacturing facility through the manufacturing process and back to the patient to raw material we need access to certain raw material to conduct our clinical trial and manufacture our product these raw material are generally available from multiple source purchased worldwide and normally available in quantity adequate to meet the need of our business we attempt to manage the risk associated with our supply chain by inventory management relationship management and evaluation of alternative source when feasible for more information see item risk factor we may not be able to obtain material or supply necessary to conduct clinical trial or to manufacture and sell our product which could limit our ability to generate revenue human capitalgilead success depends on the work of it dedicated employee who embrace shared sense of purpose and culture of excellence our human capital objective is to make gilead an employer of choice for the best talent in our industry gilead key priority for human capital management include inclusion and diversity health and safety total reward employee development and engagement the compensation and talent committee of our board of director oversees our overall human capital management inclusion diversityinclusion is gilead core value and we believe building an inclusive and diverse workforce is critical to enabling gilead mission our global inclusion and diversity council is responsible for governance of these matter tracking progress on our goal and promoting culture of inclusion the global inclusion and diversity council is chaired by our chairman and chief executive officer and includes member of our leadership team in we introduced our advancing black leadership strategy multi year initiative that outline our commitment to create internal and external pipeline for diverse talent and to build awareness capability and accountability among our people manager part of this strategy we set clear target for representation within our overall workforce and executive population including goal to increase the percentage of female black and hispanic employee with well defined annual target through gilead also implemented multiple program to train manager on inclusion and diversity topic and created strategy and initiative focused on attracting developing and retaining diverse talent and driving an inclusive culture in our workplace which organizational leader were required to regularly review starting in in addition our employee resource group erg support diverse employee and aim to raise awareness of different culture within the workplace cultivate diversity business strength and support gilead talent acquisition strategy to source attract and recruit diverse candidate executive sponsor and leader of our erg contribute to the advancement of our inclusion and diversity commitment through service on our global inclusion and diversity council we believe gilead inclusive and diverse workforce is the foundation for innovation and productivity gilead commitment to equal employment opportunity furthers it effort to cultivate and celebrate an equitable culture of belonging of december gilead approximately employee and gilead global workforce wa approximately female additionally woman represented of gilead leadership defined vice president level and above in the based on our employee voluntary self identification our workforce wa white asian hispanic black and other health and safetygilead is committed to providing workplace for it employee that promotes health safety wellness and productivity we have workplace safety training and security program together with various compliance protocol to support this commitment we routinely train and educate our employee on workplace safety and security in response to the covid pandemic we implemented job site enhancement and risk protocol including health screening covid testing and vaccine requirement reconfiguration of work and common space to allow for physical distancing in our effort to support the safe occupancy of our site gilead also maintains robust contact tracing and notification process for any employee who report covid infection total rewardsgilead compensation and benefit program are designed to help attract develop and retain the industry most talented workforce our total reward program which varies by country includes competitive base salary and incentive compensation stock award an employee stock purchase plan saving plan with company match that vest immediately health and welfare and other valuable benefit such flexible work arrangement flexible spending account paid time family leave family care resource fertility adoption and surrogacy assistance student loan repayment and tuition assistance employee assistance program and global wellbeing reimbursement among many others each year we reassess our total reward package to confirm whether it offer benefit and incentive that align with our total reward philosophy are pay for performance company and are committed to addressing pay equity our employee salary are informed by market based range and are assessed annually through performance and career development review our policy is that compensation decision are made without regard to personal characteristic such gender race color national or ethnic origin age disability sexual orientation gender identity or expression genetic information religion or veteran status we also conduct an annual pay equity review of employee compensation in an effort to strive to make our pay practice gender and race neutral employee development and engagementemployee development and engagement maximizes the potential and performance of each member of our workforce and is critical to achieving our business goal gilead offer number of internal and external professional management and leadership development training program to help our employee develop technical cross functional and leadership skill and tool to grow their career in addition employee can receive reimbursement for tuition expense incurred while pursuing undergraduate graduate or certificate course at an accredited college or university we strive to be the employer of choice in our industry our listening strategy gather input from our employee to shape our engagement strategy and program and measure our progress in addition to ongoing internal and external data collection and benchmarking we conducted comprehensive review of the employee experience in and in including through the use of employee survey the result of these survey play key role in determining the direction of our culture well the company broader response to emerging development for example in response to the covid pandemic we provided meaningful benefit to employee and refined our approach to flexible work arrangement we believe our flexible work program position to be competitive for talent and support employee well being while also creating the collaborative environment and connection that fuel innovation environmental social and governance esg investing in corporate responsibility is core to our business strategy and reflects our value of accountability inclusion teamwork excellence and integrity this is in service to our mission to advance global health by providing innovative therapeutic in area of unmet need in way that is socially responsible and environmentally sustainable gilead esg program reflect this commitment to our stakeholder esg strategy and performance are overseen by the nominating and corporate governance committee of our board of director and managed by corporate responsibility committee comprised of leader from key department across our company the corporate responsibility committee is responsible for reviewing esg issue and appropriate integrating them into our overall business strategy and operation additional information about this program and esg highlight are available in gilead year in review on gilead website at http www gilead com medium file pdfs yir pdfs gilead yir_desktop pdf our esg goal are aspirational and may change statement regarding these goal and related initiative are not guarantee or promise that they will be met seasonality of operationsour worldwide product sale do not reflect any significant degree of seasonality in end user demand however in the fluctuation in wholesaler inventory level impact our product sale we typically observe strong wholesaler and sub wholesaler purchase of our product in the fourth quarter resulting in inventory draw down by wholesaler and sub wholesaler in the subsequent first quarter several other factor including government budget annual grant cycle for federal and state fund adverse change in economic condition increased competition and other buying pattern also could impact the product sale recorded in particular quarter for more information see item risk factor we face challenge in accurately forecasting sale because of the difficulty in predicting demand for our product and fluctuation in purchasing pattern or wholesaler inventory government regulationour operation and activity are subject to extensive regulation by numerous government authority in the the eu and other country including law and regulation governing the testing manufacture safety efficacy labeling storage record keeping approval advertising and promotion of our product result of these regulation product development and product approval process are very expensive and time consuming which ha significant impact on our capital expenditure and result of operation the regulatory requirement applicable to drug development and approval are subject to change any legal and regulatory change may impact our operation in the future country regulatory agency such fda in the and ema and ec in the eu well the national authority of the eu member state must approve drug before it can be sold in the respective country or country the general process for drug approval in the is summarized below many other country including country in the eu and the eu under centralized procedure have similar regulatory structure testingbefore we can test drug candidate in human we must study the drug in laboratory experiment and in animal to generate data to support the drug candidate potential benefit and safety we submit this data to fda in an investigational new drug ind application seeking it approval to test the compound in human clinical trialsif fda accepts the ind the drug candidate can be studied in human clinical trial to determine if the drug candidate is safe and effective these clinical trial involve three separate phase that often overlap can take many year and are very expensive these three phase which are subject to considerable regulation are follows phase the drug candidate is given to small number of healthy human control subject or patient suffering or at risk from the indicated disease to test for safety dose tolerance pharmacokinetics metabolism distribution and excretion phase the drug candidate is given to limited patient population to determine the effect of the drug candidate in treating or preventing the disease the best dose of the drug candidate and the possible side effect and safety risk of the drug candidate it is not uncommon for drug candidate that appears promising in phase clinical trial to fail in the more rigorous and extensive phase clinical trial phase if drug candidate appears to be effective and have an appropriate safety profile in phase clinical trial phase clinical trial are commenced to confirm those result phase clinical trial are conducted over longer term involve significantly larger population are conducted at numerous site in different geographic region and are carefully designed to provide reliable and conclusive data regarding the safety and benefit of drug candidate it is not uncommon for drug candidate that appears promising in phase clinical trial to fail in the more rigorous and extensive phase clinical trial fda approval processwhen we believe that the data from our clinical trial show an acceptable benefit risk profile we submit the appropriate filing usually in the form of new drug application biologics license application or supplemental application with fda seeking approval to sell the drug candidate for particular use at fda discretion fda may hold public hearing where an independent advisory committee of expert advisor asks additional question and make recommendation regarding the drug candidate this committee make recommendation to fda that is not binding but is generally followed by fda if fda agrees that the drug ha met the required level of safety and efficacy for particular use it will approve the application and allow to sell the drug in the for that use it is not unusual however for fda to decline to approve an application because it belief that the drug candidate is not safe enough or efficacious enough not have an appropriate benefit risk profile or because it doe not believe that the data submitted is reliable or conclusive at any point in this process the development of drug candidate can be stopped for number of reason including safety concern lack of treatment benefit or manufacturing issue we can not be certain that any clinical trial that we are currently conducting or any that we conduct in the future will be completed successfully or within any specified time period we may choose or fda may require to delay or suspend our clinical trial at any time if it appears that patient are being exposed to an unacceptable health risk or if the drug candidate doe not appear to have sufficient treatment benefit even after approving drug fda may also require phase non registrational study to explore scientific question to further characterize safety and efficacy during commercial use of our drug fda may also require to provide additional data or information improve our manufacturing process procedure or facility or may require extensive surveillance to monitor the safety or benefit of our product candidate if it determines that our filing doe not contain adequate evidence of the safety and benefit of the drug in addition even if fda approves drug it could limit the us of the drug fda can withdraw approval if it doe not believe that we are complying with regulatory standard or if concern about the safety or efficacy are uncovered or occur after approval in addition to obtaining fda approval for each drug we obtain fda approval of the manufacturing facility for any drug we sell including those of company who manufacture our drug for all of these facility are subject to periodic inspection by fda fda must also approve foreign establishment that manufacture product to be sold in the and these facility are subject to periodic regulatory inspection our manufacturing facility located in california also must be licensed by the state of california in compliance with local regulatory requirement our manufacturing facility in canada ireland and netherlands also must obtain local license and permit in compliance with local regulatory requirement may employ one of several tool to facilitate and expedite the development and review of drug including fast track designation breakthrough therapy designation accelerated approval designation and priority review designation fast track designation is designed to facilitate the development and review of drug that treat serious condition and fill an unmet medical need breakthrough therapy designation is designed to expedite the development and review of drug that treat serious condition where preliminary clinical evidence demonstrates substantial improvement over available therapy accelerated approval of drug may be granted by fda where the drug treat serious condition fill an unmet medical need and ha been studied for safety and efficacy priority review designation mean fda goal is to take action on an application within six month of filing fda may grant priority review designation to drug that would provide significant improvement in the safety or effectiveness of treatment diagnosis or prevention of serious condition eu regulatory system and approval processin the eu our product are subject to variety of eu and eu member state regulation governing clinical trial commercial sale and distribution we are required to obtain marketing authorization in the eu before we can market our medicinal product on the relevant market the conduct of clinical trial in the eu is governed by among others directive ec and directive ec and the eu ich good clinical practice rule these impose legal and regulatory obligation that are similar to those provided in applicable law the conduct of clinical trial in the eu must be approved by the competent authority of each eu member state in which the clinical trial take place and positive opinion must be obtained from the relevant ethic committee in the relevant member state in the eu legislator adopted regulation eu no to replace directive ec and to introduce coordinated procedure for authorization of clinical trial this regulation entered into application in january marketing authorization holder manufacturer importer wholesaler and distributor of medicinal product placed on the market in the eu are required to comply with number of regulatory requirement including pharmacovigilance gmp compliance and the requirement to obtain manufacturing import and or distribution license issued by the competent authority of the eu member state failure to comply with these requirement may lead to the imposition of civil criminal or administrative sanction including suspension of marketing or manufacturing authorization pricing and reimbursementsuccessful commercialization of our product depends in part on the availability of third party payer reimbursement for the cost of such product and related treatment and medical service in the market where we sell our product government health authority private health insurer and other organization generally provide reimbursement in the the eu and other significant or potentially significant market for our product and product candidate government authority and third party payer are increasingly attempting to limit or regulate the price of medical product and service significant portion of our sale of the majority of our product are subject to substantial discount from their list price including rebate we may be required to pay to medicaid agency or discount we may be required to pay to covered entity under section of the public health service act result the price increase we implement from time to time on certain product may have limited effect on our net product sale in certain market in addition standard reimbursement structure may not adequately reimburse for innovative therapy our product mature pricing pressure from private insurer and government payer often result in reduction of the net product price further new branded or generic product are introduced into major market our ability to maintain pricing and market share may be affected for more information see item risk factor our existing product are subject to reimbursement pressure from government agency and other third party required rebate and other discount on our product and other pricing pressure and we face challenge in accurately forecasting sale because of the difficulty in predicting demand for our product and fluctuation in purchasing pattern or wholesaler inventory care fraud and abuse law anti bribery lawswe are subject to various federal and state law pertaining to health care fraud and abuse including anti kickback law and false claim law anti kickback law make it illegal for prescription drug manufacturer to knowingly and willingly solicit offer receive or pay any remuneration in exchange for or to induce the referral of business reimbursed by federal healthcare program including the purchase or prescription of particular drug false claim law generally prohibit anyone from knowingly presenting or causing to be presented false or fraudulent claim for payment by federal and certain state payer including medicare and medicaid or knowingly making using or causing to be made or used false record or statement material to false or fraudulent claim in addition fda regulates written and verbal communication about our product in addition to federal law state also have consumer protection and false claim law due to the breadth of the statutory provision and the attention being given to them by law enforcement authority our sale marketing patient support medical clinical and public affair activity may be subject to scrutiny under these law for example recently ha been enhanced scrutiny by government enforcement authority of company sponsored patient assistance program including co pay assistance program and manufacturer donation to third party charity that provide such assistance reimbursement support offering clinical education program and promotional speaker program similarly in europe interaction between pharmaceutical company and physician are subject to strict law regulation industry self regulation code of conduct and physician code of professional conduct applicable including the eu member state anti corruption law and the uk bribery act in addition the foreign corrupt practice act and similar worldwide anti bribery law generally prohibit company and their intermediary from making improper payment for the purpose of obtaining or retaining business our policy mandate compliance with these anti bribery law we operate in part of the world that have experienced governmental corruption to some degree in certain circumstance strict compliance with anti bribery law may conflict with local custom and practice or may require to interact with doctor and hospital some of which may be state controlled in manner that is different than local custom despite our training and compliance program our internal control policy and procedure may not protect from unlawful act committed by our employee or agent violation of fraud and abuse law or anti bribery law may be punishable by criminal and or civil sanction including fine and civil monetary penalty well the possibility of exclusion from federal health care program including medicare and medicaid violation can also lead to the imposition of corporate integrity agreement or similar government oversight program even if we disagree with the government perspective that we have violated any rule or guidance any similar violation by our competitor could also negatively impact the reputation of our industry and increase governmental and public scrutiny over our business and our product for more information see item risk factor we are impacted by evolving law regulation and legislative or regulatory action applicable to the health care industry environmentwe are subject to number of law and regulation that require compliance with federal state and local regulation for the protection of the environment the regulatory landscape continues to evolve and we anticipate additional regulation in the future law and regulation are implemented and under consideration to mitigate the effect of climate change mainly caused by greenhouse gas emission our business is not energy intensive therefore we do not anticipate being subject to cap and trade system or other mitigation measure that would materially impact our capital expenditure operation or competitive position other informationwe are subject to the information requirement of the security exchange act of exchange act therefore we file periodic report proxy and information statement and other information with security and exchange commission sec sec maintains website www sec gov that contains report proxy and information statement and other information regarding issuer that file electronically with sec our website is www gilead com through link on the investor page of our website under the financials sec filing section we make available the following filing free of charge soon reasonably practicable after they are electronically filed with or furnished to sec our annual report on form quarterly report on form current report on form and any amendment to those report filed or furnished pursuant to section or of the exchange act website reference are provided throughout this document for convenience the content on the referenced website doe not constitute part of and is not incorporated by reference into this annual report on form risk factor in evaluating our business you should carefully consider the following discussion of material risk event and uncertainty that make an investment in speculative or risky in addition to the other information in this annual report on form manifestation of any of the following risk and uncertainty could in circumstance we may or may not be able to accurately predict materially and adversely affect our business and operation growth reputation including the commercial or scientific reputation of our product prospect product pipeline and sale operating and financial result financial condition cash flow liquidity and stock price we note these factor for investor permitted by the private security litigation reform act of it is not possible to predict or identify all such factor our operation could also be affected by factor event or uncertainty that are not presently known to or that we currently do not consider to present significant risk to our operation therefore you should not consider the following risk to be complete statement of all the potential risk or uncertainty that we face product and commercialization riskscertain of our product subject to additional or heightened risk hivwe receive substantial portion of our revenue from sale of our product for the treatment and prevention of hiv infection during the year ended december sale of our hiv product accounted for approximately of our total product sale we may be unable to sustain or increase sale of our hiv product for any number of reason including market share gain by competitive product including generic or the inability to introduce new hiv medication necessary to remain competitive in such case we may need to scale back our operation including our future drug development and spending on research and development effort for example many of our hiv product contain tenofovir alafenamide taf which belongs to the nucleoside class of antiviral therapeutic if there are any change to the treatment or prevention paradigm for hiv that cause nucleoside based therapeutic to fall of favor our hiv product sale would be adversely impacted veklurywe face risk related to our supply and distribution of veklury which wa approved by food and drug administration fda in october treatment for patient hospitalized with coronavirus disease covid in january treatment for non hospitalized adult and adolescent patient who are at high risk of progression to severe covid including hospitalization or death and in april treatment for pediatric patient who are day of age and older weighing at least kg and are either hospitalized with covid or have mild to moderate covid and are considered at high risk for progression to severe covid including hospitalization or death while veklury sale generally reflect covid related rate and severity of infection and hospitalization well the availability uptake and effectiveness of vaccine and alternative treatment for covid we are unable to accurately predict our revenue or supply need over the short and long term due to the dynamic nature of the covid pandemic if we do not accurately forecast demand or manufacture veklury at level to align with actual demand then we may experience product shortage or build excess inventory that may need to be written off we also remain subject to significant public attention and scrutiny over the complex decision made regarding clinical data supply allocation distribution and pricing of veklury all of which affect our corporate reputation cell therapyadvancing novel and personalized therapy such yescarta or tecartus which are chimeric antigen receptor car cell therapy creates significant challenge including educating and certifying medical personnel regarding the procedure and the potential side effect such cytokine release syndrome and neurologic toxicity in compliance with the risk evaluation and mitigation strategy program required by fda securing sufficient supply of other medication to manage side effect such tocilizumab and corticosteroid which may not be available in sufficient quantity may not adequately control the side effect and or may have detrimental impact on the efficacy of cell therapy developing and maintaining robust and reliable process for engineering patient cell in our facility and infusing them back into the patient and conditioning patient with chemotherapy in advance of administering our therapy which may increase the risk of adverse side effect use of engineered cell potential cancer treatment is recent development and may not be broadly accepted by physician patient hospital cancer treatment center payer and others in the medical community while fda ha approved some cell therapy including yescarta and tecartus we must continue to demonstrate to the medical community the potential advantage of cell therapy compared to existing and future therapeutic for challenge related to the reimbursement of yescarta and tecartus see also our existing product are subject to reimbursement pressure from government agency and other third party required rebate and other discount on our product and other pricing pressure we rely on third party site to collect patient white blood cell known apheresis center well shipper courier and hospital for the logistical collection of patient white blood cell and ultimate delivery of yescarta and tecartus to patient these vendor may encounter disruption or difficulty that could result in product loss and regulatory action apheresis center may also choose not to participate in our quality certification process or we may be unable to complete such certification in timely manner or at all which could delay or constrain our manufacturing and commercialization effort we operate new automated car cell therapy manufacturing facility in frederick maryland which received fda approval for commercial production in april we have not previously manufactured our product in an automated facility on commercial scale and result we may require additional time and resource in order to effectively increase manufacturing capacity we also operate new retroviral vector manufacturing facility in oceanside california which received fda approval for commercial production in october we also have not previously manufactured viral vector on commercial scale and result we may require additional time and resource in order to effectively increase manufacturing capacity in addition we may not be able to produce or otherwise obtain an amount of viral vector supply sufficient to satisfy demand for our finished product if we are unable to meet product demand we will have difficulty meeting sale forecast for our finished product our success depends on developing and commercializing new product or expanding the indication for existing product if we are unable to launch commercially successful new product or new indication for existing product our business will be adversely impacted the launch of commercially successful product is necessary to grow our business cover our substantial expense and offset revenue loss when existing product lose market share due to factor such competition and loss of patent exclusivity there are many difficulty and uncertainty inherent in drug development and the introduction of new product the product development cycle is characterized by significant investment of resource long lead time and unpredictable outcome due to the nature of developing medicine for human use we expend significant time and resource on our product pipeline without any assurance that we will recoup our investment or that our effort will be commercially successful high rate of failure is inherent in the discovery and development of new product and failure can occur at any point in the process including late in the process after substantial investment we face challenge in accurately forecasting sale because of the difficulty in predicting demand for our product and fluctuation in purchasing pattern or wholesaler inventory we may be unable to accurately predict demand for our product including the uptake of new product demand depends on number of factor for example product demand may be adversely affected if physician do not see the benefit of our product additionally the non retail sector in the which includes government institution including state aid drug assistance program the department of veteran affair correctional facility and large health maintenance organization tends to be le consistent in term of buying pattern and often cause quarter over quarter fluctuation that do not mirror actual patient demand for our product federal and state budget pressure well the annual grant cycle for federal and state fund may cause purchasing pattern to not reflect patient demand for our product we expect to continue to experience fluctuation in the purchasing pattern of our non retail customer in light of the budget crisis faced by many european country we have observed variation in purchasing pattern induced by cost containment measure in europe we believe these measure have caused some government agency and other purchaser to reduce inventory of our product in the distribution channel and we may continue to see this trend in the future sell and distribute most of our product in the exclusively through the wholesale channel for the year ended december approximately of our product sale in the were to three wholesaler amerisourcebergen corporation cardinal health inc and mckesson corporation the wholesaler with we have entered into inventory management agreement make estimate to determine end user demand and may not be accurate in matching their inventory level to actual end user demand result change in inventory level held by those wholesaler can cause our operating result to fluctuate unexpectedly if our sale to these wholesaler do not match end user demand in addition inventory is held at retail pharmacy and other non wholesaler location with whom we have no inventory management agreement and no control over buying pattern adverse change in economic condition increased competition or other factor may cause retail pharmacy to reduce their inventory of our product which would reduce their order from wholesaler and consequently the wholesaler order from even if end user demand ha not changed in addition we have observed that strong wholesaler and sub wholesaler purchase of our product in the fourth quarter typically result in inventory draw down by wholesaler and sub wholesaler in the subsequent first quarter inventory in the distribution channel fluctuates from quarter to quarter we may continue to see fluctuation in our earnings and mismatch between prescription demand for our product and our revenue we face significant competition from global pharmaceutical and biotechnology company specialized pharmaceutical firm and generic drug manufacturer new branded or generic product entering major market affect our ability to maintain pricing and market share our product compete with other available product based primarily on efficacy safety tolerability acceptance by doctor ease of patient compliance ease of use price insurance and other reimbursement coverage distribution and marketing number of company are pursuing the development of product and technology that may be competitive with our existing product or research program these competing company include large pharmaceutical and biotechnology company and specialized pharmaceutical firm acting either independently or together with other such company furthermore academic institution government agency and other public and private organization conducting research may seek patent protection or may establish collaborative arrangement for competitive product or program we may be adversely impacted if any of these competitor gain market share result of new technology commercialization strategy or otherwise our existing product are subject to reimbursement pressure from government agency and other third party required rebate and other discount on our product and other pricing pressure product reimbursementssuccessful commercialization of our product depends in part on the availability and amount of third party payer reimbursement for our product and related treatment and medical service in the market where we sell our product our product mature pricing pressure from private insurer and government payer often result in reduction of the net product price legislative and regulatory action affecting government prescription drug procurement and reimbursement program occur relatively frequently for example in september fda issued final rule implementing pathway for the importation of certain prescription drug from canada this rule is subject to ongoing litigation we may be adversely impacted by any such legislative and regulatory action though it is difficult to predict the impact if any on the use and reimbursement of our product product pricing discount and rebatesin the the european union eu and other significant or potentially significant market for our product and product candidate government authority and third party payer are increasingly attempting to limit or regulate the price of medical product and service the volume of drug pricing related legislation ha dramatically increased in recent year including congress ha enacted law requiring manufacturer refund on certain amount of discarded drug from single use vial beginning in and eliminating the existing cap on medicaid rebate amount beginning in congress ha enacted the inflation reduction act of the act which among other change requires the department of health and human service to negotiate medicare price for certain drug starting with drug in adding drug in and and adding drug in and subsequent year imposes an inflation based rebate on medicare part utilization starting in and part utilization beginning october and restructures the medicare part benefit to cap out of pocket expense for part beneficiary beginning in and effective january increase part plan contribution in the catastrophic coverage phase and increase manufacturer discount contribution across coverage phase such that manufacturer must pay discount in the initial coverage phase and discount in the catastrophic phase on drug utilized by all part beneficiary including low income subsidy patient we continue to evaluate the impact of the act on our business but expect the act will increase our payment obligation under the redesigned part discount program limit the price we can charge and increase the rebate we must provide government program for our product thereby reducing our profitability and negatively impacting our financial result in addition it is unclear how certain provision of the act will be implemented there may be additional legislation or rulemaking related to the act and select provision may become subject to legal challenge in the future therefore the full impact of the act on the profitability of our business and the pharmaceutical industry whole remains uncertain at this time many state legislature are considering or have already passed into law legislation that seek to indirectly or directly regulate pharmaceutical drug pricing such requiring manufacturer to publicly report proprietary pricing information creating review board for price and encouraging the use of generic drug these initiative and such other legislation may cause added pricing pressure on our product and the resulting impact on our business is uncertain many country outside the including the eu member state have established complex and lengthy procedure to obtain price approval and coverage reimbursement and periodically review their pricing and reimbursement decision the outcome of these review can not be predicted and could have an adverse effect on the pricing and reimbursement of our medical product in the eu member state reduction in the pricing of our medical product in one member state could affect the price in other member state and have negative impact on our financial result substantial portion of our product sale is subject to significant discount from list price including rebate that we may be required to pay state medicaid agency and discount provided to covered entity under section of the public health service act change to the program or the medicaid program at the federal or state level could have material adverse effect on our business for example the continued growth of the program limit the price we may charge on an increasing percentage of sale change to the calculation of rebate under the medicaid program could substantially increase our medicaid rebate obligation and decrease the price we charge covered entity we recently implemented contract pharmacy integrity initiative for our branded hepatitis virus hcv product this integrity initiative will not involve any product from asegua therapeutic llc our integrity initiative requires covered entity that enter into bill to ship to arrangement with contract pharmacy for our branded hcv product to provide claim level data for unit dispensed from such contract pharmacy covered entity without an in house pharmacy that choose not to participate in the initiative can designate single contract pharmacy for shipment certain manufacturer that have implemented other contract pharmacy integrity program have received enforcement letter from the department of health and human service hhs asserting that those program violate the statute have been referred to the hhs office of inspector general for assessment of civil monetary penalty and have been subject to administrative dispute resolution proceeding brought on behalf of covered entity these manufacturer are currently challenging hhs position in ongoing litigation although we believe that our integrity initiative complies with the requirement of the statute additional legal or legislative development with respect to the program including potential litigation with hhs may negatively impact our ability to implement or continue our integrity initiative in addition standard reimbursement structure may not adequately reimburse for innovative therapy for example beginning in fiscal year cm established new severity adjusted diagnosis related group drg for medicare inpatient reimbursement of car cell product such yescarta and tecartus while the new drg ha significantly higher base payment amount than the prior drg the payment available may not be sufficient to reimburse some hospital for their cost of care for patient receiving yescarta and tecartus when reimbursement is not aligned well to account for treatment cost medicare beneficiary may be denied access this misalignment could impact the willingness of some hospital to offer the therapy and of doctor to recommend the therapy additionally in the eu there are barrier to reimbursement in individual country that could limit the uptake of yescarta and tecartus moreover we estimate the rebate we will be required to pay in connection with sale during particular quarter based on claim data from prior quarter in the actual rebate claim are typically made by payer one to three quarter in arrears actual claim and payment may vary significantly from our estimate may experience adverse impact resulting from the importation of our product from lower price market or the distribution of illegally diverted or counterfeit version of our product price for our product are based on local market economics and competition and sometimes differ from country to country our sale in country with relatively higher price may be reduced if product can be imported and resold into those country from lower price market for example sale could also be affected if fda permit importation of drug from canada we have entered into agreement with generic drug manufacturer well licensing agreement with the medicine patent pool united nation backed public health organization which allow generic drug manufacturer to manufacture generic version of certain of our product for distribution in certain low and middle income country we may be adversely affected if any generic version of our product whether or not produced and or distributed under these agreement are exported to the the eu or market with higher price in the eu we are required to permit product purchased in one eu member state to be sold in another member state purchase of our product in member state where our selling price are relatively low for resale in member state in which our selling price are relatively high can affect the inventory level held by our wholesaler and can cause the relative sale level in the various country to fluctuate from quarter to quarter and not reflect the actual consumer demand in any given quarter additionally diverted product may be used in country where they have not been approved and patient may source the diverted product outside the legitimate supply chain these diverted product may be handled shipped and stored inappropriately which may affect the efficacy of the product and could harm patient and adversely impact we are also aware of the existence of various supplier around the world that without gilead authorization purport to source our product and generic version of our product and sell them for use in country where those product have not been approved result patient may be at risk of taking unapproved medication that may not be they purport to be may not have the potency they claim to have or may contain harmful substance which could harm patient and adversely impact further third party have illegally distributed and sold and may continue to illegally distribute and sell illegally diverted and counterfeit version of our medicine which do not meet the rigorous quality standard of our manufacturing and supply chain for example part of civil enforcement lawsuit in coordination with law enforcement and pursuant to court order we seized thousand of bottle of gilead labeled medication with counterfeit supply chain documentation our investigation revealed that pharmaceutical distributor that are not authorized by gilead to sell gilead medicine sold purportedly genuine gilead medicine sourced from an illegal counterfeiting scheme to independent pharmacy nationwide illegally diverted and counterfeit version of gilead branded medicine exist and may pose serious risk to patient health and safety our action to stop or prevent the distribution and sale of illegally diverted and counterfeit version of our medicine around the world may be costly and unsuccessful which may adversely affect patient and our reputation and business including our product revenue and financial result product development and supply chain riskswe face risk in our clinical trial including the potential for unfavorable result delay in anticipated timeline and disruption we are required to demonstrate the safety and efficacy of product candidate that we develop for each intended use through extensive preclinical study and clinical trial the result from these study do not always accurately predict result in later large scale clinical trial even successfully completed large scale clinical trial may not result in marketable product we face numerous risk and uncertainty with our clinical trial that could result in delay or prevent completion of the development and approval of our product candidate including challenge in clinical trial protocol design our ability to enroll patient in clinical trial the possibility of unfavorable or inadequate trial result to support further development of our product candidate including failure to meet trial primary endpoint safety issue arising from our clinical trial and the need to modify or delay our clinical trial or to perform additional trial for example in october we announced that fda issued complete response letter for our biologics license application for bulevirtide for the treatment of adult with hepatitis delta virus infection in addition see note goodwill and intangible asset of the note to consolidated financial statement included in part ii item of this annual report on form for discussion of the partial in process research and development impairment charge that we recognized during the three month ended march related to asset we acquired from immunomedics inc immunomedics in result we may be unable to successfully complete our clinical trial on our anticipated timeline or at all based on trial result it is possible that fda and other regulatory authority do not approve our product candidate or that any market approval include significant limitation on the product use in addition clinical trial involving our commercial product can raise new safety issue for our existing product which could adversely impact our business further we may make strategic decision to discontinue development of our product candidate if for example we believe commercialization will be difficult relative to other opportunity in our pipeline therefore our product candidate may never be successfully commercialized and we may be unable to recoup the significant and clinical trial expense incurred we expect to expend significant time and resource on our clinical trial activity without any assurance that we will recoup our investment or that our effort will be commercially successful there are also risk associated with the use of third party in our clinical trial activity we extensively outsource our clinical trial activity and usually perform only small portion of the start up activity in house we rely on independent third party contract research organization cro to perform most of our clinical study including document preparation site identification screening and preparation pre study visit training program management patient enrollment ongoing monitoring site management and bioanalytical analysis many important aspect of the service performed for by the cro are out of our direct control if there is any dispute or disruption in our relationship with our cro our clinical trial may be delayed moreover in our regulatory submission we rely on the quality and validity of the clinical work performed by third party cro if any of our cro process methodology or result were determined to be invalid or inadequate our own clinical data and result and related regulatory approval may be adversely affected we may face manufacturing difficulty delay or interruption including at our third party manufacturer and corporate partner our product which are manufactured at our own facility or by third party manufacturer and corporate partner are the result of complex highly regulated manufacturing process we depend on third party manufacturer and corporate partner to perform manufacturing activity effectively and on timely basis for the majority of our active pharmaceutical ingredient and drug product these third party are independent entity subject to their own unique operational and financial risk that are out of our control we and our third party manufacturer and corporate partner are subject to good manufacturing practice gmp which are extensive regulation governing manufacturing process stability testing record keeping and quality standard defined by fda and european medicine agency ema well comparable regulation in other jurisdiction manufacturing operation are also subject to routine inspection by regulatory agency any adverse development affecting or resulting from our manufacturing operation or the operation of our third party manufacturer and corporate partner may result in shipment delay inventory shortage lot failure product withdrawal or recall or other interruption in the commercial supply of our product we have incurred and will continue to incur inventory write off charge and other expense for product that fail to meet specification and quality standard and we may need to undertake costly remediation effort or seek more costly manufacturing alternative such development could increase our manufacturing cost cause to lose revenue or market share and damage our reputation in addition manufacturing issue may cause delay in our clinical trial and application for regulatory approval for example if we are unable to remedy any deficiency cited by fda or other regulatory agency in their inspection our existing product and the timing of regulatory approval of product candidate in development could be adversely affected further there is risk that regulatory agency in other country where marketing application are pending will undertake similar additional review or apply heightened standard of review which could delay the regulatory approval for product in those country our business may be adversely affected if approval of any of our product candidate were delayed or if production of our product were interrupted we may not be able to obtain material or supply necessary to conduct clinical trial or to manufacture and sell our product which could limit our ability to generate revenue we need access to certain supply and product to conduct our clinical trial and to manufacture and sell our product if we are unable to purchase enough of these material or find suitable alternative material in timely manner our development effort for our product candidate may be delayed or our ability to manufacture and sell our product could be limited of key component and material must be named in the new drug application or marketing authorization application filed with the regulatory authority for any product candidate for which we are seeking marketing approval and significant delay can occur if the qualification of new supplier is required even after manufacturer is qualified by the regulatory authority the manufacturer must continue to expend time money and effort in the area of production and quality control to maintain full compliance with gmp manufacturer are subject to regular periodic inspection by regulatory authority following initial approval if result of these inspection regulatory authority determines that the equipment facility laboratory or process do not comply with applicable regulation and condition of product approval the regulatory authority may suspend the manufacturing operation if the manufacturing operation of any of the single supplier for our product are suspended we may be unable to generate sufficient quantity of commercial or clinical supply of product to meet market demand in addition if delivery of material from our supplier are interrupted for any reason we may be unable to ship certain of our product for commercial supply or to supply our product candidate in development for clinical trial also some of our product and the material that we utilize in our operation are manufactured by only one supplier or at only one facility which we may not be able to replace in timely manner and on commercially reasonable term or at all problem with any of the single supplier or facility we depend on including in the event of disaster such an earthquake equipment failure or other difficulty may negatively impact our development and commercialization effort significant portion of the raw material and intermediate used to manufacture our antiviral product are supplied by third party manufacturer and corporate partner outside of the result any political or economic factor in specific country or region including any change in or interpretation of trade regulation compliance requirement or tax legislation that would limit or prevent third party outside of the from supplying these material could adversely affect our ability to manufacture and supply our antiviral product to meet market need and have material and adverse effect on our operating result if we were to encounter any of these difficulty our ability to conduct clinical trial on product candidate and to manufacture and sell our product could be impaired regulatory and other legal risksour operation depend on compliance with complex fda and comparable international regulation failure to obtain broad approval on timely basis or to maintain compliance could delay or halt commercialization of our product the product we develop must be approved for marketing and sale by regulatory authority and once approved are subject to extensive regulation by fda ema and comparable regulatory agency in other country we have filed and anticipate that we will continue to file for marketing approval in additional country and for additional indication and product these and any future marketing application we file may not be approved by the regulatory authority on timely basis or at all even if marketing approval is granted for these product there may be significant limitation on their use we can not state with certainty when or whether any of our product candidate under development will be approved or launched whether we will be able to develop license or acquire additional product candidate or product or whether any product once launched will be commercially successful further how we manufacture and sell our product is subject to extensive regulation and review for example under fda rule we are often required to conduct post approval clinical study to ass known serious risk signal of serious risk or to identify an unexpected serious risk in certain circumstance we may be required to implement risk evaluation and mitigation strategy program for our product which could include medication guide patient package insert communication plan to healthcare provider restriction on distribution or use of product and other element fda deems necessary to assure safe use of the drug discovery of previously unknown problem with our marketed product or product candidate including serious safety resistance or drug interaction issue or problem with our manufacturing safety reporting or promotional activity may result in regulatory approval being delayed denied or granted with significant restriction on our product including limitation on or the withdrawal of the product from the market failure to comply with these or other requirement imposed by fda could result in significant civil monetary penalty fine suspension of regulatory approval product recall seizure of product and criminal prosecution are impacted by evolving law regulation and legislative or regulatory action applicable to the healthcare industry the healthcare industry is subject to various federal state and international law and regulation pertaining to drug reimbursement rebate price reporting healthcare fraud and abuse and data privacy and security in the these law include anti kickback and false claim law law and regulation relating to the medicare and medicaid program and other federal and state program such the medicaid rebate statute and the statute law that regulate written and verbal communication about our product individual state law relating to pricing and sale and marketing practice the health insurance portability and accountability act and other federal and state law relating to the privacy and security of health information actual or alleged violation of these law or any related regulation may be punishable by criminal and or civil sanction including in some instance substantial fine civil monetary penalty exclusion from participation in federal and state healthcare program including medicare medicaid and department of veteran affair and department of defense health program action executive overseeing our business and significant remediation measure negative publicity or other consequence these law and regulation are broad in scope and subject to changing and evolving interpretation which could require to incur substantial cost associated with compliance or to alter one or more of our sale or marketing practice the resulting impact on our business is uncertain and could be material in addition government price reporting and payment regulation are complex and we are continually assessing the method by which we calculate and report pricing in accordance with these obligation our methodology for calculation are inherently subjective and may be subject to review and challenge by various government agency which may disagree with our interpretation if the government disagrees with our reported calculation we may need to restate previously reported data and could be subject to additional financial and legal liability there also continues to be enhanced scrutiny of company sponsored patient assistance program including co pay assistance program and manufacturer donation to third party charity that provide such assistance there ha also been enhanced scrutiny by government on reimbursement and other patient support offering clinical education program and promotional speaker program if we or our agent and vendor are deemed to have failed to comply with law regulation or government guidance in any of these area we could be subject to criminal or civil sanction any similar violation by our competitor could also negatively impact our industry reputation and increase scrutiny over our business and our product for description of our government investigation and related litigation see note commitment and contingency of the note to consolidated financial statement included in part ii item of this annual report on form we are subject to risk if significant safety issue arise for our marketed product or our product candidate additional study are conducted after obtaining marketing approval for our product and our product are used over longer period of time by many patient including patient with underlying health problem or those taking other medicine we expect to continue finding new issue related to safety resistance or drug interaction any such issue may require change to our product label such additional warning contraindication or even narrowed indication or to halt sale of product regulatory authority have been moving towards more active and transparent pharmacovigilance and are making greater amount of stand alone safety information and clinical trial data directly available to the public through website and other mean such periodic safety update report summary risk management plan summary and various adverse event data safety information without the appropriate context and expertise may be misinterpreted and lead to misperception or legal action our success depends to significant degree on our ability to obtain and defend our patent and other intellectual property right both domestically and internationally and to operate without infringing upon the patent or other proprietary right of third party patent and other proprietary right are very important to our business part of our business strategy we actively seek patent protection both in the and internationally and file additional patent application when appropriate to cover improvement in our compound product and technology our success depends to significant degree on our ability to obtain patent and license to patent right preserve trade secret and internal know how defend against infringement of our patent and effort to invalidate them and operate without infringing on the intellectual property of others patent application are confidential for period of time after filing we may not know if our competitor have filed application for technology covered by our pending application or if we were the first to invent or first to file an application directed toward the technology that is the subject of our patent application if competitor file patent application covering our technology we may have to participate in litigation post grant proceeding before the patent and trademark office or other proceeding to determine the right to patent or validity of any patent granted such litigation and proceeding are unpredictable and expensive and could divert management attention from other operation such that even if we are ultimately successful we may be adversely impacted patent covering our existing compound product and process and those that we will likely file in the future may not provide complete or adequate protection filing patent application is fact intensive and complex process we may file patent application that ultimately do not result in patent or have patent that do not provide adequate protection for the related product future litigation or other proceeding regarding the enforcement or validity of our existing patent or any future patent could result in the invalidation of our patent or substantially reduce their protection in addition we may face criticism result of our legitimate use of the patent system to protect our investment in new and useful innovation in medicine generic manufacturer have sought and may continue to seek fda approval to market generic version of our product through an abbreviated new drug application anda the application process typically used by manufacturer seeking approval of generic drug for description of our anda litigation see note commitment and contingency of the note to consolidated financial statement included in part ii item of this annual report on form anda litigation and related settlement and license agreement in some case may result in loss of exclusivity for our patent sooner than we would otherwise expect in addition loss of exclusivity may be earlier than expected under these settlement and license agreement under certain circumstance for example settlement and license agreement with generic manufacturer typically include acceleration clause that permit generic entry before the agreed upon entry date in certain circumstance and generic manufacturer may continue to challenge the patent protecting our product the entry of generic version of our product ha and may in the future lead to market share and price erosion if we are found to infringe the valid patent of third party we may be required to pay significant monetary damage or we may be prevented from commercializing product or may be required to obtain license from these third party we may not be able to obtain alternative technology or any required license on commercially reasonable term or at all if we fail to obtain these license or alternative technology we may be unable to develop or commercialize some or all of our product for example we are aware of patent and patent application owned by other party that such party may claim to cover the use of our product and research activity for description of our pending patent litigation see note commitment and contingency of the note to consolidated financial statement included in part ii item of this annual report on form furthermore we also rely on unpatented trade secret and improvement unpatented internal know how and technological innovation we protect these right mainly through confidentiality agreement with our corporate partner employee consultant and vendor we can not be certain that these party will comply with these confidentiality agreement that we have adequate remedy for any breach or that our trade secret internal know how or technological innovation will not otherwise become known or be independently discovered by our competitor under some of our agreement invention become jointly owned by and our corporate partner and in other case become the exclusive property of one party in certain circumstance it can be difficult to determine who owns particular invention and dispute could arise regarding those invention we could be adversely affected if our trade secret internal know how technological innovation or confidential information become known or independently discovered by competitor or if we enter into dispute over ownership of invention we face potentially significant liability and increased expense from litigation and government investigation relating to our product and operation we are involved in number of litigation investigation and other dispute related matter that require to expend substantial internal and financial resource these matter could require to pay significant monetary amount including royalty payment for past and future sale for example on february we reached an agreement with viiv healthcare company and related party collectively viiv for global resolution of all claim related to our sale of biktarvy pursuant to which gilead agreed to make one time payment of billion and an ongoing royalty at rate of on future sale of biktarvy and the bictegravir component of bictegravir containing product in the october and viiv granted gilead broad worldwide license and covenant not to sue relating to any past present or future development or commercialization of bictegravir we expect these matter will continue to require high level of internal and financial resource for the foreseeable future these matter have reduced and are expected to continue to reduce our earnings and require significant management attention addition the testing manufacturing marketing and use of our commercial product well product candidate in development involve substantial risk of product liability claim these claim may be made directly by consumer healthcare provider pharmaceutical company or others we have limited insurance for product liability that may arise and claim may exceed our coverage for description of our litigation investigation and other dispute related matter see note commitment and contingency of the note to consolidated financial statement included in part ii item of this annual report on form the outcome of such legal proceeding or any other legal proceeding that may be brought against the investigation or any other investigation that may be initiated and any other dispute related matter are inherently uncertain and adverse development or outcome can result in significant expense monetary damage penalty or injunctive relief against operational risksour business ha been and may in the future be adversely affected by outbreak of epidemic pandemic or contagious disease including the ongoing covid pandemic actual or threatened outbreak of epidemic pandemic or contagious disease or other public health emergency may significantly disrupt our global operation and adversely affect our business financial condition and result of operation we have seen with the covid pandemic outbreak can result in global supply chain and logistics disruption and distribution constraint the impact of an outbreak or other public health crisis on our result of operation and financial condition would depend on numerous evolving factor but could involve higher operating expense lower demand for our product result of governmental business and individual action taken in response to such an event including quarantine travel restriction and interruption to healthcare service which can impact enrollment in or operation of our clinical trial or limit patient ability or willingness to access and seek care challenge associated with the safety of our employee and safe occupancy of our job site and financial market volatility and significant macroeconomic uncertainty in global market an outbreak or public health emergency also could amplify many of the other risk described throughout the risk factor section of this annual report on form we face risk associated with our global operation our global operation are accompanied by certain financial political economic and other risk including those listed below foreign currency exchange for the year ended december approximately of our product sale were outside the because significant percentage of our product sale is denominated in foreign currency primarily the euro we face exposure to adverse movement in foreign currency exchange rate overall we are net receiver of foreign currency and therefore we benefit from weaker dollar and are adversely affected by stronger dollar our hedging program doe not eliminate our exposure to currency fluctuation we may be adversely impacted if the dollar appreciates significantly against certain currency and our hedging program doe not sufficiently offset the effect of such appreciation for example see part ii item of this annual report on form for discussion of our exposure to movement in foreign currency exchange rate primarily in the euro and the impact from foreign currency exchange net of hedge for the year ended december interest rate and inflation we hold interest generating asset and interest bearing liability including our available for sale debt security and our senior unsecured note and credit facility fluctuation in interest rate including the federal reserve recent increase in interest rate could expose to increased financial risk in addition high inflation such what we are seeing in the current economic environment ha adversely impacted and may continue to adversely impact our business and financial result anti bribery we are subject to the foreign corrupt practice act and similar worldwide anti bribery law that govern our international operation with respect to payment to government official our international operation are heavily regulated and require significant interaction with foreign official we operate in part of the world that have experienced governmental corruption to some degree in certain circumstance strict compliance with anti bribery law may conflict with local custom and practice or may require to interact with doctor and hospital some of which may be state controlled in manner that is different than local custom it is possible that certain of our practice may be challenged under these law in addition our internal control policy and procedure may not protect from reckless or criminal act committed by our employee and agent enforcement activity under anti bribery law could subject to administrative and legal proceeding and action which could result in civil and criminal sanction including monetary penalty and exclusion from healthcare program risk inherent in conducting global business include restrictive government action against our intellectual property and other foreign asset such nationalization expropriation the imposition of compulsory license or similar action including waiver of intellectual property protection protective economic policy taken by foreign government such trade protection measure and import and export licensing requirement which may result in the imposition of trade sanction or similar restriction by the or other government business interruption stemming from natural or man made disaster such climate change earthquake hurricane flooding fire extreme heat drought or actual or threatened public health emergency or effort taken by third party to prevent or mitigate such disaster such public safety power shutoffs and facility shutdown for which we may not have sufficient insurance for example our corporate headquarters in foster city and certain and manufacturing facility are located in california seismically active region in the event of major earthquake we may not carry sufficient earthquake insurance and significant recovery time could be required to resume operation political instability or disruption in geographic region where we operate regardless of cause including war terrorism social unrest and political change including in china russia and ukraine our aspiration goal and disclosure related to environmental social and governance esg matter expose to numerous risk including risk to our reputation and stock price institutional and individual investor are increasingly using esg screening criterion to determine whether gilead qualifies for inclusion in their investment portfolio we are frequently asked by investor and other stakeholder to set ambitious esg goal and provide new and more robust disclosure on goal progress toward goal and other matter of interest to esg stakeholder in response we have adapted the tracking and reporting of our corporate responsibility program to various evolving esg framework and we have established and announced goal and other objective related to esg matter these goal statement reflect our current plan and aspiration and are not guarantee that we will be able to achieve them our effort to accomplish and accurately report on these goal and objective present numerous operational reputational financial legal and other risk any of which could have material negative impact including on our reputation and stock price our ability to achieve any goal or objective including with respect to environmental and diversity initiative is subject to numerous risk many of which are outside of our control example of such risk include the availability and cost of low or non carbon based energy source and technology evolving regulatory requirement affecting esg standard or disclosure the availability of supplier that can meet our sustainability diversity and other standard our ability to recruit develop and retain diverse talent in our labor market and the impact of our organic growth and acquisition or disposition of business or operation the standard for tracking and reporting on esg matter are relatively new have not been harmonized and continue to evolve our selection of disclosure framework that seek to align with various reporting standard may change from time to time and may result in lack of consistent or meaningful comparative data from period to period in addition regulatory authority may impose mandatory disclosure requirement with respect to esg matter for example in march security and exchange commission sec proposed rule change that would require company to make certain climate related disclosure including information about climate related risk greenhouse gas emission and certain climate related financial statement metric our process and control may not reflect evolving standard for identifying measuring and reporting esg matter immediately or at all our interpretation of reporting standard may differ from those of others and such standard may change over time any of which could result in significant revision to our goal or reported progress in achieving such goal in addition enhancement to our process and control to reflect evolving reporting standard may be costly and require additional resource if our esg practice do not meet evolving investor or other stakeholder expectation and standard then our reputation our ability to attract or retain employee and our attractiveness an investment business partner or acquiror could be negatively impacted similarly our failure or perceived failure to pursue or fulfill our goal target and objective or to satisfy various reporting standard within the timeline we announce or at all could also have similar negative impact and expose to government enforcement action and private litigation we depend on relationship with third party for sale and marketing performance technology development logistics and commercialization of product failure to maintain these relationship poor performance by these company or dispute with these third party could negatively impact our business we rely on number of collaborative relationship with third party for our sale and marketing performance in certain territory in some country we rely on international distributor for sale of certain of our product some of these relationship also involve the clinical development of these product by our partner reliance on collaborative relationship pose number of risk including the risk that we are unable to control the resource our corporate partner devote to our program or product dispute may arise with respect to the ownership of right to technology developed with our corporate partner disagreement with our corporate partner could cause delay in or termination of the research development or commercialization of product candidate or result in litigation or arbitration contract with our corporate partner may fail to provide significant protection or may fail to be effectively enforced if one of these partner fails to perform our corporate partner have considerable discretion in electing whether to pursue the development of any additional product and may pursue alternative technology or product either on their own or in collaboration with our competitor our corporate partner with marketing right may choose to pursue competing technology or to devote fewer resource to the marketing of our product than they do to product of their own development and our distributor and our corporate partner may be unable to pay given these risk there is great deal of uncertainty regarding the success of our current and future collaborative effort if these effort fail our product development or commercialization of new product could be delayed or revenue from product could decline due to the specialized and technical nature of our business the failure to attract develop and retain highly qualified personnel could adversely impact our future success will depend in large part on our continued ability to attract develop and retain highly qualified scientific technical and management personnel well personnel with expertise in clinical testing governmental regulation and commercialization our ability to do so also depends in part on how well we maintain strong workplace culture that is attractive to employee in addition competition for qualified personnel in the biopharmaceutical field is intense and there is limited pool of qualified potential employee to recruit we face competition for personnel from other company university public and private research institution government entity and other organization additionally change to immigration and work authorization law and regulation could make it more difficult for employee to work in or transfer to one of the jurisdiction in which we operate significant cybersecurity incident could give rise to legal liability and regulatory action under data protection and privacy law and adversely affect our business and operation we are dependent upon information technology system infrastructure and data including our kite konnect platform which is critical to maintain chain of identity and chain of custody of yescarta and tecartus the multitude and complexity of our computer system make them inherently vulnerable to service interruption or destruction malicious intrusion and ransomware attack likewise data privacy or cybersecurity incident or breach by employee or others can result in the exposure of sensitive data including our intellectual property or trade secret or the personal information of our employee patient customer or other business partner to unauthorized person or to the public cybersecurity attack and incident are increasing in their frequency sophistication and intensity malicious actor seek to steal money gain unauthorized access to destroy or manipulate data and disrupt operation and some of their attack may not be recognized or discovered until launched or after initial entry into the environment such novel or zero day attack that are launched before patch are available and defense can be readied malicious actor are also increasingly developing method to avoid prevention detection and alerting capability including employing counter forensic tactic making response activity more difficult such attack and incident include for example the deployment of harmful malware ransomware denial of service social engineering and other mean to affect service reliability and operation and threaten data confidentiality integrity and availability our business and technology partner face similar risk and any security breach of their system could adversely affect our security posture like many company we have experienced cybersecurity incident including data breach and service interruption when cybersecurity incident occur our policy is to respond and address them in accordance with applicable governmental regulation and other legal requirement including our cybersecurity protocol there can be no assurance that our effort in response to cybersecurity incident well our investment to protect our information technology infrastructure and data will shield from significant loss brand and reputational harm and potential liability or prevent any future interruption or breach of our system such cybersecurity incident can cause the loss of critical or sensitive information including personal information and could give rise to legal liability and regulatory action under data protection and privacy law globally are also imposing new data privacy and security requirement including new and greater monetary fine for privacy violation for example the general data protection regulation gdpr established regulation regarding the handling of personal data and non compliance with the gdpr may result in monetary penalty of up to four percent of worldwide revenue in addition new domestic data privacy and security law such the california consumer privacy act and the california privacy right act and other law that have been or may be passed similarly introduce requirement with respect to personal information and non compliance with such law may result in liability through private action subject to statutorily defined damage in the event of certain data breach and enforcement other change or new law or regulation associated with the enhanced protection of personal information could greatly increase our cost of providing our product and service or even prevent from offering certain service in jurisdiction in which we operate strategic and financial riskswe are subject to risk associated with engaging in business acquisition licensing arrangement collaboration option equity investment asset divestiture and other strategic transaction we have engaged in and may in the future engage in such transaction part of our business strategy we may not identify suitable transaction in the future and if we do we may not complete such transaction in timely manner on cost effective basis or at all including the possibility that governmental entity or regulatory body may delay or refuse to grant approval for the consummation of the transaction if we are successful in making an acquisition or closing licensing arrangement or collaboration the product intellectual property and technology that are acquired or licensed may not be successful or may require significantly greater resource and investment than anticipated part of our annual impairment testing of our goodwill and other indefinite lived intangible asset in the fourth quarter and earlier if impairment indicator exist required under generally accepted accounting principle we may need to recognize impairment charge related to the product intellectual property and technology that are acquired or licensed for example result of an impairment analysis we conducted following our receipt of data in march from the phase tropic study evaluating trodelvy in patient with hormone receptor positive human epidermal growth receptor negative metastatic breast cancer we recognized partial in process research and development impairment charge on our consolidated statement of income during for option structured deal there is no assurance that we will elect to exercise our option right and it is possible that disagreement uncertainty or other circumstance may arise including with respect to whether our option right have been appropriately triggered which may hinder our ability to realize the expected benefit for equity investment in our strategic partner such in connection with our collaboration with arcus bioscience inc and galapagos nv the value of our equity investment may fluctuate and decline in value if we are not successful in the execution or implementation of these transaction our financial condition cash flow and result of operation may be adversely affected and our stock price could decline we have paid substantial amount of cash and incurred additional debt to finance our strategic transaction additional indebtedness and lower cash balance could result in downgrade of our credit rating limit our ability to borrow additional fund or refinance existing debt on favorable term increase our vulnerability to adverse economic or industry condition and reduce our financial flexibility to continue with our capital investment stock repurchase and dividend payment for example result of the cash used and the debt issued in connection with our acquisition of immunomedics in global rating downgraded our credit rating we may be adversely impacted by any failure to overcome these additional risk change in our effective income tax rate could reduce our earnings we are subject to income tax in the and various foreign jurisdiction due to economic and political condition various country are actively considering and have made change to existing tax law and we can not predict the form or timing of such change our effective tax rate are affected by change in the mix of earnings in country with differing statutory tax rate change in the valuation of deferred tax asset and liability the introduction of new tax and change in tax law regulation administrative practice and interpretation including in the germany and ireland we are also subject to the examination of our tax return and other tax matter by the internal revenue service and tax authority in various foreign jurisdiction there are differing interpretation of tax law and regulation and result significant dispute may arise with these tax authority involving issue of the timing and amount of deduction and allocation of income among various tax jurisdiction we may be adversely affected by the resolution of one or more of these exposure in any reporting period item unresolved staff comment not applicable property our corporate headquarters are located in foster city california where we house our administrative manufacturing and activity we also have administrative facility in raleigh north carolina and washington and we have facility in emeryville oceanside and santa monica california seattle washington frederick maryland morris plain new jersey edmonton canada and dublin ireland our principal manufacturing facility are in el segundo la verne oceanside and san dimas california edmonton canada cork ireland and hoofddorp netherlands for more information about our manufacturing facility see item business our manufacturing facility our global operation include office in europe north america asia south america africa australia and the middle east we believe that our existing property including both owned and leased site are adequate and suitable for the conduct of our business we believe our capital resource are sufficient to purchase lease or construct any additional facility required to meet our expected long term growth need item legal proceeding for description of our significant pending legal proceeding see note commitment and contingency legal proceeding of the note to consolidated financial statement included in part ii item of this annual report on form item mine safety disclosure not applicable ii item market for registrant common equity related stockholder matter and issuer purchase of equity security market informationour common stock is traded on the nasdaq global select market under the symbol gild holdersas of february we had approximately stockholder of record of our common stock dividendsfor the year ended december and we paid quarterly dividend we expect to continue to pay quarterly dividend although the amount and timing of any future dividend are subject to declaration by our board of director additional information is included in note stockholder equity of the note to consolidated financial statement included in item of this annual report on form security authorized for issuance under equity compensation plansthe following table provides certain information with respect to our equity compensation plan in effect of december in million except per share amount number of common share to be issued upon exercise of outstanding option and right weighted average exercise price of outstanding option and right number of common share remaining available for future issuance under equity compensation plan excluding security reflected in column plan category equity compensation plan approved by security holder equity incentive employee stock purchase plan total equity compensation plan approved by security equity compensation plan not approved by security holder ______________________________________________________ includes million restricted stock unit performance share unit and phantom share these award have no exercise price and are not included in the weighted average exercise price of outstanding award under our employee stock purchase plan participant are permitted to purchase our common stock at discount on certain date through payroll deduction within pre determined purchase period accordingly these number are not determinable graph the following graph compare our cumulative total stockholder return for the past five year to two index the standard poor stock index index and the nasdaq biotechnology index nbi index the stockholder return shown on the graph below is not necessarily indicative of future performance and we do not make or endorse any prediction to future stockholder return comparison of cumulative total return on investment for the past five year ______________________________________________________ this section is not soliciting material is not deemed filed with the security and exchange commission sec and is not to be incorporated by reference in any of our filing under the security act of amended the security act or the security exchange act of exchange act whether made before or after the date hereof and irrespective of any general incorporation language in any such filing show the cumulative return on investment assuming an investment of in our common stock the nbi index and the index on december and assuming that all dividend were reinvested issuer purchase of equity securitiesin the first quarter of our board of director authorized new billion stock repurchase program program with no fixed expiration purchase under the program may be made in the open market or in privately negotiated transaction the billion stock repurchase program authorized by our board of director in the first quarter of program wa completed in the fourth quarter of we started repurchase under the program in december of december the remaining authorized repurchase amount under the program wa billion table below summarizes our stock repurchase activity for the three month ended december total numberof sharespurchased in thousand averageprice paidper sharetotal number ofshares purchasedas part of publiclyannounced program in thousand maximum fairvalue of sharesthat may yet bepurchased underthe program in million maximum fairvalue of sharesthat may yet bepurchased underthe program in million october october november november december december total ______________________________________________________ the difference between the total number of share purchased and the total number of share purchased part of publicly announced program is due to share of common stock withheld by from employee restricted stock award in order to satisfy applicable tax withholding obligation item reserved management discussion and analysis of financial condition and result of operationsthe following discussion and analysis is intended to provide material information around event and uncertainty knownto management relevant to an assessment of the financial condition and result of operation of gilead and should therefore be read in conjunction with our audited consolidated financial statement and the accompanying note to consolidated financial statement and other disclosure included in this annual report on form including the disclosure under part item risk factor where other material event and uncertainty not otherwise discussed below are disclosed certain amount and percentage herein may not sum or recalculate due to rounding additional information related to the comparison of our result of operation between the year and is included in item management discussion and analysis of financial condition and result of operation of our form filed with the security and exchange commission sec management overviewstrategy and outlookgilead science inc gilead we our or is biopharmaceutical company that ha pursued and achieved breakthrough in medicine for more than three decade with the goal of creating healthier world for all people we are committed to advancing innovative medicine to prevent and treat life threatening disease including hiv viral hepatitis and cancer we operate in more than country worldwide with headquarters in foster city california since our strategic ambition have been to bring transformative therapy to patient by ii be the biotech employer and partner of choice and iii deliver shareholder value in sustainable and responsible manner our strategic priority for and beyond reflecting how we plan to deliver those ambition are maximize near term revenue growth ii maximize impact of long active hiv iii expand and deliver on oncology program iv champion an environment of inclusion and employee growth and remove barrier to speed in execution we plan to provide consistent execution on portfolio with quality depth and breadth including continued growth in our leading hiv portfolio which is poised to shape the long acting market following our first lenacapavir approval well strong commercial performance and clinical momentum for our fast growing oncology business key business updatesduring we continued to advance our portfolio receiving approval across various therapeutic area indication and geography we ended the year with sunlenca receiving it first approval in the for heavily treatment experienced individual following the first european market approval by the european commission ec this is the first twice yearly subcutaneous hiv medicine to be approved we also continued to broaden therapy available in oncology receiving approval for additional indication of yescarta and tecartus and the approval of trodelvy for the treatment of adult patient with unresectable locally advanced or metastatic hormone receptor positive human epidermal growth factor receptor negative hr breast cancer who have received endocrine based therapy and at least two additional systemic therapy in the metastatic setting in term of capital resource we continued to invest in our business and research and development pipeline through acquisition and collaboration we also continued to provide shareholder return in the form of dividend and share repurchase the following highlight are taken from press release recently issued reader are encouraged to review all press release available on our website at www gilead com the content on the referenced website doe not constitute part of and is not incorporated by reference into this annual report on form virology in december we announced food and drug administration fda approval of sunlenca in combination with other antiretroviral for the treatment of hiv infection in heavily treatment experienced adult with multi drug resistant hiv infection in november we announced the ec authorized an extended indication and line extension for low dosage tablet form of biktarvy for the treatment of hiv in virologically suppressed child who are at least year of age and weigh at least kg in november we announced fda approval of vemlidy for the treatment of chronic hepatitis virus hbv infection in pediatric patient year and older with compensated liver disease in october we announced that merck co inc merck and gilead plan to resume their phase study under an amended protocol the study will evaluate an investigational once weekly oral combination treatment regimen of merck islatravir at lower weekly dose and gilead lenacapavir in august we announced that ec ha granted marketing authorization for sunlenca lenacapavir for the treatment of hiv infection in combination with other antiretroviral in adult with multi drug resistant hiv infection for whom it is otherwise not possible to construct suppressive antiviral regimen in july we received positive opinion from european medicine agency ema committee for medicinal product for human use chmp for veklury to be granted full marketing authorization for the treatment of coronavirus disease covid in adult and adolescent with pneumonia requiring supplemental oxygen and adult who do not require supplemental oxygen and are at increased risk of developing severe covid in may we announced fda lifted the clinical hold placed on the investigational new drug application to evaluate injectable lenacapavir for hiv treatment and pre exposure prophylaxis following the agency review of the storage and compatibility data of lenacapavir injection with an alternate vial made from aluminosilicate glass in april fda approved supplemental new drug application for veklury for the treatment of pediatric patient under year of age for the treatment of covid oncologycell therapy in december we entered into an agreement to acquire tmunity therapeutic inc tmunity clinical stage private biotech company which will provide with preclinical and clinical program including an armored car technology platform that ha the potential to be applied to variety of car to enhance anti tumor activity well rapid manufacturing process the transaction closed in february in december we entered into strategic collaboration with arcellx inc arcellx to co develop and co commercialize cart ddbcma late stage clinical asset in development for the treatment of multiple myeloma the transaction closed in january in december we announced the transfer of the marketing authorization for yescarta in japan from daiichi sankyo co ltd to gilead in in december we received approval from the ministry of health labour and welfare in japan for yescarta for the initial treatment of relapsed or refractory large cell lymphoma lbcl in october we received european marketing authorization for yescarta use in adult with second line diffuse lbcl additionally ec granted marketing authorization for tecartus for the treatment of adult cell precursor acute lymphoblastic leukemia all and in canada we received conditional marketing authorization for yescarta for follicular lymphoma fl after two or more line of systemic therapy in july we received positive opinion from ema chmp for tecartus for the treatment of adult patient year of age and above with cell precursor all in june ec approved yescarta for the treatment of adult patient with fl after three or more line of systemic therapy in april fda approved commercial production at our new car cell therapy manufacturing facility in frederick maryland in april fda granted approval to yescarta initial treatment for adult with lbcl that is refractory to or relapse within month of first line chemoimmunotherapy other in february we announced that fda ha approved trodelvy for the treatment of adult patient with unresectable locally advanced or metastatic hr breast cancer who have received endocrine based therapy and at least two additional systemic therapy in the metastatic setting in january we announced that ema ha validated type ii variation of the marketing authorization application for trodelvy for the treatment of adult patient unresectable or metastatic hr breast cancer who have received endocrine based therapy and at least two additional systemic therapy in the metastatic setting in december we acquired the remaining right to an anti antibody developed by jounce therapeutic inc jounce for the treatment of solid tumor in october we announced strategic collaboration with macrogenics inc macrogenics to develop bispecific antibody to treat various cancer the agreement includes an upfront payment by of million to macrogenics and an exclusive option granted to on an investigational and bispecific in august we announced an agreement with everest medicine everest to transfer all development and commercialization right to gilead for trodelvy in greater china south korea and other asian market in april we entered into strategic research collaboration agreement with dragonfly therapeutic inc dragonfly to develop natural killer cell engager based immunotherapy for oncology and inflammation indication in march we announced result from the phase tropic study evaluating trodelvy in patient with hr mbc who received prior endocrine therapy cyclin dependent kinase cdk inhibitor and two to four line of chemotherapy inflammation in january we announced collaboration and licensing agreement with evoq therapeutic inc evoq to advance evoq proprietary nanodisc technology for the treatment of rheumatoid arthritis and lupus in september we completed the acquisition of mirobio ltd mirobio for million in cash mirobio is based biotechnology company focused on restoring immune balance with agonist targeting immune inhibitory receptor key financial result in million except percentage and per share amount revenue net income attributable to gilead diluted earnings per share attributable to gilead total revenue were billion in and remained relatively flat compared to primarily due to increased sale in hiv cell therapy and trodelvy offset by lower sale of veklury net income attributable to gilead wa billion or diluted earnings per share attributable to gilead in compared to billion or diluted earnings per share attributable to gilead in the decrease wa primarily due to the following item net of their related tax effect partial in process research and development ipr impairment charge of billion during the three month ended march related to asset we acquired from immunomedics inc immunomedics in million charge related to the termination of the trodelvy collaboration agreement with everest and higher expense partially offset by billion charge for settlement related to bictegravir litigation in the fourth quarter of that not repeat in result of operationsrevenuesthe following table summarizes the period over period change in our total revenue year ended december ended december in million except percentage europeother internationaltotalu europeother internationaltotalchangeproduct sale hiv hbv cell total product royalty contract and other total revenue ________________________________see note revenue of the note to consolidated financial statement included in item of this annual report on form for further disaggregation of revenue by product hivhiv product sale increased by to billion in compared to primarily due to continued higher demand for biktarvy worldwide and favorable pricing dynamic partially offset by the impact of the loss of exclusivity for truvada in the channel inventory dynamic and unfavorable foreign currency exchange impact part of our favorable pricing dynamic resulted from shift in channel mix and we expect channel mix to remain similar in product sale decreased by to billion in compared to primarily due to lower demand driven by reduced hospitalization rate in the and europe partially offset by higher demand in other international sale of veklury generally reflect covid related rate and severity of infection and hospitalization well the availability uptake and effectiveness of vaccination and alternative treatment for covid result future sale of veklury are difficult to predict and may vary significantly from one period to the next hcvhcv product sale decreased by to billion in compared to primarily due to unfavorable foreign currency exchange impact fewer patient start and unfavorable pricing dynamic hbv hdvhbv and hdv product sale increased by to million in compared to primarily due to higher demand for vemlidy and the continued adoption of hepcludex in europe cell therapycell therapy product sale which include yescarta and tecartus increased by to billion in compared to primarily due to higher demand for yescarta in lbcl in the and europe well for tecartus in all and mantle cell lymphoma trodelvytrodelvy product sale increased by to million in compared to primarily due to the continued adoption in metastatic triple negative breast cancer in the and europe otherother product sale decreased by to million in compared to primarily due to lower demand for ambisome and loss of exclusivity for letairis gross to net deductionsthe following table summarizes the period over period change in gross to net deduction in million except percentage product sale gross to net deduction rebate and chargebacks sale return discount and other total gross to net deduction of gross product net product sale foreign currency exchange impactwe generally face exposure to movement in foreign currency exchange rate primarily in the euro we use foreign currency exchange contract to hedge portion of our foreign currency exposure of our total product sale and were generated outside the in and respectively foreign currency exchange net of hedge had an unfavorable impact on our total product sale of million in based on comparison using foreign currency exchange rate from and expensesthe following table summarizes the period over period change in our cost and expense in million except percentage of good sold product gross bpsresearch and development expense acquired in process research and development expense in process research and development impairment nmselling general and administrative expense ________________________________nm not meaningfulproduct gross marginproduct gross margin increased to in compared to in primarily driven by billion charge for settlement related to bictegravir litigation in the fourth quarter of that did not repeat in the increase wa partially offset by higher royalty expense driven by biktarvy royalty the reversal of million litigation reserve in the third quarter of that did not repeat in and change in product mix research and development expensesresearch and development expense increased by million in compared to primarily due to higher clinical development spend related mostly to trodelvy and the arcus bioscience inc arcus collaboration well inflationary increase acquired in process research and development expensesacquired in process research and development expense of million in were primarily related to million charge associated with our acquisition of mirobio million charge associated with the dragonfly collaboration an million charge associated with the jounce collaboration and acquisition of and million charge associated with the macrogenics collaboration acquired in process research and development expense of million in were primarily related to million charge associated with an option exercised under the arcus collaboration see note acquisition and note collaboration and other arrangement of the note to consolidated financial statement included in item of this annual report on form for additional information in process research and development impairmentin connection with our acquisition of immunomedics in we allocated portion of the purchase price to acquired ipr intangible asset approximately billion wa assigned to ipr intangible asset related to trodelvy for treatment of patient with hr breast cancer in march we received data from the phase tropic study evaluating trodelvy in patient with hr mbc who have received prior endocrine therapy inhibitor and two to four line of chemotherapy third line plus patient based on our evaluation of the study result and in connection with the preparation of the financial statement for the first quarter we updated our estimate of the fair value of our hr ipr intangible asset to billion of march our estimate of fair value used probability weighted income approach that discount expected future cash flow to the present value the expected cash flow included cash flow from hr mbc for third line plus patient and patient in earlier line of therapy which are the subject of separate clinical study our revised discounted cash flow were lower primarily due to delay in launch timing for third line plus patient which caused decrease in our market share assumption based on the expected competitive environment there were no change in our plan or assumption related to our estimated cash flow for patient in the earlier line of therapy we determined the revised estimated fair value wa below the carrying value of the asset and result we recognized partial impairment charge of billion in in process research and development impairment on our consolidated statement of income during the three month ended march the remaining balance of the hr ipr intangible asset at the time of the assessment related to cash flow from earlier line of therapy where we have phase pivotal study in development in addition to the revised cash flow related to the third line plus patient setting if future event result in adverse change in the key assumption used in determining fair value including the timing of product launch information on the competitive landscape of treatment in this indication change to the probability of technical or regulatory success failure to obtain anticipated regulatory approval or discount rate among others additional impairment may be recorded and could be material to our financial statement no other ipr impairment charge were recorded in or general and administrative expensesselling general and administrative expense increased by million in compared to primarily due to million charge associated with the termination of the trodelvy license collaboration agreement with everest which had provided everest with broad commercialization and development right to trodelvy in certain asia territory we terminated the existing agreement and reacquired the trodelvy right in these territory other spending increase in included increased promotional and marketing investing mostly in trodelvy and cell therapy well higher corporate activity and inflationary increase slightly offset by decrease in donation to the gilead foundation in compared to interest expense and other income expense netthe following table summarizes the period over period change in our interest expense and other income expense net in million except percentage expense other income expense net interest expense decreased by million in compared to primarily due to lower outstanding debt balance the change in other income expense net for compared to primarily reflects higher interest income due to rising interest rate partially offset by higher net unrealized loss from equity security income taxesthe following table summarizes the period over period change in our income tax expense in million except percentage before income tax income tax expense effective tax our effective tax rate decreased in compared to primarily due to beneficial change in jurisdictional mix of income and lower state tax liquidity and capital resourceswe continually evaluate our liquidity and capital resource including our access to external capital to ensure that we can adequately and efficiently finance our operation liquiditycash cash equivalent and marketable debt security were billion and billion of december and respectively cash and cash equivalent increased by million from december to december the following table summarizes our cash flow activity in million cash provided by used in operating activity investing activity financing activity effect of exchange rate change on cash and cash equivalent operating activitiesnet cash provided by operating activity is derived by adjusting our net income for non cash item and change in operating asset and liability net cash provided by operating activity wa billion in compared to billion in the decrease wa primarily due to the billion payment made in the first quarter of in connection with the legal settlement related to bictegravir litigation well higher income tax payment made and higher operating expense in investing activitiesnet cash used in investing activity wa billion in compared to billion in the decrease wa primarily due to lower net purchase of marketable debt and equity security partially offset by higher capital expenditure and other acquisition activitiesnet cash used in financing activity wa billion in compared to billion in in we utilized cash for billion of debt repayment billion of dividend payment and billion of common stock repurchase in we utilized cash for billion of debt repayment billion of dividend payment and million of common stock repurchase capital resourceswe believe our existing capital resource including cash and cash equivalent marketable debt security and our revolving credit facility supplemented by cash flow generated from our operation will be adequate to satisfy our capital need for the foreseeable future of december our material cash requirement consisted primarily of the repayment of outstanding borrowing income tax payment including the remaining obligation for the one time repatriation transition tax from the tax cut and job act purchase of inventory operating lease obligation capital expenditure and milestone and other payment related to our collaborative agreement see note acquisition collaboration and other arrangement debt and credit facility lease commitment and contingency and income tax of the note to consolidated financial statement included in item of this annual report on form for additional information we enter into certain unconditional purchase obligation capital expenditure project and other commitment in the normal course of business there have been no change to these commitment during the year that would have material impact on the company ability to meet either short term or long term cash requirement our future capital requirement will depend on many factor including but not limited to the following the commercial performance of our current and future product the progress and scope of our effort including preclinical study and clinical trial the cost timing and outcome of regulatory review the expansion of our sale and marketing capability the possibility of acquiring additional manufacturing capability or office facility the possibility of acquiring other company or new product debt service requirement future dividend subject to declaration by our board of director the establishment of additional collaborative relationship with other company and cost associated with the defense settlement and adverse result of government investigation and litigation we may in the future require additional funding which could be in the form of proceeds from equity or debt financing if such funding is required we can not guarantee that it will be available to on favorable term if at all we may choose to repay certain of our long term debt obligation prior to maturity date based on our assessment of current and long term liquidity and capital requirementscritical accounting estimatessee note organization and summary of significant accounting policy of the note to consolidated financial statement included in item of this annual report on form for information about our significant accounting policy and how estimate are involved in the preparation of our financial statement we believe the following reflect the critical accounting estimate used in the preparation of our consolidated financial statement rebate and chargebacks rebate and chargebacks are determined using complex estimation process and are subject to uncertainty in part due to the lag between the date of the product sale and the date the related rebate or chargeback claim are settled in developing our estimate of rebate and chargebacks we consider the following product sale including product mix and pricing historical and estimated payer mix statutory discount requirement and contractual term historical claim experience and processing time lag estimated patient population known market event or trend market research channel inventory data obtained from our major wholesaler and other pertinent internal or external information the following table summarizes the consolidated activity and ending balance in our rebate and chargebacks account including adjustment made relating to previous year sale result of change in estimate in million balance at beginning of yeardecrease increase to product salespaymentsbalance at end of yearyear ended december activity related to sale activity related to sale prior to total year ended december activity related to sale activity related to sale prior to total our net product sale in include the impact of million for change in rebate and chargeback estimate related to sale prior to historically our actual rebate and chargebacks claimed for prior period have varied by le than from our estimate valuation of intangible assetsdetermining the fair value of intangible asset whether part of business combination or impairment assessment involves the use of probability weighted income approach that discount expected future cash flow to present value and requires the use of critical estimated input including identification of product candidate with sufficient substance requiring separate recognition estimate of projected future cash flow including revenue and operating profit related to the product or product candidate which for example include significant input such addressable patient population treatment duration and projected market share the probability of technical and regulatory success for unapproved product candidate considering their stage of development the time and resource needed to complete the development and approval of product candidate an appropriate discount rate based on the estimated weighted average cost of capital for company with profile similar to our profile representing the rate that market participant would use to value the intangible asset the life of the potential commercialized product and associated risk including the inherent difficulty and uncertainty in developing product candidate such obtaining fda and other regulatory approval and risk related to the viability of and potential alternative treatment in any future target market these estimate are subject to uncertainty due to the high rate of failure inherent in the discovery and development of new product delay that can occur in development approval and product launch process unanticipated decision made by regulatory agency advent of competing product unexpected change in and global financial market and other unanticipated event and circumstance if future event result in adverse change in the critical assumption used in determining fair value impairment charge on our intangible asset may be recorded and could be material to our financial statement for example in we recognized billion impairment charge related to our hr ipr intangible asset related to an expected delay in launch timing which caused decrease in our market share assumption based on the expected competitive environment legal contingencieswe are party to various legal action certain significant matter are described in note commitment and contingency of the note to consolidated financial statement included in item of this annual report on form input to the accrual recorded and disclosure provided in relation to these matter include the probability of certain outcome of the case the determination to whether an exposure is reasonably estimable and the amount of potential exposure these input are subject to uncertainty due to change in the legal fact and circumstance of the case status of the proceeding applicable law the view of legal counsel and the view of any judge or jury involved in the case upon the final resolution of such matter it is possible that there may be loss in excess of the amount recorded and such amount could have material adverse effect on our result of operation cash flow or financial position we periodically reassess these matter when additional information becomes available and adjust our estimate and assumption when fact and circumstance indicate the need for any change for example in the fourth quarter of we recorded an accrual of billion in other current liability on our consolidated balance sheet for the settlement related to bictegravir litigation income taxeswe are subject to income tax in the and various foreign jurisdiction including ireland critical input in determining our provision for income tax and related tax balance include forecast of our future income and expense potential tax planning strategy and determination of the probability of certain tax position being sustained upon examination by tax authority these input are subject to uncertainty due to potential change in fact and circumstance economic and political condition change to existing tax law and new regulation or interpretation by tax authority change in these condition could have material adverse impact on our result of operation and financial position quantitative and qualitative disclosure about market riskwe are exposed to market risk that may result from change in foreign currency exchange rate interest rate and credit and equity price to reduce certain of these risk we enter into various type of foreign currency derivative hedging transaction follow investment guideline and monitor outstanding receivables part of our risk management program we may also enter into other transaction such interest rate derivative hedge needed foreign currency exchange rate risk we have operation in more than country worldwide result our financial result could be significantly affected by factor such change in foreign currency exchange rate or weak economic condition in the foreign market in which we distribute our product our operating result are exposed to change in foreign currency exchange rate between the dollar and various foreign currency the most significant of which is the euro when the dollar strengthens against these currency the relative value of sale made in the respective foreign currency decrease conversely when the dollar weakens against these currency the relative value of such sale increase overall we are net receiver of foreign currency and therefore we benefit from weaker dollar and are adversely affected by stronger dollar approximately of our product sale were denominated in foreign currency during to partially mitigate the impact of change in currency exchange rate on net cash flow from our foreign currency denominated sale we enter into foreign currency exchange forward contract we also hedge certain monetary asset and liability denominated in foreign currency which reduces but doe not eliminate our exposure to currency fluctuation between the date transaction is recorded and the date that cash is collected or paid in general the market risk of these contract are offset by corresponding gain and loss on the transaction being hedged of december and we had open foreign currency forward contract with notional amount of billion and billion respectively hypothetical adverse movement in foreign currency exchange rate compared with the dollar relative to exchange rate of december and would have resulted in reduction in fair value of these contract of approximately million and million respectively and if realized would have negatively affected earnings over the remaining life of the contract the analysis doe not consider the impact that hypothetical change in foreign currency exchange rate would have on anticipated transaction that these foreign currency sensitive instrument were designed to offset interest rate and credit risk our portfolio of available for sale debt security and our senior unsecured note create an exposure to interest rate and credit risk with respect to our investment portfolio we adhere to an investment policy that requires to limit amount invested in security based on credit rating maturity industry group and investment type and issuer except for security issued by the government the goal of our investment policy in order of priority are follows safety and preservation of principal and diversification of risk liquidity of investment sufficient to meet cash flow requirement and competitive after tax rate of return the following table summarizes the expected maturity and average interest rate of our interest generating asset and interest bearing liability of december expected maturitytotal fair value in million except percentage for sale debt security average interest liabilitiessenior unsecured fixed rate note including current portion average interest _______________________________ amount represent principal balance in addition to the senior unsecured fixed rate note we have billion five year revolving credit facility that matures in june there were no amount outstanding under the five year revolving credit facility of december see note debt and credit facility of the note to consolidated financial statement included in item of this annual report on form for additional information price risk we hold share of common stock of certain publicly traded biotechnology company primarily in connection with license and collaboration agreement these equity security are measured at fair value with any change in fair value recognized in earnings the fair value of these equity security wa approximately billion and billion of december and respectively change in fair value of these equity security are impacted by the volatility of the stock market and change in general economic condition among other factor hypothetical increase or decrease in the stock price of these equity security would have increased or decreased their fair value of december and by approximately million and million respectively financial statement and supplementary data gilead science inc index to consolidated financial statement and supplementary datayears ended december and contentsreport of independent registered public accounting firm pcaob id consolidated financial statement consolidated balance statement of statement of comprehensive income loss statement of stockholder statement of cash to consolidated financial of independent registered public accounting firm to the stockholder and the board of director of gilead science inc opinion on the financial statementswe have audited the accompanying consolidated balance sheet of gilead science inc the company of december and the related consolidated statement of income comprehensive income stockholder equity and cash flow for each of the three year in the period ended december and the related note collectively referred to the consolidated financial statement in our opinion the consolidated financial statement present fairly in all material respect the financial position of the company at december and and the result of it operation and it cash flow for each of the three year in the period ended december in conformity with generally accepted accounting principle we also have audited in accordance with the standard of the public company accounting oversight board united state pcaob the company internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission framework and our report dated february expressed an unqualified opinion thereon basis for opinion these financial statement are the responsibility of the company management our responsibility is to express an opinion on the company financial statement based on our audit we are public accounting firm registered with the pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether the financial statement are free of material misstatement whether due to error or fraud our audit included performing procedure to ass the risk of material misstatement of the financial statement whether due to error or fraud and performing procedure that respond to those risk such procedure included examining on test basis evidence regarding the amount and disclosure in the financial statement our audit also included evaluating the accounting principle used and significant estimate made by management well evaluating the overall presentation of the financial statement we believe that our audit provide reasonable basis for our opinion critical audit mattersthe critical audit matter communicated below are matter arising from the current period audit of the financial statement that were communicated or required to be communicated to the audit committee and that relate to account or disclosure that are material to the financial statement and involved our especially challenging subjective or complex judgment the communication of critical audit matter doe not alter in any way our opinion on the consolidated financial statement taken whole and we are not by communicating the critical audit matter below providing separate opinion on the critical audit matter or on the account or disclosure to which they relate government and commercial rebatesdescription of the matteras more fully described in note the company estimate reduction to it revenue for amount payable to payer and healthcare provider in the united state under various government and commercial rebate program in the period that the related sale occur rebate may vary by product payer and individual payer plan some of which may not be known at the point of sale estimated reduction to revenue are based on product sale historical and expected payer mix discount rate and various other estimated and actual data adjusted for current period expectation auditing the company estimated reduction to revenue for rebate wa complex and involved significant judgment particularly in assessing the reasonableness of estimated payer mix applied to sale during the period this estimate relies heavily on historical data that is adjusted for change in payer mix expectation over time we addressed the matter in our auditwe evaluated and tested the design and operating effectiveness of the company internal control over management estimation and review of reduction from revenue for rebate program including control to ass the payer mix assumption we also tested the completeness and accuracy of data utilized in the control and the accuracy of calculation supporting management estimate to test management estimation methodology for determining the payer mix our audit procedure included among others analytically evaluating management estimate evaluating evidence contrary to the estimated amount performing sensitivity analysis on the rate used in the estimate and performing comparison of actual payment related to amount accrued during the current and prior year valuation of in process research and development intangible assetdescription of the matterduring the company recognized billion impairment charge related to it in process research and development ipr intangible asset related to trodelvy for treatment of patient with hormone receptor positive human epidermal growth factor receptor negative hr breast cancer at december this intangible asset had remaining carrying value of billion discussed in note intangible asset with indefinite useful life related to ipr project acquired in business combination are measured at their respective fair value of the acquisition date and are considered indefinite lived until the completion or abandonment of the associated effort the company test indefinite lived intangible asset for impairment on an annual basis and in between annual test if they become aware of any event or change that would indicate the fair value of the asset are below their carrying amount an impairment charge is recognized to the degree the carrying value exceeds the fair value discussed in note the company estimated the fair value of the ipr intangible asset related to trodelvy for patient with hr breast cancer in connection with both an interim impairment assessment of march and an annual impairment assessment of october auditing the fair value of this ipr intangible asset wa complex due to the significant judgment required in estimating the fair value in particular the fair value estimate required the use of valuation methodology that wa sensitive to significant assumption discount rate probability of technical and regulatory success addressable patient population treatment duration and projected market share which were affected by expected future market or economic condition how we addressed the matter in our auditwe evaluated and tested the design and operating effectiveness of the company internal control over the determination of the estimated fair value of the ipr intangible asset related to trodelvy for patient with hr breast cancer for both the interim and annual impairment assessment for example we tested control over management review of the valuation methodology and the significant assumption used to develop the fair value estimate we also tested management control to validate that the data used in the fair value estimate were complete and accurate to test the estimated fair value of this asset at both the interim and annual assessment date our audit procedure among others included evaluating the company use of an appropriate valuation methodology with assistance from valuation specialist evaluating sensitivity analysis to determine which assumption had the greatest impact on the fair value determination and testing the completeness and accuracy of the underlying data our audit procedure over the most significant assumption included comparing the assumption to current industry market and economic trend to historical result of the company business and other guideline company within the industry and to other relevant factor for example we evaluated the probability of technical and regulatory success by considering the phase of development of the clinical project and the company history of obtaining regulatory approval in addition we evaluated the expected addressable patient population by comparing the company estimate to external industry forecast ernst young llpwe have served the company auditor since san jose california february science inc consolidated balance sheetsdecember in million except per share amount asset cash and cash equivalent short term marketable debt account receivable prepaid and other current total current property plant and equipment long term marketable debt intangible asset other long term total asset liability and stockholder equity current liability account payable accrued other current current portion of long term debt and other obligation total current long term debt long term income tax deferred tax other long term commitment and contingency note stockholder equity preferred stock par value per share share authorized none outstanding common stock par value per share authorized and share issued and outstanding additional paid in accumulated other comprehensive retained total gilead stockholder noncontrolling interest total stockholder total liability and stockholder equity see accompanying note science inc consolidated statement of income year ended december in million except per share amount product sale royalty contract and other total cost and expense cost of good research and development acquired in process research and development in process research and development selling general and administrative total cost and operating interest expense other income expense net income before income income tax expense net net loss attributable to noncontrolling net income attributable to gilead basic earnings per share attributable to gilead share used in basic earnings per share attributable to gilead diluted earnings per share attributable to gilead share used in diluted earnings per share attributable to gilead see accompanying note science inc consolidated statement of comprehensive income loss year ended december in million income other comprehensive income loss net foreign currency translation loss available for sale debt security net unrealized gain loss net of tax impact of and respectively reclassification to net income net of tax impact of and net change cash flow hedge net unrealized gain loss net of tax impact of and reclassification to net income net of tax impact of and respectively net change other comprehensive income loss comprehensive income loss comprehensive loss attributable to noncontrolling comprehensive income loss attributable to gilead see accompanying note science inc consolidated statement of stockholder equity in million except per share amount gilead stockholder equity noncontrollinginteresttotalstockholders equitycommon stock additionalpaid incapitalaccumulatedothercomprehensive income loss retainedearningssharesamountbalance of december cumulative effect from the adoption of new accounting standard change in noncontrolling interest net income loss other comprehensive income loss net of tax issuance under employee stock purchase issuance under equity incentive stock based compensation repurchase of common stock dividend declared per share balance of december net income loss other comprehensive income net of tax issuance under employee stock purchase issuance under equity incentive stock based compensation repurchase of common stock dividend declared per share balance of december net income loss other comprehensive loss net of tax issuance under employee stock purchase issuance under equity incentive stock based compensation repurchase of common stock dividend declared per share balance of december see accompanying note science inc consolidated statement of cash flow year ended december in million activity net income adjustment to reconcile net income to net cash provided by operating activity depreciation amortization stock based compensation deferred income tax net loss from equity acquired in process research and development in process research and development change in operating asset and liability account receivable net inventory prepaid expense and account income tax payable accrued liability net cash provided by operating investing activity purchase of marketable debt security proceeds from sale of marketable debt proceeds from maturity of marketable debt acquisition including in process research and development net of cash acquired purchase of equity security capital expenditure other net cash used in investing activity financing activity proceeds from debt financing net of issuance cost proceeds from issuance of common repurchase of common stock repayment of debt and other obligation payment of dividend other net cash provided by used in financing activity effect of exchange rate change on cash and cash equivalent net change in cash and cash cash and cash equivalent at beginning of cash and cash equivalent at end of period supplemental disclosure of cash flow information interest paid net of amount capitalized income tax paid see accompanying note science inc note to consolidated financial organization and summary of significant accounting policiesorganizationgilead science inc gilead we our or is biopharmaceutical company that ha pursued and achieved breakthrough in medicine for more than three decade with the goal of creating healthier world for all people we are committed to advancing innovative medicine to prevent and treat life threatening disease including hiv viral hepatitis and cancer we operate in more than country worldwide with headquarters in foster city california our portfolio of marketed product includes ambisome atripla biktarvy cayston complera descovy descovy for prep emtriva epclusa eviplera genvoya harvoni hepcludex hepsera jyseleca letairis odefsey ranexa sovaldi stribild sunlenca tecartus trodelvy truvada truvada for prep tybost veklury vemlidy viread vosevi yescarta and zydelig the approval status of hepcludex and jyseleca vary worldwide and hepcludex and jyseleca are not approved in the we also sell and distribute authorized generic version of epclusa and harvoni in the through our separate subsidiary asegua therapeutic llc in addition we sell and distribute certain product through our corporate partner under collaborative agreement we have one operating segment which primarily focus on the discovery development and commercialization of innovative medicine in area of unmet medical need our chief executive officer the chief operating decision maker codm manages and allocates resource to the operation of our company on an entity wide basis managing and allocating resource on an entity wide basis enables our codm to ass the overall level of resource available and how to best deploy these resource across function and research and development project based on unmet medical need scientific data probability of technical and regulatory successful development market potential and other consideration and necessary reallocate resource among our internal portfolio and external opportunity to best support the long term growth of our business see note revenue for summary of disaggregated revenue by product and geographic region summary of significant accounting policiesbasis of presentationthe accompanying consolidated financial statement have been prepared in accordance with generally accepted accounting principle and include the account of gilead our wholly owned subsidiary and certain variable interest entity vies for which we are the primary beneficiary all intercompany transaction have been eliminated for consolidated entity where we own or are exposed to le than of the economics we record net income or loss attributable to noncontrolling interest in our consolidated statement of income equal to the percentage of the economic or ownership interest retained in such entity by the respective noncontrolling party when we obtain variable interest in another entity we ass at the inception of the relationship and upon occurrence of certain significant event whether the entity is vie and if so whether we are the primary beneficiary of the vie based on our power to direct the activity of the vie that most significantly impact the vie economic performance and our obligation to absorb loss or the right to receive benefit from the vie that could potentially be significant to the vie the preparation of these consolidated financial statement requires to make estimate and judgment that affect the reported amount of asset liability revenue and expense and related disclosure on an ongoing basis we evaluate our significant accounting policy and estimate we base our estimate on historical experience and on various market specific and other relevant assumption that we believe to be reasonable under the circumstance the result of which form the basis for making judgment about the carrying value of asset and liability that are not readily apparent from other source estimate are assessed each period and updated to reflect current information actual result may differ significantly from these estimate certain amount and percentage herein may not sum or recalculate due to rounding beginning in the second quarter of expense related to development milestone and other collaboration payment made prior to regulatory approval of developed product were reclassified from research and development expense to acquired in process research and development expense on our consolidated statement of income concurrently we reclassified the cash payment related to these expense from other to acquisition including in process research and development net of cash acquired within investing activity in the consolidated statement of cash flow we believe this presentation assist user of the financial statement to better understand the total cost incurred to acquire in process research and development ipr project prior period have been revised to reflect this classification resulting in reduction of previously reported research and development expense of million and million for the year ended december and respectively recognition product saleswe recognize revenue from product sale when control of the product transfer to the customer which is generally upon shipment or delivery or in certain case upon the corresponding sale by our customer to third party revenue are recognized net of estimated rebate and chargebacks cash discount for prompt payment distributor fee sale return provision and other related deduction these deduction to product sale are referred to gross to net deduction and are estimated and recorded in the period in which the related product sale occur our payment term to customer generally range from to day however payment term differ by jurisdiction by customer and in some instance by type of product revenue from product sale net of gross to net deduction are recorded only to the extent significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross to net deduction is subsequently resolved tax assessed by governmental authority and collected from customer are excluded from product sale if we expect at contract inception that the period between the transfer of control and corresponding payment from the customer will be one year or le we do not adjust the amount of consideration for the effect of financing component shipping and handling activity are considered to be fulfillment activity and not separate performance obligation gross to net deduction rebate and chargebacksrebates and chargebacks are based on contractual arrangement or statutory requirement and include amount due to payer and healthcare provider under various program these amount may vary by product payer and individual plan provider qualified under certain program can purchase our product through wholesaler or other distributor at discount the wholesaler or distributor then charge the discount back to rebate and chargebacks are estimated primarily based on product sale including product mix and pricing historical and estimated payer mix and discount rate among other input which require significant estimate and judgment we ass and update our estimate each reporting period to reflect actual claim and other current information chargebacks that are payable to our direct customer are generally classified reduction of account receivable on our consolidated balance sheet rebate that are payable to third party payer and healthcare provider are recorded in accrued rebate on our consolidated balance sheet cash discountswe estimate cash discount based on contractual term historical customer payment pattern and our expectation regarding future customer payment pattern distributor feesunder our inventory management agreement with our significant wholesaler we pay the wholesaler fee primarily for compliance with certain contractually determined covenant such the maintenance of agreed upon inventory level these distributor fee are based on contractually determined fixed percentage of sale allowance for sale returnsallowances are made for estimated sale return by our customer and are recorded in the period the related revenue is recognized we typically permit return if the product is damaged defective or otherwise can not be used by the customer in the we typically permit return six month prior to and up to one year after the product expiration date outside the return are only allowed in certain country on limited basis our estimate of sale return are based primarily on analysis of our historical product return pattern industry information reporting the return rate for similar product and contractual agreement term we also take into consideration known or expected change in the marketplace specific to each product royalty contract and other revenuesroyalty revenue is recognized in the period in which the obligation is satisfied and the corresponding sale by our corporate partner occur contract and other revenue are recognized when the performance obligation is satisfied research and development expensesresearch and development expense are recorded when incurred and consist primarily of clinical study performed by contract research organization cro material and supply expense reimbursement to the collaboration partner personnel cost including salary benefit and stock based compensation expense and overhead allocation consisting of various support and infrastructure cost from time to time we enter into development and collaboration agreement in which we share expense with collaborative partner we record payment received from our collaborative partner for their share of the development cost reduction of research and development expense study cost are significant component of research and development expense most of our clinical study are performed by third party cro we monitor level of performance under each significant contract including the extent of patient enrollment and other activity through communication with our cro we accrue cost for clinical study performed by cro over the service period specified in the contract and adjust our estimate if required based upon our ongoing review of the level of effort and cost actually incurred by the cro all of our material cro contract are terminable by upon written notice and we are generally only liable for actual service completed by the cro and certain non cancelable expense incurred at any point of termination payment we make for service prior to the service being rendered are recorded prepaid asset within prepaid and other current asset on our consolidated balance sheet and are expensed the service are provided acquired in process research and development expensesacquired in process research and development expense are recorded when incurred and reflect cost of externally developed ipr project acquired directly in transaction other than business combination that do not have an alternative future use including upfront and milestone payment related to various collaboration and the cost of right to ipr project selling general and administrative expensesselling general and administrative expense are recorded when incurred and consist primarily of personnel cost facility and overhead cost outside marketing advertising and legal expense and other general and administrative cost related to sale and marketing finance human resource legal and other administrative activity advertising expense within selling general and administrative expense including promotional expense are recorded when incurred and were million million and million for the year ended december and respectively stock based compensationwe provide stock based compensation in the form of various type of equity based award including restricted stock unit rsus performance share unit psus and stock option and through our employee stock purchase plan and the international employee stock purchase plan together amended the espp stock based compensation expense is based on the estimated fair value of the award on the grant date or the first date of the espp purchase period and recognized over the requisite service period on our consolidated statement of income using the straight line expense attribution approach reduced for estimated forfeiture we estimate forfeiture based on our historical experience the requisite service period could be shorter than the vesting period if an employee is retirement eligible or if an employee terminates due to death or disability the estimated fair value of rsus is based on the closing price of our common stock on the grant date for psus depending on the term of the award fair value on the date of grant is determined based on either the monte carlo valuation methodology or the closing stock price on the date of grant for stock option and espp award estimated fair value is based on the black scholes option valuation model estimated input to that model include expected volatility based on blend of historical volatility of our common stock price along with implied volatility for traded option on our common stock ii expected term in year based on the weighted average period award are expected to remain outstanding using historical cancellation and exercise data contractual term and vesting term of the award iii risk free interest rate based on observed interest rate appropriate for the term of the stock based award and iv expected dividend yield based on our history and expectation of dividend payment earnings per sharebasic earnings per share attributable to gilead is calculated based on net income attributable to gilead on our consolidated statement of income divided by the weighted average number of share of our common stock outstanding during the period diluted earnings per share attributable to gilead is calculated based on net income attributable to gilead on our consolidated statement of income divided by the weighted average number of share of our common stock and other dilutive security outstanding during the period the potentially dilutive share of our common stock resulting from the assumed exercise of outstanding stock option and equivalent are determined under the treasury stock method cash and cash equivalent we consider highly liquid investment with insignificant interest rate risk and an original maturity of three month or le on the purchase date to be cash equivalent debt securitiesall of our marketable debt security are classified available for sale and carried at estimated fair value we determine the appropriate classification of our marketable debt security at the time of purchase and reevaluate such designation at each balance sheet date unrealized gain and loss on available for sale debt security are reported in accumulated other comprehensive income on our consolidated balance sheet until realized at which point they are reclassified into other income expense net on our consolidated statement of income interest amortization of purchase premium and discount and expected credit loss if any are also recorded in other income expense net on our consolidated statement of income the cost of security sold is based on the specific identification method we regularly review our investment for decline in fair value below their amortized cost basis to determine whether the impairment is due to credit related factor or noncredit related factor our review includes the creditworthiness of the security issuer the severity of the unrealized loss whether we have the intent to sell the security and whether it is more likely than not that we will be required to sell the security before the recovery of their amortized cost base when we determine that portion of the unrealized loss is due to an expected credit loss we recognize the loss amount in other income expense net with corresponding allowance against the carrying value of the security we hold the portion of the unrealized loss related to factor other than credit loss is recognized in accumulated other comprehensive income account receivabletrade account receivable are recorded net of allowance for wholesaler chargebacks related to government and other program cash discount for prompt payment and estimated credit loss estimate of our allowance for credit loss consider number of factor including existing contractual payment term individual customer circumstance historical payment pattern of our customer review of the local economic environment and it potential impact on expected future customer payment pattern and government funding and reimbursement practice inventoriesinventories are recorded at the lower of cost or net realizable value with cost determined on first in first out basis we periodically review our inventory to identify obsolete slow moving excess or otherwise unsaleable item if obsolete slow moving excess or unsaleable item are observed and there are no alternate us for the inventory we record write down to net realizable value through charge to cost of good sold on our consolidated statement of income the determination of net realizable value requires judgment including consideration of many factor such estimate of future product demand product net selling price current and future market condition and potential product obsolescence among others when future commercialization is considered probable and the future economic benefit is expected to be realized based on management judgment we capitalize pre launch inventory cost prior to regulatory approval number of factor are considered including the current status in the regulatory approval process potential impediment to the approval process such safety or efficacy anticipated initiative that could impact the indication in which the compound will be used viability of commercialization and marketplace trend equity securitiesequity security with readily determinable fair value including those for which we have elected the fair value option are recorded at fair market value and unrealized gain and loss are included in other income expense net on our consolidated statement of income equity security without readily determinable fair value are recorded using the measurement alternative of cost le impairment if any adjusted for observable price change in orderly transaction for identical or similar investment of the same issuer any impairment or adjustment are recorded in other income expense net on our consolidated statement of income for investment in entity over which we have significant influence but do not meet the requirement for consolidation and have not elected the fair value option we use the equity method of accounting with our share of the underlying income or loss of such entity reported in other income expense net on our consolidated statement of income our investment in equity security are classified in prepaid and other current asset or other long term asset on our consolidated balance sheet generally depending on marketability and whether the security are subject to lock up provision we regularly review our security for indicator of impairment plant and equipmentproperty plant and equipment is stated at cost le accumulated depreciation and amortization depreciation and amortization are recognized using the straight line method repair and maintenance cost are expensed incurred estimated useful life in year are generally follows descriptionestimated useful life building and improvementsshorter of year or useful lifelaboratory and manufacturing computer equipment and improvementsshorter of useful life or lease termsee impairment of long lived asset for additional information leaseswe determine if an arrangement contains lease at inception and classify each lease operating or financing right of use asset and lease liability are recognized at the commencement date based on the present value of the lease payment over the lease term which is the non cancelable period stated in the contract adjusted for any option to extend or terminate when it is reasonably certain that we will exercise that option right of use asset are adjusted for prepaid lease payment lease incentive and initial direct cost incurred operating lease expense for the minimum lease payment is recognized on straight line basis over the lease term we account for lease and nonlease component in our lease agreement single lease component in determining lease asset and liability in addition we do not recognize the right of use asset and liability for lease with lease term of one year or le most of our operating lease do not provide an implicit interest rate we generally utilize collateralized incremental borrowing rate applied in portfolio approach when relevant based on the information available at the commencement date to determine the lease liability acquisition including goodwill intangible asset and contingent considerationwe account for business combination using the acquisition method of accounting which generally requires that asset acquired including ipr project and liability assumed be recorded at their fair value of the acquisition date on our consolidated balance sheet any excess of consideration over the fair value of net asset acquired is recorded goodwill the determination of estimated fair value requires to make significant estimate and assumption result we may record adjustment to the fair value of asset acquired and liability assumed within the measurement period which may be up to one year from the acquisition date with the corresponding offset to goodwill transaction cost associated with business combination are expensed they are incurred intangible asset related to ipr project are considered to be indefinite lived until the abandonment or completion of the associated effort which generally occurs when regulatory approval is obtained goodwill and indefinite lived intangible asset are not amortized and instead are tested for impairment annually or more frequently if event or change in circumstance indicate that it is more likely than not that the asset are impaired intangible asset with finite useful life are amortized over their estimated useful life primarily on straight line basis and are also periodically reviewed for change in fact or circumstance resulting in reduction to the estimated useful life of the asset requiring the acceleration of amortization see impairment of long lived asset for additional information in determining the initial fair value of an intangible asset or when quantitative analysis is required to determine any impairment we use probability weighted income approach that discount expected future cash flow to present value using discount rate that is based on the estimated weighted average cost of capital for company with profile similar to and represents the rate that market participant would use to value the intangible asset these cash flow model require the use of level fair value measurement and input including estimated revenue which for example include significant input such addressable patient population treatment duration projected market share assessment of the asset life cycle and competitive trend impacting the asset cost and probability of technical and regulatory success among other factor in connection with certain acquisition we may be required to pay future consideration that is contingent upon the achievement of specified development regulatory approval or sale based milestone event we record contingent consideration resulting from business combination at it fair value on the acquisition date each reporting period thereafter we revalue these obligation and record increase or decrease in their fair value on our consolidated statement of income until such time that the payment is made increase or decrease in fair value of the contingent consideration liability can result from update to assumption such the expected timing or probability of achieving the specified milestone change in projected revenue or change in discount rate we determine net asset acquired do not meet the definition of business combination under the acquisition method of accounting the transaction is accounted for an asset acquisition and therefore no goodwill is recorded and contingent consideration generally is not recognized at the acquisition date in an asset acquisition upfront payment allocated to ipr project at the acquisition date and subsequent milestone payment are expensed incurred on our consolidated statement of income unless there is an alternative future use impairment of long lived assetslong lived asset including property plant and equipment and finite lived intangible asset are reviewed for impairment whenever fact or circumstance either internally or externally may indicate that the carrying value of an asset may not be recoverable should there be an indication of impairment we test for recoverability by comparing the estimated undiscounted future cash flow expected to result from the use of the asset over it useful life to the carrying amount of the asset or asset group if the asset or asset group is determined to be impaired any excess of the carrying value of the asset or asset group over it estimated fair value is recognized an impairment loss derivativeswe recognize all derivative instrument either asset or liability at fair value on our consolidated balance sheet unrealized change in the fair value of derivative designated part of hedge transaction are recorded in accumulated other comprehensive income for our hedge related to forecasted product sale the unrealized gain or loss in accumulated other comprehensive income are reclassified into product sale on our consolidated statement of income when the respective hedged transaction affect earnings change in the fair value of derivative that are not part of hedge transaction are recorded each period in other income expense net on our consolidated statement of income using regression analysis we ass both at inception and on an ongoing basis whether the derivative that are used in hedging transaction are effective in offsetting the change in cash flow or fair value of the hedged item if we determine that forecasted transaction is probable of not occurring we discontinue hedge accounting for the affected portion of the hedge instrument and any related unrealized gain or loss on the contract is recognized in other income expense net on our consolidated statement of income contingencieswe recognize accrual for loss contingency to the extent that we conclude that loss is both probable and reasonably estimable we accrue the best estimate of loss within range however if no estimate in the range is better than any other then we accrue the minimum amount in the range if we determine that material loss is reasonably possible we disclose the possible loss or range of loss or that the amount of loss can not be estimated at this time income taxesour income tax provision is computed under the liability method significant estimate are required in determining our provision for income tax some of these estimate are based on interpretation of applicable tax law or regulation deferred tax asset and liability are determined based on the difference between the financial statement and tax basis of asset and liability using enacted tax rate in effect for the year in which the difference are expected to reverse we record valuation allowance to reduce our deferred tax asset to the amount that are more likely than not to be realized we consider future taxable income ongoing tax planning strategy and our historical financial performance in assessing the need for valuation allowance if we expect to realize deferred tax asset for which we have previously recorded valuation allowance we will reduce the valuation allowance in the period in which such determination is first made we recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authority based on the technical merit of the position the tax benefit recognized in the consolidated financial statement for particular tax position is based on the largest benefit that is more likely than not to be realized the amount of unrecognized tax benefit utb is adjusted appropriate for change in fact and circumstance such significant amendment to existing tax law new regulation or interpretation by tax authority new information obtained during tax examination or resolution of an examination we recognize both accrued interest and penalty where appropriate related to utb in income tax expense on our consolidated statement of income we have elected to account for the tax on global intangible low taxed income enacted part of the tax cut and job act component of tax expense in the period in which the tax is incurred currency translation and transactionsour consolidated financial statement are presented in dollar the functional currency for most of our foreign subsidiary is their local currency revenue expense gain and loss for non dollar functional currency entity are translated into dollar using average currency exchange rate for the period asset and liability for such entity are translated using exchange rate that approximate the rate at the balance sheet date foreign currency translation adjustment are recorded component of accumulated other comprehensive income on our consolidated balance sheet foreign currency transaction gain and loss on transaction not denominated in functional currency are recorded in other income expense net on our consolidated statement of income fair value measurementswe apply fair value accounting for all financial and non financial asset and liability that are recognized or disclosed at fair value in the financial statement on recurring basis we define fair value the price that would be received from selling an asset or paid to transfer liability in an orderly transaction between market participant at the measurement date when determining the fair value measurement for asset and liability which are required to be recorded at fair value we consider the principal or most advantageous market in which we would transact and the market based risk measurement or assumption that market participant would use in pricing the asset or liability such risk inherent in valuation technique transfer restriction and credit risk we determine the fair value using the fair value hierarchy which establishes three level of input that may be used to measure fair value follows level input include quoted price in active market for identical asset or liability level input include observable input other than level input such quoted price for similar asset or liability in active market quoted price for identical or similar asset or liability in market that are not active or other input that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability and level input include unobservable input that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability our level asset and liability include those whose fair value measurement are determined using pricing model discounted cash flow methodology or similar valuation technique and significant management judgment or estimation revenuesdisaggregation of revenue the following table summarizes our total revenue year ended december ended december ended december in million europeother internationaltotalu europeother internationaltotalu europeother internationaltotalproduct sale complera revenue share symtuza other hiv total hiv hepatitis virus hcv ledipasvir sofosbuvir sofosbuvir velpatasvir other hcv total hepatitis virus hbv hepatitis delta virus hdv other hbv hdv total hbv cell therapy total cell therapy other total other total product royalty contract and other total revenue _______________________________ represents our revenue from cobicistat emtricitabine ftc and tenofovir alafenamide taf in symtuza darunavir ftc taf fixed dose combination product commercialized by janssen science ireland unlimited company janssen see note collaboration and other arrangement for additional information includes atripla emtriva sunlenca and tybost amount consist of sale of harvoni and the authorized generic version of harvoni sold by our separate subsidiary asegua therapeutic llc amount consist of sale of epclusa and the authorized generic version of epclusa sold by our separate subsidiary asegua therapeutic llc includes vosevi and sovaldi includes hepcludex and hepsera includes cayston jyseleca ranexa and zydelig from major customersthe following table summarizes revenue from each of our customer who individually accounted for or more of our total revenue year ended december percentage of total revenue cardinal health inc mckesson revenue recognized from performance obligation satisfied in prior periodsthe following table summarizes revenue recognized from performance obligation satisfied in prior period year ended december in million share with janssen and royalty for license of intellectual property change in estimate _______________________________ see note collaboration and other arrangement for additional information contract balancesour contract asset which consist of unbilled amount primarily from arrangement where the licensing of intellectual property is the only or predominant performance obligation totaled million and million of december and respectively contract liability which generally result from receipt of advance payment before our performance under the contract were million and million of december and respectively fair value measurement the following table summarizes the type of asset and liability measured at fair value on recurring basis by level within the fair value hierarchy december in million level available for sale debt security treasury security government agency security non government security certificate of deposit corporate debt security residential mortgage and asset backed security equity security money market equity investment in galapagos nv galapagos equity investment in arcus bioscience inc arcus other publicly traded equity deferred compensation foreign currency derivative contract total liability liability for myr gmbh myr contingent consideration deferred compensation foreign currency derivative contract total _______________________________ see note collaboration and other arrangement for additional information level inputsavailable for sale debt securitiesfor our available for sale debt security we estimate the fair value by reviewing trading activity and pricing of the measurement date and by taking into consideration valuation obtained from third party pricing service the pricing service utilize industry standard valuation model including both income based and market based approach for which all significant input are observable either directly or indirectly to estimate the fair value these input include reported trade of and broker dealer quote on the same or similar security issuer credit spread benchmark security prepayment default projection based on historical data and other observable input foreign currency derivative contractssubstantially all of our foreign currency derivative contract have maturity within an month time horizon and all are with counterparties that have minimum credit rating of or equivalent by global rating moody investor service inc or fitch rating inc we estimate the fair value of these contract by taking into consideration the valuation obtained from third party valuation service that utilizes an income based industry standard valuation model for which all significant input are observable either directly or indirectly these input include foreign currency exchange rate secured overnight financing rate and swap rate these input where applicable are observable at commonly quoted interval unsecured notesthe total estimated fair value of our senior unsecured note determined using level input based on their quoted market value were approximately billion and billion of december and respectively and the carrying value were billion and billion of december and respectively level inputscontingent considerationin connection with our first quarter acquisition of myr we recorded liability for contingent consideration which is revalued each reporting period until the related contingency is resolved the contingent consideration wa estimated using probability weighted scenario for food and drug administration fda approval of hepcludex the following table summarizes the change in fair value of our contingent consideration year ended december in million balance addition change in valuation assumption effect of foreign exchange remeasurement ending balance ________________________________ included in research and development expense on our consolidated statement of income and primarily related to increasing discount rate and updated probability rate estimate included in other income expense net on our consolidated statement of income liability related to future royaltieswe recorded liability related to future royalty part of our fourth quarter acquisition of immunomedics inc immunomedics which is subsequently amortized using the effective interest method over the remaining estimated life the fair value of the liability related to future royalty were billion and billion of december and respectively and the carrying value wa billion of december and see note debt and credit facility for additional information nonrecurring fair value measurementsduring we recorded partial impairment charge of billion related to certain ipr asset see note goodwill and intangible asset for additional information there were no indicator of impairment noted during fair value level transfersthere were no transfer between level level and level in the period presented available for sale debt security and equity security available for sale debt securitiesthe following table summarizes our available for sale debt security december in million amortized costgross unrealized gainsgross unrealized lossesestimated fair valueamortized costgross unrealized gainsgross unrealized lossesestimated fair valueu treasury security government agency non government certificate of corporate debt residential mortgage and asset backed total the following table summarizes information related to available for sale debt security that have been in continuous unrealized loss position classified by length of time december than month or longertotal in million gross unrealized lossesestimated fair valuegross unrealized lossesestimated fair valuegross unrealized lossesestimated fair valueu treasury security government agency security non government security certificate of deposit corporate debt security residential mortgage and asset backed security total december than month or longertotal in million gross unrealized lossesestimated fair valuegross unrealized lossesestimated fair valuegross unrealized lossesestimated fair valueu treasury security government agency security non government security certificate of deposit corporate debt security residential mortgage and asset backed security total no allowance for credit loss wa recognized for investment with unrealized loss of december we do not currently intend to sell and it is not more likely than not that we will be required to sell such investment before recovery of their amortized cost base the unrealized loss were primarily driven by broader change in interest rate with no adverse condition identified that would prevent the issuer from making scheduled principal and interest payment following table summarizes the classification of our available for sale debt security in our consolidated balance sheet in million december and cash equivalent short term marketable debt long term marketable debt total the following table summarizes our available for sale debt security by contractual maturity december in million amortized costfair valuewithin one year after one year through five after five year through ten after ten total equity securitiesequity security measured at fair valuethe following table summarizes the classification of our equity security measured at fair value on recurring basis on our consolidated balance sheet in million december and cash equivalent prepaid and other current asset other long term asset total ________________________________ prepaid and other current asset and other long term asset include our equity method investment in arcus and galapagos respectively for which we elected and applied the fair value option we believe it best reflects the underlying economics of these investment our investment in galapagos is classified in other long term asset due to certain lock up provision in our amended subscription agreement with them which extend to august other equity securitiesequity method investment and other equity investment without readily determinable fair value were million and million of december and respectively and were excluded from the table above these amount were included in other long term asset on our consolidated balance sheet unrealized gain and loss net unrealized loss recognized on equity security were million million and billion for the year ended december and respectively and were included in other income expense net on our consolidated statement of income related party transactionduring the year ended december and gilead donated certain equity security at fair value to the gilead foundation california nonprofit public benefit corporation the foundation the foundation is related party certain of our officer also serve director of the foundation the donation expense of million and million wa recorded within selling general and administrative expense on our consolidated statement of income during the for the year ended december and respectively derivative financial instrumentsour operation in foreign country expose to market risk associated with foreign currency exchange rate fluctuation between the dollar and various foreign currency primarily the euro to manage this risk we hedge portion of our foreign currency exposure related to outstanding monetary asset and liability well forecasted product sale using foreign currency exchange forward contract in general the market risk related to these contract is offset by corresponding gain and loss on the hedged transaction the credit risk associated with these contract is driven by change in interest and currency exchange rate and result varies over time by working only with major bank and closely monitoring current market condition we seek to limit the risk that counterparties to these contract may be unable to perform we also seek to limit our risk of loss by entering into contract that permit net settlement at maturity therefore our overall risk of loss in the event of counterparty default is limited to the amount of any unrealized gain on outstanding contract those contract that have positive fair value at the date of default we do not enter into derivative contract for trading purpose the derivative instrument we use to hedge our exposure for certain monetary asset and liability that are denominated in non functional currency are not designated hedge the derivative instrument we use to hedge our exposure for forecasted product sale are designated cash flow hedge and have maturity of month or le of december and we held foreign currency exchange contract with outstanding notional amount of billion and billion respectively while all our derivative contract allow the right to offset asset and liability we have presented amount in our consolidated balance sheet on gross basis the following table summarizes the classification and fair value of derivative instrument including the potential effect of offsetting december assetsderivative liability in million classificationfair valueclassificationfair valuederivatives designated hedge foreign currency exchange contractsprepaid and other current asset other current liability foreign currency exchange contractsother long term other long term total derivative designated derivative not designated hedge foreign currency exchange contractsprepaid and other current other current total derivative not designated total derivative presented gross on the consolidated balance sheet gross amount not offset on the consolidated balance sheet derivative financial instrument cash collateral received pledged net amount legal offset assetsderivative liability in million classificationfair valueclassificationfair valuederivatives designated hedge foreign currency exchange contractsprepaid and other current asset other current liability foreign currency exchange contractsother long term other long term total derivative designated derivative not designated hedge foreign currency exchange contractsprepaid and other current asset other current liability total derivative not designated hedge total derivative presented gross on the consolidated balance sheet gross amount not offset on the consolidated balance sheet derivative financial instrument cash collateral received pledged net amount legal offset the following table summarizes the effect of our derivative contract on our consolidated financial statement year ended december in million designated hedge gain loss recognized in accumulated other comprehensive income gain loss reclassified from accumulated other comprehensive income to product sale derivative not designated hedge gain loss recognized in other income expense net the majority of gain and loss related to the hedged forecasted transaction reported in accumulated other comprehensive income of december are expected to be reclassified to product sale within month there were no discontinuance of cash flow hedge for the year presented the cash flow effect of our derivative contract for the year ended december and were included within net cash provided by operating activity on our consolidated statement of cash flow acquisitionsmirobioon september we acquired all of the outstanding share capital of mirobio ltd mirobio privately held based biotechnology company focused on restoring immune balance with agonist targeting immune inhibitory receptor for million in cash result mirobio became our wholly owned subsidiary we accounted for the transaction an asset acquisition and recorded million charge to acquired in process research and development expense on our consolidated statement of income during the remaining purchase price relates to various other asset acquired and liability assumed myrin the first quarter of we completed the acquisition of myr german biotechnology company myr focus on the development and commercialization of therapeutic for the treatment of hdv the acquisition provided gilead with hepcludex which wa conditionally approved by european medicine agency ema in july for the treatment of chronic hdv infection in adult with compensated liver disease upon closing myr became wholly owned subsidiary of gilead the financial result of myr were included in our consolidated financial statement from the date of the acquisition aggregate consideration for this acquisition of billion or billion primarily consisted of billion or billion paid upon closing and contingent consideration of up to million subject to customary adjustment representing potential future milestone payment upon fda approval of hepcludex the fair value of this contingent liability estimated using probability weighted scenario for fda approval wa million of the acquisition date of december the fair value of the liability wa million and wa included in other current liability on our consolidated balance sheet of december the fair value of the liability wa million and wa included in other long term obligation see note fair value measurement for additional information the acquisition of myr wa accounted for business combination using the acquisition method of accounting the following table summarizes estimated fair value of asset acquired and liability assumed of the acquisition date in million amountintangible asset finite lived intangible asset acquired ipr deferred income tax net other asset and liability net total identifiable net total consideration intangible assetsthe finite lived intangible asset of million represents the estimated fair value of hepcludex for hdv in europe of the acquisition date the fair value wa determined by applying the income approach using unobservable input to estimate probability weighted net cash flow attributable to hepcludex for hdv in europe and discount rate of the discount rate used represents the estimated rate that market participant would use to value this intangible asset this intangible asset is being amortized over an estimated useful life of year acquired ipr consists of hepcludex for hdv in all other region without regulatory approval including the united state the estimated aggregate fair value of billion of the acquisition date wa determined by applying the income approach using unobservable input level under the fair value measurement and disclosure guidance to estimate probability weighted net cash flow attributable to this asset and discount rate of the discount rate used represents the estimated rate that market participant would use to value this intangible asset deferred income taxesthe net deferred tax liability wa based upon the difference between the estimated financial statement basis and tax basis of net asset acquired and an estimate for the final pre acquisition net operating loss of myr goodwill the excess of the consideration transferred over the fair value of asset acquired and liability assumed of million wa recorded goodwill which primarily reflects the future economic benefit arising from other asset acquired that could not be individually identified and separately recognized goodwill recognized for myr is not expected to be deductible for income tax purpose the one year measurement period wa completed in the first quarter of with adjustment recorded to the fair value of asset acquired and liability assumed of million see note goodwill and intangible asset for additional information immunomedicsin the fourth quarter of we completed the acquisition of immunomedics company focused on the development of antibody drug conjugate technology for cash consideration of billion upon closing immunomedics became wholly owned subsidiary of gilead the acquisition wa financed with the majority of the proceeds from the september senior unsecured note offering an additional billion borrowing under new senior unsecured term loan facility and cash on hand in we repaid the borrowing under the senior unsecured term loan facility recorded share based compensation expense of million related to the cash settlement of the accelerated share based compensation expense attributable to the post combination period which wa primarily recorded in selling general and administrative expense and research and development expense on our consolidated statement of income for the year ended december we also recorded other acquisition related expense of million primarily representing closing cost and related fee in selling general and administrative expense on our consolidated statement of income for the year ended december the acquisition of immunomedics wa accounted for business combination using the acquisition method of accounting the following table summarizes fair value of asset acquired and liability assumed of the acquisition date in million amountcash and cash equivalent intangible asset finite lived intangible acquired ipr outlicense deferred tax liability liability related to future royalty other asset and liability total identifiable net total consideration transferred inventoriesthe fair value step up adjustment of million included in inventory of million of the acquisition date wa primarily determined by the estimated selling price of finished inventory le the cost to complete the manufacturing process and selling effort the step up adjustment wa recorded in cost of good sold on our consolidated statement of income the inventory wa sold to customer and in research and development expense on our consolidated statement of income for inventory used for clinical purpose intangible assetsthe finite lived intangible asset of billion represents the estimated fair value of trodelvy for metastatic triple negative breast cancer tnbc of the acquisition date the fair value wa determined by applying the income approach using unobservable input to estimate probability weighted net cash flow attributable to trodelvy for metastatic tnbc and discount rate of the discount rate used represents the estimated rate that market participant would use to value this intangible asset this intangible asset is being amortized over an estimated useful life of year acquired ipr asset consist of trodelvy for hormone receptor positive human epidermal growth factor receptor negative hr breast cancer trodelvy for non small cell lung cancer and trodelvy for urothelial cancer uc the estimated aggregate fair value of billion of the acquisition date wa determined by applying the income approach using unobservable input level under the fair value measurement and disclosure guidance to estimate probability weighted net cash flow attributable to these asset and discount rate of the discount rate used represents the estimated rate that market participant would use to value these intangible asset trodelvy for uc wa granted accelerated approval by fda in april and billion wa reclassified to finite lived intangible from ipr trodelvy for hr breast cancer wa partially impaired in the first quarter of but wa subsequently granted approval by fda in february and billion will be reclassified to finite lived intangible from ipr in the first quarter of see note goodwill and intangible asset for additional information we also recorded an intangible asset related to license and supply agreement with everest medicine everest which wa entered into by immunomedics prior to the acquisition under the agreement everest wa granted an exclusive license to develop and commercialize trodelvy in certain territory in asia and make certain sale milestone and royalty payment to the acquisition date fair value of million wa determined by estimating the probability weighted net cash flow attributable to the outlicense and discount rate of the discount rate represents the estimated rate that market participant would use to value this intangible asset this intangible asset wa being amortized over an estimated useful life of year on straight line basis up until we reacquired the right from everest in the fourth quarter of see note collaboration and other arrangement for additional information income taxesthe net deferred tax liability wa based upon the difference between the estimated financial statement basis and tax basis of net asset acquired and an estimate for the final pre acquisition net operating loss of immunomedics liability related to future royaltieswe assumed liability related to funding arrangement which wa originally entered into by immunomedics and rpi finance trust rpi prior to our acquisition of immunomedics under the funding agreement rpi ha the right to receive certain royalty amount subject to certain reduction based on the net sale of trodelvy for each calendar quarter during the term of the agreement through approximately the acquisition date fair value of the liability wa estimated billion which wa primarily determined based on current estimate of future royalty payment to rpi over the life of the arrangement using the real option method and an effective annual interest rate of the input used for valuation of this liability are unobservable and are considered level under the fair value measurement and disclosure guidance the liability related to future royalty wa categorized debt and primarily included in long term debt net on our consolidated balance sheet see note fair value measurement and debt and credit facility for additional information goodwill the excess of the consideration transferred over the fair value of asset acquired and liability assumed of billion wa recorded goodwill which primarily reflects the future economic benefit arising from other asset acquired that could not be individually identified and separately recognized goodwill recognized for immunomedics is not expected to be deductible for income tax purpose forty seven inc forty seven in the second quarter of we completed the acquisition of forty seven clinical stage immuno oncology company focused on developing therapy targeting cancer immune evasion pathway and specific cell targeting approach for total consideration of billion net of acquired cash upon closing forty seven became wholly owned subsidiary of gilead we accounted for the transaction an asset acquisition since the lead asset magrolimab represented substantially all the fair value of the gross asset acquired during the year ended december we recorded billion charge representing an acquired ipr asset with no alternative future use in acquired in process research and development expense and stock based compensation expense of million primarily in research and development expense on our consolidated statement of income property plant and equipmentthe following table summarizes our property plant and equipment net december in million and land improvement building and improvement including leasehold improvement laboratory and manufacturing office computer equipment and other construction in le accumulated depreciation and total ________________________________ includes million and million of unamortized capitalized software cost of december and respectively the net book value of our property plant and equipment in the wa billion and billion of december and respectively the corresponding amount in international location wa million and million of december and respectively all individual international location accounted for le than of the total balance goodwill and intangible asset goodwillthe following table summarizes the change in the carrying amount of goodwill december in million balance goodwill resulting from acquisition measurement period adjustment ending balance in goodwill decreased by million result of finalizing the amount of acquired net operating loss of myr which resulted in decrease to the net deferred tax liability acquired of december there were no accumulated goodwill impairment loss intangible assetsthe following table summarizes our intangible asset net december in million gross carryingamountaccumulatedamortizationforeign currency translation adjustmentnet carrying amountgross carryingamountaccumulatedamortizationforeign currency translation adjustmentnet carrying amountfinite lived asset intangible asset sofosbuvir intangible asset axicabtagene intangible asset intangible asset total finite lived indefinite lived asset ipr total intangible asset _______________________________ in february fda granted approval of trodelvy for use in adult patient with unresectable locally advanced or metastatic hr breast cancer who have received endocrine based therapy and at least two additional systemic therapy in the metastatic setting accordingly the related ipr intangible asset of billion will be reclassified to finite lived asset in the first quarter of amortization expenseaggregate amortization expense related to finite lived intangible asset wa billion billion and billion for the year ended december and respectively and is primarily included in cost of good sold on our consolidated statement of income the following table summarizes the estimated future amortization expense associated with our finite lived intangible asset of december in million total assessmentsno indicator of impairment were noted for the year ended december and except described under ipr impairment below the weighted average discount rate used in our quantitative assessment for ipr intangible asset during those year other than for the assessment described below were and respectively ipr impairmentin connection with our acquisition of immunomedics in we allocated portion of the purchase price to acquired ipr intangible asset approximately billion wa assigned to ipr intangible asset related to trodelvy for treatment of patient with hr breast cancer in march we received data from the phase tropic study evaluating trodelvy in patient with hr metastatic breast cancer who have received prior endocrine therapy cyclin dependent kinase inhibitor and two to four line of chemotherapy third line plus patient based on our evaluation of the study result and in connection with the preparation of the financial statement for the first quarter we updated our estimate of the fair value of our hr ipr intangible asset to billion of march our estimate of fair value used probability weighted income approach that discount expected future cash flow to the present value which requires the use of level fair value measurement and input including estimated revenue cost and probability of technical and regulatory success the expected cash flow included cash flow from hr metastatic breast cancer for third line plus patient and patient in earlier line of therapy which are the subject of separate clinical study our revised discounted cash flow were lower primarily due to delay in launch timing for third line plus patient which caused decrease in our market share assumption based on the expected competitive environment of march there were no change in our plan or assumption related to our estimated cash flow for patient in the earlier line of therapy we used discount rate of which is based on the estimated weighted average cost of capital for company with profile similar to ours and represents the rate that market participant would use to value the intangible asset we determined the revised estimated fair value wa below the carrying value of the asset and result we recognized partial impairment charge of billion in in process research and development impairment on our consolidated statement of income during the three month ended march other financial informationaccounts receivable netthe following table summarizes our account receivable net december in million receivable le allowance for le allowance for cash discount and le allowance for credit account receivable net the majority of our trade account receivable arises from product sale in the and europe inventoriesthe following table summarizes our inventory december in million material work in finished total reported inventory other long term asset total _______________________________ amount primarily consist of raw material inventory of december included million of fair value adjustment resulting from the immunomedics acquisition there were no fair value adjustment in total inventory of december other current liabilitiesthe following table summarizes the component of other current liability december in million and employee benefit income tax allowance for sale accrual for settlement related to bictegravir litigation other accrued other current liability _______________________________ see note commitment and contingency for additional information collaboration and other arrangement we enter into licensing and strategic collaboration and other similar arrangement with third party for the development and commercialization of certain product and product candidate these arrangement may involve two or more party who are active participant in the operating activity of the collaboration and are exposed to significant risk and reward depending on the commercial success of the activity these arrangement may include non refundable upfront payment expense reimbursement or payment by for option to acquire certain right contingent obligation by for potential development and regulatory milestone payment and or sale based milestone payment royalty payment revenue or profit sharing arrangement cost sharing arrangement and equity investment under the financial term of these arrangement we may be required to make payment upon achievement of various developmental regulatory and commercial milestone which could be significant future milestone payment if any will be reflected in our consolidated statement of income when the corresponding event become probable in connection with the regulatory approval milestone payment made will be capitalized intangible asset and will be amortized to cost of good sold through the term of these collaboration arrangement in addition we may be required to pay significant royalty on future sale if product related to these arrangement are commercialized the payment of these amount however is contingent upon the occurrence of various future event which have high degree of uncertainty dragonflyin april we entered into strategic research collaboration agreement the dragonfly collaboration agreement with dragonfly therapeutic inc dragonfly to develop natural killer nk cell engager based immunotherapy for oncology and inflammation indication under the term of the dragonfly collaboration agreement we received an exclusive worldwide license from dragonfly for the targeting investigational immunotherapy program well option after the completion of certain preclinical activity to license exclusive worldwide right to develop and commercialize additional nk cell engager program using the dragonfly tri specific nk engager platform upon the closing of the dragonfly collaboration agreement we made million upfront payment to dragonfly and we made an additional million payment related to target selection in connection with an august amendment to the agreement which were recorded in acquired in process research and development expense on our consolidated statement of income during the year ended december these payment were classified acquisition including in process research and development net of cash acquired in investing activity on our consolidated statement of cash flow for the year ended december in addition dragonfly is eligible to receive performance based development and regulatory milestone payment of up to million related to the program with further commercial milestone payment and royalty on worldwide net sale if successful if we exercise our option on additional nk cell engager program dragonfly would be eligible to receive opt in payment and performance based development regulatory and commercial milestone payment and royalty on worldwide net sale on these optioned program well merck co inc merck on march we entered into license and collaboration agreement with merck sharp dohme corp subsidiary of merck to jointly develop and commercialize long acting investigational treatment in hiv that combine gilead investigational capsid inhibitor lenacapavir and merck investigational nucleoside reverse transcriptase translocation inhibitor islatravir the collaboration is initially focused on long acting oral and injectable formulation the term of the agreement gilead and merck share global development and commercialization cost at and respectively across the oral and injectable formulation program for long acting oral product if approved gilead would lead commercialization in the and merck would lead commercialization in the european union eu and rest of the world for long acting injectable product if approved merck would lead commercialization in the and gilead would lead commercialization in the eu and rest of the world under the term of the agreement gilead and merck would jointly promote the combination product in the and certain other major market if successful we would share global product revenue with merck equally until product revenue surpass certain pre determined per formulation revenue tier upon passing billion in net product sale for the oral combination in given calendar year our share of revenue would increase to for any revenue above the threshold for such calendar year upon passing billion in net product sale for the injectable combination in given calendar year our share of revenue will increase to for any revenue above the threshold for such calendar year reimbursement of cost to or from merck are recorded within research and development expense on our consolidated statement of income expense recognized under the agreement were not material for the year ended december and no revenue have been recognized under the agreement for the year ended december and we will also have the option to license certain of merck investigational oral integrase inhibitor to develop in combination with lenacapavir reciprocally merck will have the option to license certain of gilead investigational oral integrase inhibitor to develop in combination with islatravir each company may exercise it option for such investigational oral integrase inhibitor of the other company within the first five year after execution of the agreement following completion of the first phase clinical trial of that integrase inhibitor upon exercise of an option the company will split development cost and revenue unless the non exercising company decides to opt out in which case the non exercising company will be paid royalty in december merck announced the decision of the party to stop all dosing of participant in the phase clinical study evaluating an oral weekly combination treatment regimen of lenacapavir and islatravir following the decision of fda to place clinical hold on the investigational new drug application for certain formulation of islatravir in september merck announced that the study would resume under an amended protocol with lower dose of islatravir arcuson may we entered into transaction with arcus publicly traded oncology focused biopharmaceutical company which included entry into an option license and collaboration agreement the collaboration agreement and common stock purchase agreement and an investor right agreement together and subsequently amended the stock purchase agreement in accordance with the term of the collaboration agreement and stock purchase agreement which closed on july we made an upfront payment of million and acquired approximately million share of arcus common stock for approximately million of the total million initial cash payment including transactional cost made under the agreement we recorded million an equity investment which wa calculated based on arcus closing stock price on the closing date of the transaction the remaining million wa attributed to the acquired license and option right of million representing ipr asset with no alternative future use ii million of an issuance premium for the equity purchase and iii million of direct transactional cost these amount were expensed acquired in process research and development expense during the year ended december on our consolidated statement of income under the stock purchase agreement we have the right to purchase from arcus additional share up to maximum of of the outstanding voting stock of arcus over five year period ending in the third quarter of we are also subject to three year standstill ending in the second quarter of restricting certain other activity on our part on may in separate secondary equity offering we acquired million share of common stock of arcus for approximately million in the first quarter of we also acquired approximately million additional share of arcus common stock for million result we currently own total of million share of arcus which represented approximately of the issued and outstanding voting stock of arcus immediately following the closing of the first quarter transaction to the collaboration agreement gilead had the right to opt in to all current and future clinical stage product candidate for up to ten year following the closing of the transaction in november we exercised our option to three of arcus clinical stage program and amended the collaboration agreement the option exercise and amendment transaction closed in december triggering collaboration opt in payment of million and waiving the million option continuation payment which would have been due to arcus in the third quarter of the net option charge of million is included within acquired in process research and development expense on our consolidated statement of income for the year ended december the collaboration opt in payment of million were recorded in other current liability on our consolidated balance sheet of december and paid to arcus in january our payment to arcus were included within net cash used in investing activity on our consolidated statement of cash flow in the first quarter of under the amended collaboration agreement the company co develop and share the global cost related to these clinical program we recorded million of such cost in research and development expense on our consolidated statement of income for the year ended december if the optioned molecule achieve regulatory approval the company will co commercialize and equally share profit in the gilead will hold exclusive commercialization right outside the subject to any right of arcus existing collaboration partner and will pay to arcus tiered royalty percentage of net sale ranging from the mid teen to low twenty under the collaboration agreement we may also pay an additional million at our option on each of the fourth sixth and eighth anniversary of the agreement unless terminated early to maintain the right to opt in to future arcus program for the duration of the contact term pionyron june we entered into transaction with pionyr privately held company pursuing novel biology in the field of immuno oncology which included entry into two separate merger agreement one contemplating the initial acquisition of equity interest in pionyr and the other providing the exclusive option subject to certain term and condition to acquire the remaining outstanding capital stock of pionyr together the pionyr merger and option agreement and service agreement on july we closed the transaction and made cash payment of million we account for our investment in pionyr using the equity method of accounting because our equity interest provides with the ability to exercise significant influence over pionyr our investment in pionyr consisting of the transaction price noted above and transaction cost exceeded our pro rata portion of pionyr net asset at transaction closing we determined that the resulting basis difference primarily relates to pionyr ipr which ha no alternative future use and that pionyr is not business defined in accounting standard result we immediately recorded charge for this basis difference of million in acquired in process research and development expense on our consolidated statement of income during the year ended december the carrying value of our equity method investment in pionyr wa zero of december and the estimated fair value of our exclusive option to acquire the remaining outstanding capital stock of pionyr is approximately million based on probability weighted option pricing model using unobservable input which are considered level under the fair value measurement and disclosure guidance the estimated amount is recorded in other long term asset on our consolidated balance sheet we may choose to exercise our exclusive option to purchase the remaining equity interest from pionyr current shareholder for million option exercise fee and up to billion in potential future milestone payment upon achievement of certain development and regulatory milestone such option to purchase will expire following the earliest occurrence of specified event including the delivery of data following completion of certain phase trial by pionyr under the service agreement we made an initial cash funding of million and recorded charge in acquired in process research and development expense on our consolidated statement of income during the year ended december in addition we committed to provide additional payment of up to million to pionyr upon achievement of certain development milestone we accrued million in milestone payment related to the initiation of two phase study with charge to acquired in process research and development expense on our consolidated statement of income during the year ended december and the payment wa made in the first quarter of tizonaon july we entered into transaction with tizona privately held company developing cancer immunotherapy which included entry into two separate merger agreement one contemplating the initial acquisition of equity interest in tizona and the other providing the exclusive option subject to certain term and condition to acquire the remaining outstanding capital stock of tizona together the tizona merger and option agreement and development agreement august we closed the transaction with tizona and made cash payment of million to tizona shareholder in accordance with the term of the tizona merger and option agreement we account for our investment in tizona using the equity method of accounting because our equity interest provides with the ability to exercise significant influence over tizona our investment in tizona consisting of the transaction price noted above and transaction cost exceeded our pro rata portion of tizona net asset at transaction closing we determined that the resulting basis difference primarily relates to tizona ipr with no alternative future use and that tizona is not business defined in accounting standard result during the year ended december we immediately recorded charge for this basis difference of million in acquired in process research and development expense on our consolidated statement of income the carrying value of our equity method investment in tizona wa zero of december and the estimated fair value of our exclusive option to acquire the remaining outstanding capital stock of tizona is approximately million based on probability weighted option pricing model using unobservable input which are considered level under the fair value measurement and disclosure guidance the estimated amount is recorded in other long term asset on our consolidated balance sheet we may choose to exercise our exclusive option to purchase the remaining equity interest from tizona current shareholder for million option exercise fee and up to billion in potential future milestone payment upon achievement of certain development and regulatory milestone such option to purchase will expire following the earliest occurrence of specified event including the delivery of data following completion of certain phase trial by tizona under the development agreement we committed to provide funding to tizona of million which wa recorded in acquired in process research and development expense on our consolidated statement of income during the year ended december tango therapeutic inc tango on august we entered into transaction with tango privately held company pursuing innovative targeted immune evasion therapy for patient with cancer through it proprietary crispr enabled functional genomics target discovery platform which included entry into an amended and restated research collaboration and license agreement and stock purchase agreement together the tango collaboration and stock purchase agreement upon entering into this transaction we made an upfront payment of million and million equity investment in tango during the year ended december we recorded the million upfront expense in acquired in process research and development expense on our consolidated statement of income in the third quarter of we made an additional million equity investment tango became publicly traded company in and accordingly our equity investment ha since been recorded in prepaid and other current asset on our consolidated balance sheet at fair market value under the tango collaboration and stock purchase agreement gilead ha the right to option up to program over the seven year collaboration for up to million per program in opt in extension and milestone payment for the product that tango opts to co develop and co promote the party will equally split profit and loss well development cost in the for product that tango doe not opt to co develop and co promote we will pay tango up to low double digit tiered royalty on net sale we will provide tango milestone payment and royalty on sale outside of the jounce therapeutic inc jounce on september we entered into transaction with jounce publicly traded company developing novel cancer immunotherapy which included entry into license registration right and stock purchase agreement together jounce license and stock purchase agreement in october we closed this transaction and made total payment of million we recorded million upfront expense in acquired in process research and development expense on our consolidated statement of income and million an equity investment in other long term asset on our consolidated balance sheet representing approximately of the issued and outstanding voting stock of jounce immediately following the transaction which wa calculated based on jounce closing stock price on the closing date of the transaction in december we amended our existing license agreement with jounce enabling to buy out the remaining contingent payment potentially due under the license agreement for million which wa expensed to acquired in process research and development expense on our consolidated statement of income and wa paid in going forward we will be solely responsible for all further research development and commercialization of the immunotherapy specified in the license agreement collaborationin we closed license and collaboration agreement with galapagos clinical stage biotechnology company based in belgium for the development and commercialization of filgotinib selective inhibitor being evaluated for inflammatory disease indication the filgotinib agreement under the term of the filgotinib agreement amended in the agreement we obtained an exclusive worldwide royalty bearing sublicensable license for filgotinib and product containing filgotinib in december gilead and galapagos amended their agreement to allow galapagos to assume development manufacturing commercialization and certain other right for filgotinib in europe in connection with the amendment to the agreement gilead agreed to irrevocably pay galapagos million or approximately million of this total amount gilead paid million or approximately million in january an additional million or approximately million in april and million or approximately million in we accrued the full amount of this liability with charge to research and development expense on our consolidated statement of income for the year ended december in addition galapagos will no longer be eligible to receive any future milestone payment relating to filgotinib in europe global collaborationin august we closed an option license and collaboration agreement the galapagos collaboration agreement and subscription agreement the galapagos subscription agreement each with galapagos pursuant to which the party entered into global collaboration that cover galapagos current and future product portfolio other than filgotinib pursuant to the galapagos subscription agreement we purchased million new ordinary share of galapagos and were issued warrant that confer the right to subscribe from time to time for number of new share to be issued by galapagos sufficient to bring the number of share owned by to of the issued and outstanding share at the time of our exercise we currently own million share or approximately of the share issued and outstanding at the time of last purchase in we are subject to year standstill restricting our ability to acquire voting security of galapagos exceeding more than of the then issued and outstanding voting security of galapagos we agreed not to without the prior consent of galapagos dispose of any equity security of galapagos prior to the second anniversary of the closing of the galapagos subscription agreement or dispose of any equity security of galapagos thereafter until the fifth anniversary of the closing of the galapagos subscription agreement if after such disposal we would own le than of the then issued and outstanding voting security of galapagos subject to certain exception and termination event in april we amended the galapagos subscription agreement to extend the initial lock up provision for certain galapagos share from august to august with respect to program in galapagos current and future pipeline if we exercise our option to program we will pay million option exercise fee per program in addition galapagos will receive tiered royalty ranging from to on net sale in our territory of each galapagos product optioned by if we exercise our option for program the party will share equally in development cost and mutually agreed commercialization cost incurred subsequent to our exercise of the option we may terminate the collaboration in it entirety or on program by program and country by country basis with advance notice well following other customary termination event we have two designees appointed to galapagos board of director janssencomplera eviplera and odefseyin we entered into license and collaboration agreement with janssen formerly tibotec pharmaceutical to develop and commercialize fixed dose combination of our truvada and janssen non nucleoside reverse transcriptase inhibitor rilpivirine this combination wa approved in the and eu in and is sold under the brand name complera in the and eviplera in the eu the agreement wa amended in to expand the collaboration to include another product containing janssen rilpivirine and our emtricitabine and tenofovir alafenamide odefsey under the amended agreement janssen granted an exclusive license to complera eviplera and odefsey worldwide but retained right to distribute both combination product in certain country outside of the neither party is restricted from combining it drug with any other drug product except those which are similar to the component of complera eviplera and odefsey we are responsible for manufacturing complera eviplera and odefsey and have the lead role in registration distribution and commercialization of both product except in the country where janssen distributes janssen ha exercised right to co detail the combination product in some of the country where we are the selling party the financial provision of the amendment the selling party set the price of the combined product and the party share revenue based on the ratio of the net selling price of the party component subject to certain restriction and adjustment we retain specified percentage of janssen share of revenue including up to in major market sale of these product are included in product sale and janssen share of revenue is included in cost of good sold on our consolidated statement of income cost of good sold relating to janssen share wa million million and million for the year ended december and respectively termination of the agreement may be on product or country basis and will depend on the circumstance including withdrawal of product from the market material breach by either party or expiry of the revenue share payment term we may terminate the agreement without cause with respect to the country where we sell the product in which case janssen ha the right to become the selling party for such country if the product ha launched but ha been on the market for fewer than year symtuzain we amended license and collaboration agreement with janssen to develop and commercialize fixed dose combination of janssen darunavir and our cobicistat emtricitabine and tenofovir alafenamide gilead compound this combination wa approved in the and eu in july and september respectively and is sold under the brand name symtuza under the term of the amendment we granted janssen an exclusive license to symtuza worldwide janssen is responsible for manufacturing registration distribution and commercialization of symtuza worldwide we are responsible for the intellectual property related to the gilead compound and are the exclusive supplier of the gilead compound neither party is restricted from combining it drug with any other drug product except those which are similar to the component of symtuza janssen set the price of symtuza and the party share revenue based on the ratio of the net selling price of the party component subject to certain restriction and adjustment the intellectual property license and supply obligation related to the gilead compound are accounted for single performance obligation the license wa deemed to be the predominant item to which the revenue share relates we recognize our share of the symtuza revenue in the period when the corresponding sale of symtuza by janssen occur we record our share of the symtuza revenue product sale on our consolidated statement of income primarily because we supply the gilead compound to janssen for symtuza termination of the agreement may be on product or country basis and will depend on the circumstance including withdrawal of product from the market material breach by either party or expiry of the revenue share payment term janssen may terminate the agreement without cause on country by country basis in which case gilead ha the right to become the selling party for such country if the product ha launched but ha been on the market for fewer than year janssen may also terminate the entire agreement without cause japan tobacco inc japan tobacco in japan tobacco granted exclusive right to develop and commercialize elvitegravir novel hiv integrase inhibitor in all country of the world excluding japan where japan tobacco retained such right effective december we entered into an agreement with japan tobacco to acquire the right to market and distribute certain product in our hiv portfolio in japan and to expand our right to develop and commercialize elvitegravir to include japan we are responsible for the marketing of the product of january we are responsible for seeking regulatory approval in our territory and are required to use diligent effort to commercialize elvitegravir for the treatment of hiv infection we bear all cost and expense associated with such commercialization effort and pay royalty to japan tobacco based on our product sale our sale of these product are included in product sale on our consolidated statement of income royalty due to japan tobacco are included in cost of good sold on our consolidated statement of income royalty expense recognized were million million and million for the year ended december and respectively under the term of the agreement we paid japan tobacco million in cash and recognized an intangible asset of million reflecting the estimated fair value of the marketing related right acquired from japan tobacco the intangible asset is being amortized over nine year representing the period over which the majority of the benefit are expected to be derived from the applicable product in our hiv portfolio the amortization expense is classified selling expense and recorded selling general and administrative expense on our consolidated statement of income termination of the agreement may be on product or country basis and will depend on the circumstance including material breach by either party or expiry of royalty payment term we may also terminate the entire agreement without cause april everest and immunomedics entered into an agreement granting everest an exclusive license to develop and commercialize trodelvy in greater china south korea singapore indonesia philippine vietnam thailand malaysia and mongolia the territory gilead subsequently acquired immunomedics in october and assumed the everest license and supply agreement which provided for certain sale milestone and royalty payment to be made to gilead and wa recorded million finite lived asset part of the purchase accounting in the fourth quarter of we reacquired all development and commercialization right for trodelvy from everest and terminated the previous agreement under the term of the new agreement gilead will make million in upfront termination payment to everest of which million wa made in with the remaining amount included in other current liability on our consolidated balance sheet of december in addition everest is eligible to receive up to million in potential additional payment upon achievement of certain regulatory and commercial milestone we accounted for the new agreement contract termination which includes the reacquisition of commercial right and the settlement of our pre existing relationship with everest result we recorded an expense of million in selling general and administrative expense on our consolidated statement of income which primarily represents the upfront cost and write off of the remaining value of the pre existing asset related to the prior agreement in addition we recorded an acquired finite lived asset with fair value of million for the commercial right reacquired for product approved in the territory other collaboration arrangement that are not individually significantduring and we entered into several collaboration equity investment and licensing arrangement well other similar arrangement that we do not consider to be individually material we recorded upfront collaboration expense related to these arrangement of million million and million for the year ended december and respectively within acquired in process research and development expense on our consolidated statement of income debt and credit facilitiesthe following table summarizes the carrying amount of our borrowing under various financing arrangement in million carrying amounttype of borrowingissue datematurity dateinterest ratedecember unsecuredseptember senior unsecuredseptember senior unsecuredseptember senior unsecuredseptember senior unsecuredmarch senior unsecurednovember senior unsecuredseptember senior unsecuredseptember senior unsecuredseptember senior unsecuredseptember senior unsecuredseptember senior unsecuredseptember senior unsecuredseptember senior unsecureddecember senior unsecuredmarch senior unsecurednovember senior unsecuredseptember senior unsecuredseptember senior unsecuredseptember total senior unsecured liability related to future total debt le current portion of long term debt and other obligation total long term debt net unsecured notesin february we repaid million of senior unsecured note prior to the march maturity by exercising par call option additionally in july we repaid billion of senior unsecured note prior to the september maturity by exercising par call option no new debt wa issued in our senior unsecured fixed rate note may be redeemed at our option at redemption price equal to the greater of of the principal amount of the note to be redeemed and ii the sum determined by an independent investment banker of the present value of the remaining scheduled payment of principal and interest on the note to be redeemed exclusive of interest accrued to the date of redemption discounted to the redemption date on semiannual basis at the treasury rate plus make whole premium which are defined in the term of the note the senior unsecured fixed rate note also have par call feature exercisable at our option to redeem the note at par in whole or in part on date ranging from two to six month prior to maturity in each case accrued and unpaid interest is also required to be redeemed to the date of redemption the billion of senior unsecured note due september also have different call feature exercisable at our option to redeem the note at par in whole or in part at any time until maturity in the event of change in control and downgrade in the rating of our senior unsecured note below investment grade by moody investor service inc and global rating the holder may require to purchase all or portion of their note at price equal to of the aggregate principal amount of the note repurchased plus accrued and unpaid interest to the date of repurchase we are required to comply with certain covenant under our note indenture governing our senior unsecured note of december and we were not in violation of any covenant liability related to future royaltiesin connection with our acquisition of immunomedics we assumed liability related to funding arrangement which wa originally entered into by immunomedics and rpi finance trust rpi prior to our acquisition of immunomedics under the funding agreement rpi ha the right to receive certain royalty amount subject to certain reduction based on the net sale of trodelvy for each calendar quarter during the term of the agreement through approximately the liability is amortized using the effective interest rate method resulting in recognition of interest expense over year the estimated timing and amount of future expected royalty payment over the estimated term will be assessed each reporting period the impact from change in estimate will be recognized in the liability and the related interest expense prospectively the liability related to future royalty wa primarily included in long term debt net on our consolidated balance sheet revolving credit facilitiesin june we entered into new billion five year revolving credit facility maturing in june the revolving credit facility the revolving credit facility can be used for working capital requirement and for general corporate purpose including without limitation acquisition of december and there were no amount outstanding under the revolving credit facility the revolving credit facility contains customary representation warranty affirmative and negative covenant and event of default of december we were in compliance with all covenant loan under the revolving credit facility bear interest at either the term secured overnight financing rate sofr plus the applicable percentage or ii the base rate plus the applicable percentage each defined in the revolving credit facility agreement we may terminate or reduce the commitment and may prepay any loan under the credit facility in whole or in part at any time without premium or penalty contractual maturity of financing obligationsthe following table summarizes the aggregate future principal maturity of our senior unsecured note of december in million total expenseinterest expense on our debt and credit facility related to the contractual coupon rate and amortization of the debt discount and issuance cost wa million in and billion in and leasesour operating lease consist primarily of property and equipment for our administrative manufacturing and activity some of our lease include option to extend the term for up to year and some include option to terminate the lease within one year after the lease commencement date of december and we did not have material finance lease operating lease expense including variable cost and short term lease wa million million and million in and respectively the following table summarizes balance sheet and other information related to our operating lease december in million except weighted average amount of use asset netother long term asset lease liability currentother accrued liability lease liability noncurrentother long term obligation weighted average remaining lease yearsweighted average discount the following table summarizes other supplemental information related to our operating lease year ended december in million paid for amount included in the measurement of lease liability right of use asset obtained in exchange for lease liability the following table summarizes maturity analysis of our operating lease liability showing the aggregate lease payment of december in million total undiscounted lease le imputed total discounted lease payment commitment and contingency legal proceedingswe are party to various legal action certain significant matter are described below we recognize accrual for such action to the extent that we conclude that loss is both probable and reasonably estimable we accrue for the best estimate of loss within range however if no estimate in the range is better than any other then we accrue the minimum amount in the range if we determine that material loss is reasonably possible and the loss or range of loss can be estimated we disclose the possible loss unless otherwise noted the outcome of these matter either is not expected to be material or is not possible to determine such that we can not reasonably estimate the maximum potential exposure or the range of possible loss we did not have any material accrual for the matter described below of december of december we recorded an accrual of billion in accrued and other current liability on our consolidated balance sheet for the previously disclosed legal settlement related to the bictegravir litigation which we paid in february related to sofosbuvirin we acquired pharmasset inc through the acquisition we acquired sofosbuvir nucleotide analog that act to inhibit the replication of hcv in we received approval from fda for sofosbuvir sold under the brand name sovaldi sofosbuvir is also included in all of our marketed hcv product we have received number of litigation claim regarding sofosbuvir while we have carefully considered these claim both prior to and following the acquisition and believe they are without merit we can not predict the ultimate outcome of such claim or range of loss we are aware of patent and patent application owned by third party that have been or may in the future be alleged by such party to cover the use of our hcv product if third party obtain valid and enforceable patent and successfully prove infringement of those patent by our hcv product we could be required to pay significant monetary damage we can not predict the ultimate outcome of intellectual property claim related to our hcv product we have spent and will continue to spend significant resource defending against these claim litigation with the university of minnesotathe university of minnesota the university ha obtained patent no the patent which purport to broadly cover nucleoside with antiviral and anticancer activity in the university filed lawsuit against in the district court for the district of minnesota alleging that the commercialization of sofosbuvir containing product infringes the patent we believe the patent is invalid and will not be infringed by the continued commercialization of sofosbuvir in the court granted our motion to transfer the case to california we have also filed petition for inter partes review with the patent and trademark office patent trial and appeal board ptab alleging that all asserted claim are invalid for anticipation and obviousness the ptab instituted one of these petition and merit hearing wa held in february in the district court for the northern district of california stayed the litigation until after the ptab concluded the inter partes review that it had initiated in may the ptab issued written decision finding the asserted claim of the university patent invalid in july the university appealed this decision and oral argument before the court of appeal for the federal circuit were held in january the litigation in the district court will remain stayed through the appeal proceeding litigation with nucana plc nucana nucana ha obtained european patent no the ep patent that allegedly cover sofosbuvir in opposition proceeding before the european patent office epo held in february the epo opposition division upheld the validity of the ep patent in amended form the epo ha scheduled the appeal hearing for march we continue to believe that the amended ep patent claim are invalid subsequent to the epo opposition decision we initiated proceeding to invalidate the counterpart of the ep patent and related patent european patent no the ep patent in the high court of england wale nucana ha also filed counterclaim against in the high court of england wale alleging patent infringement of the counterpart and seeking damage and other relief the case wa heard in january and early february in april nucana also filed lawsuit against in germany at the landgericht dsseldorf alleging patent infringement of the german counterpart of the ep patent and seeking damage and injunctive relief in april we filed an action for grant of compulsory license before the federal patent court in germany in july the dsseldorf court determined that nucana german counterpart of the ep patent is infringed and granted an injunction in august gilead filed notice of appeal regarding the dsseldorf court decision and hearing is scheduled for august litigation related to axicabtagene ciloleucelin october juno therapeutic inc and sloan kettering cancer center collectively juno filed lawsuit against in the district court for the central district of california alleging that the commercialization of axicabtagene ciloleucel sold commercially yescarta infringes patent no the patent jury trial wa held on the patent and in december the jury found that the asserted claim of the patent were valid and that we willfully infringed the asserted claim of the patent the jury also awarded juno damage in amount of million in an upfront payment and running royalty from october through the date of the jury verdict the party filed post trial motion in the first quarter of and the trial judge entered judgment in april the trial judge affirmed the jury verdict enhanced the past damage by and maintained the royalty on future yescarta sale at in april we filed an appeal seeking to reverse the judgment or obtain new trial due to error made by the trial judge and in july the appeal court heard oral argument in august the court of appeal for the federal circuit the cafc reversed the jury verdict finding the asserted claim of juno patent invalid in october juno filed petition for rehearing with the cafc in january the cafc denied juno petition for rehearing in june juno filed petition for certiorari seeking review by the supreme court the supreme court rejected juno petition in january making the cafc judgment final relating to pre exposure prophylaxisin august we filed petition requesting inter partes review of patent no and collectively hhs patent by ptab the hhs patent are assigned to the department of health and human service hhs and purport to claim process of protecting primate host from infection by an immunodeficiency retrovirus by administering combination of ftc and tenofovir disoproxil fumarate tdf or taf prior to exposure of the host to the immunodeficiency retrovirus process commonly known pre exposure prophylaxis prep in november the department of justice filed lawsuit against in the district court of delaware alleging that the sale of truvada and descovy for use prep infringes the hhs patent in february ptab declined to institute our petition for inter partes review of the hhs patent in april we filed breach of contract lawsuit against the federal government in the court of federal claim alleging violation of three material transfer agreement mtas related to the research underlying the hhs patent and two clinical trial agreement ctas by the center for disease control and prevention related to prep research although we can not predict with certainty the ultimate outcome of each of these litigation matter we believe that the federal government breached the mtas and cta that truvada and descovy do not infringe the hhs patent and that the hhs patent are invalid over prior art description of truvada use for prep and post exposure prophylaxis well because physician and patient were using the claimed method year before hhs filed the application for the patent trial for the bifurcated portion of the lawsuit in the court of federal claim wa held in june and in november the court determined that the government breached the three mtas the court also made finding of fact relating to the ctas but declined to issue decision on breach of the ctas until after trial in the delaware district court trial date for the lawsuit in the delaware district court ha been set for may separate trial at the court of federal claim to determine the damage gilead is owed based on the government breach ha yet to be set litigation with generic manufacturersas part of the approval process for some of our product fda granted new chemical entity nce exclusivity period during which other manufacturer application for approval of generic version of our product will not be approved generic manufacturer may challenge the patent protecting product that have been granted nce exclusivity one year prior to the end of the nce exclusivity period generic manufacturer have sought and may continue to seek fda approval for similar or identical drug through an abbreviated new drug application anda the application form typically used by manufacturer seeking approval of generic drug the sale of generic version of our product prior to their patent expiration would have significant negative effect on our revenue and result of operation to seek approval for generic version of product nce status generic company may submit it anda to fda four year after the branded product approval in october we received letter from lupin ltd lupin indicating that it ha submitted an anda to fda requesting permission to market and manufacture generic version of symtuza product commercialized by janssen and for which gilead share in revenue in november we along with janssen product and janssen janssen filed patent infringement lawsuit against lupin co plaintiff in the district court of delaware we separately filed an additional lawsuit against lupin asserting infringement of two additional patent in the same court this second case ha been stayed trial ha been scheduled for october in september we received letter from apotex inc and apotex corp apotex stating that they have submitted an anda for generic version of symtuza in october we along with janssen filed patent infringement lawsuit against apotex co plaintiff in the district court of delaware we separately filed an additional lawsuit against apotex asserting infringement of two additional patent in the same court starting in march we received letter from lupin laurus lab laurus and cipla ltd cipla indicating that they have submitted andas to fda requesting permission to market and manufacture generic version of biktarvy lupin laurus and cipla have challenged the validity of three of the five patent listed in the orange book associated with biktarvy we filed lawsuit against lupin laurus and cipla in may in the district court of delaware and intend to enforce and defend our intellectual property trial ha been scheduled for december european patent claimsin several party filed opposition in the epo requesting revocation of one of our granted european patent covering sofosbuvir that expires in in the epo upheld the validity of certain claim of our sofosbuvir patent we have appealed this decision seeking to restore all of the original claim and several of the original opposing party have also appealed requesting full revocation the appeal hearing wa held in november but final decision regarding the validity of the claim ha not yet been announced in several party filed opposition in the epo requesting revocation of our granted european patent relating to sofosbuvir that expires in the epo conducted an oral hearing for this opposition in and upheld the claim the original opposing party have appealed requesting full revocation the hearing for the appeal ha been scheduled for september several party filed opposition in the epo requesting revocation of our granted european patent relating to taf hemifumarate that expires in in the epo upheld the validity of the claim of our taf hemifumarate patent three party have appealed this decision the hearing for the appeal ha been scheduled for march the appeal process may take several year for all epo opposition proceeding while we are confident in the strength of our patent we can not predict the ultimate outcome of these opposition if we are unsuccessful in defending these opposition some or all of our patent claim may be narrowed or revoked and the patent protection for sofosbuvir and taf hemifumarate in the eu could be substantially shortened or eliminated entirely if our patent are revoked and no other european patent are granted covering these compound our exclusivity may be based entirely on regulatory exclusivity granted by ema if we lose patent protection for any of these compound our revenue and result of operation could be negatively impacted for the year including and succeeding the year in which such exclusivity is lost antitrust and consumer protectionwe along with bristol myers squibb company bm and johnson johnson inc have been named defendant in class action lawsuit filed in and related to various drug used to treat hiv including drug used in combination antiretroviral therapy plaintiff allege that we and the other defendant engaged in various conduct to restrain competition in violation of federal and state antitrust law and state consumer protection law the lawsuit which have been consolidated are pending in the district court for the northern district of california the lawsuit seek to bring claim on behalf of direct purchaser consisting largely of wholesaler and indirect or end payor purchaser including health insurer and individual patient plaintiff seek damage permanent injunctive relief and other relief in the second half of and first half of several plaintiff filed separate lawsuit effectively opting out of the class action case asserting claim that are substantively the same the putative class these case have been coordinated with the class action trial ha been set for may in january we along with bm and janssen product were named defendant in lawsuit filed in the superior court of the state of california county of san mateo by aetna inc on behalf of and it affiliate and subsidiary that effectively opts the aetna plaintiff out of the above class action the allegation are substantively the same those in the class action the aetna plaintiff seek damage permanent injunctive relief and other relief in september we along with generic manufacturer cipla and cipla usa inc together cipla defendant were named defendant in class action lawsuit filed in the district court for the northern district of california by jacksonville police officer and fire fighter health insurance trust jacksonville trust on behalf of end payor purchaser jacksonville trust claim that the settlement agreement between and the cipla defendant which settled patent dispute relating to patent covering our emtriva truvada and atripla product and permitted generic entry prior to patent expiry violates certain federal and state antitrust and consumer protection law the plaintiff seek damage permanent injunctive relief and other relief in february we along with bm and teva pharmaceutical industry ltd were named defendant in lawsuit filed in the first judicial district court for the state of new mexico county of santa fe by the new mexico attorney general the new mexico attorney general alleges that we and the other defendant restrained competition in violation of new mexico antitrust and consumer protection law the new mexico attorney general seek damage permanent injunctive relief and other relief while we believe these case are without merit we can not predict the ultimate outcome if plaintiff are successful in their claim we could be required to pay significant monetary damage or could be subject to permanent injunctive relief awarded in favor of plaintiff product liabilitywe have been named defendant in one class action lawsuit and various product liability lawsuit related to viread truvada atripla complera and stribild plaintiff allege that viread truvada atripla complera and or stribild caused them to experience kidney bone and or tooth injury the lawsuit which are pending in state or federal court in california delaware florida missouri and new york involve more than plaintiff plaintiff in these case seek damage and other relief on various ground for alleged personal injury and economic loss the first bellwether trial in california state court wa scheduled to begin in october but is currently stayed while the california first district court of appeal considers the merit of plaintiff theory of liability the first bellwether trial in california federal court is scheduled to begin in january we intend to vigorously defend ourselves in these action while we believe these case are without merit we can not predict the ultimate outcome if plaintiff are successful in their claim we could be required to pay significant monetary damage government investigationin we received subpoena from the attorney office for the southern district of new york requesting document related to our promotional speaker program for hiv we are cooperating with this inquiry tam litigationa former sale employee filed qui tam lawsuit against gilead in march in district court for the eastern district of pennsylvania following the government decision not to intervene in the suit the case wa unsealed in december the lawsuit alleges that certain of gilead hcv sale and marketing activity violated the federal false claim act and various state false claim act the relator seek all available relief under these statute health choice advocate llc health choice filed qui tam lawsuit against gilead in april in new jersey state court following the new jersey attorney general office decision not to intervene in the suit health choice served with their original complaint in august the lawsuit alleges that gilead violated the new jersey false claim act through our clinical educator program for sovaldi and harvoni and our hcv and hiv patient access program the lawsuit seek all available relief under the new jersey false claim act in april the trial court granted our motion to dismiss with prejudice health choice ha appealed the trial court dismissal health choice filed another qui tam lawsuit against gilead in may making similar allegation in texas state court following the texas attorney general office decision not to intervene in the suit health choice served with their original complaint in october the lawsuit alleges that gilead violated the texas medicare fraud prevention act tmfpa through our clinical educator program for sovaldi and harvoni and our hcv and hiv patient access program the lawsuit seek all available relief under the tmfpa in september the texas court of appeal for the sixth court appeal district granted our request to stay the texas litigation pending final judgment in the eastern district of pennsylvania lawsuit filed in march discussed above we intend to vigorously defend ourselves in these action while we believe these case are without merit we can not predict the ultimate outcome if any of these plaintiff are successful in their claim we could be required to pay significant monetary damage security litigationimmunomedics and several of it former officer and director have been named defendant in putative class action filed in and which were consolidated in september plaintiff filed consolidated complaint in november and an amended complaint in july plaintiff allege that immunomedics and the individual defendant violated the federal security law in connection with immunomedics biologics license application for trodelvy and seek certification of class of shareholder damage and other relief the consolidated lawsuit is pending in the district court for the district of new jersey in june plaintiff filed their motion for class certification and immunomedics submitted it opposition in july the party have agreed to settle this litigation motion seeking preliminary approval of the settlement wa granted in february the court ha not yet entered final order approving the settlement other matterswe are party to various legal action that arose in the ordinary course of our business we do not believe that these other legal action will have material adverse impact on our consolidated financial position result of operation or cash flow stockholder equity stock repurchase programsin the first quarter of our board of director authorized billion stock repurchase program program purchase under the program may be made in the open market or in privately negotiated transaction the billion stock repurchase program authorized by our board of director in the first quarter of wa completed in the fourth quarter of we started repurchase under the program in december of december the remaining authorized repurchase amount under the program wa billion the following table summarizes our stock repurchase through open market transaction under these program year ended december in million except per share amount repurchased and amount average price per share in addition to repurchase from the stock repurchase program we repurchased share of common stock withheld by from employee restricted stock award to satisfy our applicable tax withholding obligation these share are excluded from the table above use the par value method of accounting for our stock repurchase under the par value method common stock is first charged with the par value of the share involved the excess of the cost of share acquired over the par value is allocated to additional paid in capital based on an estimated average sale price per issued share with the excess amount charged to retained earnings dividendsthe following table summarizes cash dividend declared on our common stock in million except per share amount dividend per shareamountdividend per shareamountfirst quarter second third fourth total our rsus and psus have dividend equivalent right entitling holder to dividend equivalent to be paid upon vesting for each share of the underlying unit on february we announced that our board of director declared quarterly cash dividend increase of from to per share of our common stock with payment date of march to all stockholder of record of the close of business on march future dividend are subject to declaration by our board of director preferred stockwe have million share of authorized preferred stock issuable in series our board is authorized to determine the designation power preference and right of any such series there wa no preferred stock outstanding of december and accumulated other comprehensive income the following table summarizes the change in accumulated other comprehensive income by component net of tax in million foreign currency translationunrealized gain and loss on available for sale debt security net of taxunrealized gain and loss on cash flow hedge net of taxtotalbalance of december net unrealized gain loss reclassification to net income net current period other comprehensive income loss balance of december net unrealized gain loss reclassification to net income net current period other comprehensive income loss balance of december net unrealized gain loss reclassification to net income net current period other comprehensive income loss balance of december employee benefit stock based compensationequity incentive plan summaryin may our stockholder approved and we adopted the gilead science inc equity incentive plan amended the plan part of our acquisition of forty seven in we assumed the forty seven inc equity incentive plan which we subsequently amended and restated the gilead science inc equity incentive plan amended and restated the plan part of the immunomedics acquisition we assumed the immunomedics amended and restated long term incentive plan which we subsequently merged into the plan in may our stockholder approved and we adopted the gilead science inc equity incentive plan the plan the plan authorized the issuance of total of million share of common stock no award may be granted under the plan or the plan since the approval of the plan these are broad based incentive plan that provide for the grant of equity based award including rsus psus stock option and other restricted stock and performance award to employee director and consultant of december total of million share remain available for future grant under the plan rsuswe grant time based rsus to certain employee part of our annual employee equity compensation review program well to new hire employee and to non employee member of our board rsus are share based award that entitle the holder to receive freely tradable share of our common stock upon vesting rsus generally vest over three or four year from the date of grant psuswe grant psus that vest upon the achievement of specified market or performance goal which could include achieving total shareholder return compared to pre determined peer group or achieving revenue target the actual number of common share ultimately issued is calculated by multiplying the number of psus by payout percentage ranging from to and these award generally vest only when committee or subcommittee of our board ha determined that the specified market and performance goal have been achieved stock optionsoption grant are designated either non statutory or incentive stock option the exercise price of stock option may not be le than the fair market value of our common stock on the grant date and no stock option may have term in excess of year employee stock option generally vest over three or four year stock option may be settled in cash or in share of our common stock including net issuance using share otherwise purchasable under the option to pay the exercise price espp summaryunder our espp employee can purchase share of our common stock based on percentage of their compensation subject to certain limit the purchase price per share is equal to the lower of of the fair market value of our common stock on the offering date or the purchase date the espp offer six month look back feature espp purchase are settled with common stock from the espp previously authorized and available pool of share total of million share of common stock have been authorized for issuance under the espp and there were million share available for issuance under the espp of december based compensation expensethe following table summarize total stock based compensation expense included on our consolidated statement of income broken down by award type and by expense type year ended december in million stock acquisition related expense stock based compensation expense included in total cost and expense ________________________________ accelerated post acquisition stock based compensation expense of million related to the mirobio acquisition in and million and million related to the acquisition of immunomedics and forty seven respectively in year ended december in million of good sold research and development selling general and administrative stock based compensation expense included in total cost and income tax effect stock based compensation expense net of tax rsusthe following table summarize our rsu activity rsus in million except per share amount sharesweighted averagegrant date fair value per shareoutstanding of december vested forfeited outstanding of december year ended december in million except per share amount average grant date fair value of rsus granted total fair value of rsus of the respective vesting date of december there wa million of unrecognized compensation cost related to unvested rsus which is expected to be recognized over weighted average period of year following table summarize our psu activity psus in million except per share amount sharesweighted averagegrant date fair value per shareoutstanding of december vested forfeited outstanding of december year ended december in million except per share amount average grant date fair value of psus granted total fair value of psus of the respective vesting date of december there wa million of unrecognized compensation cost related to unvested psus which is expected to be recognized over weighted average period of year stock option the following table summarize activity and other information related to our stock option share in million weighted averageexercise price in dollar weighted averageremainingcontractual term year aggregate intrinsicvalue in million outstanding of december forfeited expired exercised outstanding of december exercisable of december expected to vest net of estimated forfeiture of december ________________________________ aggregate intrinsic value represents the value of our closing stock price on the last trading day of the year in excess of the weighted average exercise price multiplied by the number of option outstanding or exercisable year ended december in million except per share amount average grant date fair value of stock option granted total intrinsic value of option exercised we used the following weighted average assumption in the black scholes model to calculate the estimated fair value of the stock option award year ended december in million expected term in free interest expected dividend of december there wa million of unrecognized compensation cost related to stock option which is expected to be recognized over an estimated weighted average period of year esppthe following table summarizes our espp activity year ended december in million except per share amount amount paid by employee for share weighted average grant date fair value of espp share granted total fair value of espp share of the respective vesting date we used the following weighted average assumption in the black scholes model to calculate the estimated fair value of the espp award year ended december expected term in free interest expected dividend deferred compensationwe maintain retirement saving plan under which eligible employee may defer compensation for income tax purpose under section of the internal revenue code the gilead science plan in certain foreign subsidiary we maintain defined benefit plan required by local regulatory requirement our total matching contribution expense under the gilead science plan and other defined benefit plan wa million million and million during and respectively we maintain deferred compensation plan under which our director and key employee may defer compensation amount deferred by participant are deposited into rabbi trust the total asset and liability associated with the deferred compensation plan were million and million of december and respectively earnings per sharethe following table show the calculation of basic and diluted earnings per share attributable to gilead year ended december in million except per share amount income attributable to gilead share used in basic earnings per share attributable to gilead dilutive effect of stock option and share used in diluted earnings per share attributable to gilead basic earnings per share attributable to gilead diluted earnings per share attributable to gilead potential share of common stock excluded from the computation of diluted earnings per share attributable to gilead because their effect would have been antidilutive were million million and million during and respectively income taxesincome before income tax consists of the following year ended december in million income before income tax income tax expense consists of the following year ended december in million current state current foreign current deferred income tax expense the reconciliation between the federal statutory tax rate applied to income before income tax and our effective tax rate is summarized follows year ended december statutory state tax net of federal benefit foreign earnings at different rate research and other credit tax on foreign foreign derived intangible income deduction settlement of tax examination acquired ipr related change in valuation non taxable unrealized loss on effective tax component of our deferred tax asset and liability are follows december in million tax asset net operating loss carryforwards stock based reserve and accrual not currently excess of tax basis over book basis of intangible upfront and milestone research and other credit equity liability related to sale of future capitalized other total deferred tax asset before valuation valuation allowance total deferred tax deferred tax liability property plant and equipment excess of book basis over tax basis of intangible asset other total deferred tax liability net deferred tax asset liability the valuation allowance increased from million of december to million of december primarily due to unrealized loss on our equity investment which are subject to full valuation allowance and increased from million of december to million of december primarily due to california research and development tax credit of december we had federal net operating loss and tax credit carryforwards of approximately million and million respectively which will start to expire in if not utilized in addition we had state net operating loss and tax credit carryforwards of approximately billion and million respectively which will start to expire in and respectively if not utilized utilization of net operating loss and tax credit may be subject to an annual limitation due to ownership change limitation provided in the internal revenue code of amended and similar state provision this annual limitation may result in the expiration of the net operating loss and credit before utilization we file federal state and foreign income tax return in the and in many foreign jurisdiction for federal income tax purpose the statute of limitation is open for and onwards and and onwards for california income tax purpose for certain acquired entity the statute of limitation is open for all year from inception due to our utilization of their net operating loss and credit carried over from prior year our income tax return are subject to audit by federal state and foreign tax authority we are currently under examination by the internal revenue service and irish tax authority for our to tax year there are differing interpretation of tax law and regulation and result significant dispute may arise with these tax authority involving issue of the timing and amount of deduction and allocation of income among various tax jurisdiction we periodically evaluate our exposure associated with our tax filing position of the total unrecognized tax benefit million and million of december and respectively if recognized would reduce our effective tax rate in the period of recognition interest and penalty related to unrecognized tax benefit included income tax benefit of million income tax expense of million and income tax benefit of million on our consolidated statement of income for the year ended december and respectively accrued interest and penalty related to unrecognized tax benefit were million and million of december and respectively of december we do not believe that it is reasonably possible that our unrecognized tax benefit will significantly change in the next month following is rollforward of our total gross unrecognized tax benefit year ended december in million balance tax position related to current year reduction tax position related to prior year reduction settlement lapse of statute of limitation ending balance in connection with the tax cut and job act we recorded federal income tax payable for transition tax on the mandatory deemed repatriation of foreign earnings that is payable over an eight year period federal income tax payable for transition tax wa billion and billion of december and respectively the following table summarizes the anticipated timing of payment associated with this transition tax of december in million total subsequent eventsarcellxin january we closed an agreement to enter into global strategic collaboration with arcellx inc arcellx to co develop and co commercialize arcellx lead late stage product candidate cart ddbcma for the treatment of patient with relapsed or refractory multiple myeloma under the term of the agreement arcellx will receive an upfront cash payment of million and million equity investment well other potential contingent payment the company will share development clinical trial and commercialization cost for cart ddbcma and will jointly commercialize the product and split profit outside the we will commercialize the product and arcellx will receive royalty on sale tmunityin february we closed an agreement to acquire tmunity therapeutic tmunity clinical stage private biotech company focused on next generation car therapy and technology under the term of the agreement we acquired all outstanding share of tmunity other than those already owned by gilead for approximately million in cash consideration change in and disagreement with accountant on accounting and financial disclosure not applicable of independent registered public accounting firmto the stockholder and the board of director of gilead science inc opinion on internal control over financial reporting we have audited gilead science inc internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission framework the coso criterion in our opinion gilead science inc the company maintained in all material respect effective internal control over financial reporting of december based on the coso criterion we also have audited in accordance with the standard of the public company accounting oversight board united state pcaob the consolidated balance sheet of the company of december and the related consolidated statement of income comprehensive income stockholder equity and cash flow for each of the three year in the period ended december and the related note and our report dated february expressed an unqualified opinion thereon basis for opinion the company management is responsible for maintaining effective internal control over financial reporting and for it assessment of the effectiveness of internal control over financial reporting included in the accompanying management report on internal control over financial reporting our responsibility is to express an opinion on the company internal control over financial reporting based on our audit we are public accounting firm registered with the pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting wa maintained in all material respect our audit included obtaining an understanding of internal control over financial reporting assessing the risk that material weakness exists testing and evaluating the design and operating effectiveness of internal control based on the assessed risk and performing such other procedure we considered necessary in the circumstance we believe that our audit provides reasonable basis for our opinion definition and limitation of internal control over financial reporting company internal control over financial reporting is process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle company internal control over financial reporting includes those policy and procedure that pertain to the maintenance of record that in reasonable detail accurately and fairly reflect the transaction and disposition of the asset of the company provide reasonable assurance that transaction are recorded necessary to permit preparation of financial statement in accordance with generally accepted accounting principle and that receipt and expenditure of the company are being made only in accordance with authorization of management and director of the company and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition use or disposition of the company asset that could have material effect on the financial statement because of it inherent limitation internal control over financial reporting may not prevent or detect misstatement also projection of any evaluation of effectiveness to future period are subject to the risk that control may become inadequate because of change in condition or that the degree of compliance with the policy or procedure may deteriorate ernst young llpsan jose californiafebruary control and procedure evaluation of disclosure control and procedure an evaluation of december wa carried out under the supervision and with the participation of our management including our chief executive officer and chief financial officer of the effectiveness of our disclosure control and procedure which are defined in rule and under the security exchange act of amended the exchange act control and other procedure of company that are designed to ensure that the information required to be disclosed by company in the report that it file or submits under the exchange act is recorded processed summarized and reported within the time period specified in the security and exchange commission rule and form and that such information is accumulated and communicated to the company management including it chief executive officer and chief financial officer appropriate to allow timely decision regarding required disclosure based upon that evaluation our chief executive officer and chief financial officer concluded that our disclosure control and procedure were effective of december management report on internal control over financial reporting our management is responsible for establishing and maintaining adequate internal control over financial reporting such term is defined in rule and of the exchange act our internal control system is designed to provide reasonable assurance regarding the preparation and fair presentation of financial statement for external purpose in accordance with generally accepted accounting principle all internal control system no matter how well designed have inherent limitation and can provide only reasonable assurance that the objective of the internal control system are met under the supervision and with the participation of our management including our chief executive officer and chief financial officer we conducted an evaluation of the effectiveness of our internal control over financial reporting based on criterion established by the committee of sponsoring organization of the treadway commission coso in it internal control integrated framework based on our evaluation we concluded that our internal control over financial reporting wa effective of december our independent registered public accounting firm ernst young llp ha audited our consolidated financial statement included in item of this annual report on form and have issued report on our internal control over financial reporting of december it report on the audit of internal control over financial reporting appears above change in internal control over financial reporting our management including our chief executive officer and chief financial officer ha evaluated any change in our internal control over financial reporting that occurred during the quarter ended december and ha concluded that there wa no change during such quarter that ha materially affected or is reasonably likely to materially affect our internal control over financial reporting item other informationnot applicable item disclosure regarding foreign jurisdiction that prevent inspectionsnot applicable part iii item director executive officer and corporate governance the information required by this item concerning our director and executive officer is incorporated by reference to the section of our definitive proxy statement to be filed with the security and exchange commission pursuant to regulation in connection with our annual meeting of stockholder the proxy statement under the heading the gilead board of director nominee board structure executive officer and if applicable delinquent section report our written code of ethic applies to all of our director and employee including our executive officer including without limitation our principal executive officer principal financial officer principal accounting officer or controller or person performing similar function the code of ethic is available on our website at www gilead com in the investor section under governance governance document we intend to disclose future amendment to certain provision of the code of ethic and waiver of the code of ethic granted to executive officer and director on the website within four business day following the date of the amendment or waiver executive compensation the information required by this item is incorporated by reference to the section of the proxy statement under the heading executive compensation committee of our board of director compensation and talent committee report and compensation of non employee board member item security ownership of certain beneficial owner and management and related stockholder mattersthe information required by this item is incorporated by reference to item of our annual report on form under the heading security authorized for issuance under equity compensation plan and the section of the proxy statement under the heading security ownership of certain beneficial owner and management item certain relationship and related transaction and director independence the information required by this item is incorporated by reference to the section of the proxy statement under the heading the gilead board of director and board process item principal accountant fee and service the information required by this item is incorporated by reference to the section of the proxy statement under the heading principal accountant fee and service part iv item exhibit and financial statement schedule the following document are filed part of this annual report on form index list to consolidated financial statement report of independent registered public accounting firm pcaob id consolidated financial statement consolidated balance statement of statement of comprehensive income loss statement of stockholder statement of cash to consolidated financial all other schedule are omitted because they are not required or the required information is included in the financial statement or note thereto exhibit the following exhibit are filed herewith or incorporated by reference exhibitfootnoteexhibit numberdescription of document certificate of incorporation of registrant and restated bylaw of is made to exhibit and exhibit related to senior note dated of march between registrant and well fargo national association trustee supplemental indenture related to senior note dated of march between registrant and well fargo national association trustee including form of senior note supplemental indenture related to senior note dated of december between registrant and well fargo national association trustee including form of note supplemental indenture related to senior note dated of march between registrant and well fargo national association trustee including form of note and form of note supplemental indenture related to senior note dated of november between registrant and well fargo national association trustee including form of note and form of note supplemental indenture dated of september between registrant and well fargo bank national association trustee including form of note form of note and form of note supplemental indenture dated of september between registrant and well fargo bank national association trustee including form of note form of note form of note and form of note supplemental indenture dated of september between the registrant and well fargo bank national association trustee including form of note of registrant security gilead science inc equity incentive plan amended and restated may amendment no to gilead science inc equity incentive plan amended and restated may gilead science inc equity incentive plan form of employee stock option agreement under equity incentive plan for grant made in through form of employee stock option agreement under equity incentive plan for grant made in form of global employee stock option agreement under equity incentive plan year vest for grant made in form of global employee stock option agreement under equity incentive plan year vest for grant made in form of global employee stock option agreement under equity incentive plan year vest for grant made in form of global employee stock option agreement under equity incentive plan year vest for certain grant made in form of global employee stock option agreement under equity incentive plan year vest for certain grant commencing in form of non employee director stock option agreement under equity incentive plan for grant made in through form of non employee director stock option agreement under equity incentive plan for grant made in form of non employee director stock option agreement non under equity incentive plan for grant made in form of non employee director stock option agreement under equity incentive plan for grant made in through form of non employee director stock option agreement under equity incentive plan for grant made in form of non employee director stock option agreement under equity incentive plan for grant made in and form of non employee director stock option agreement under equity incentive plan for grant commencing in form of performance share award agreement tsr goal under equity incentive plan for grant made in form of performance share award agreement tsr goal under equity incentive plan for grant made in form of performance share award agreement tsr goal under equity incentive plan for grant made in form of performance share award agreement tsr goal under equity incentive plan for grant commencing in form of performance share award agreement revenue goal under equity incentive plan for grant made in form of performance share award agreement revenue goal under equity incentive plan for grant made in form of performance share award agreement revenue goal under equity incentive plan for grant made in form of performance share award agreement revenue goal under equity incentive plan for grant commencing in form of employee restricted stock unit issuance agreement under equity incentive plan for grant made in through form of employee restricted stock unit issuance agreement under equity incentive plan for grant made in form of global employee restricted stock unit issuance agreement under equity incentive plan year vest for grant made in form of global employee restricted stock unit issuance agreement under equity incentive plan year vest for grant made in form of global employee restricted stock unit issuance agreement under equity incentive plan year vest for grant commencing in form of global employee restricted stock unit issuance agreement under equity incentive plan year vest for certain grant made in form of global employee restricted stock unit issuance agreement under equity incentive plan year vest for certain grant commencing in form of non employee director restricted stock unit issuance agreement under equity incentive plan for grant made in form of non employee director restricted stock unit issuance agreement under equity incentive plan for grant commencing in gilead science inc equity incentive plan amended and restated april gilead science inc employee stock purchase plan amended and restated january gilead science inc deferred compensation plan amended and restated april gilead science inc severance plan amended and restated may gilead science inc corporate annual incentive plan amended and restated january offer letter between registrant and daniel day dated november stock option agreement for daniel day under equity incentive plan performance share award agreement for daniel day for tsr goal in under equity incentive plan performance share award agreement for daniel day for revenue goal in under equity incentive plan form of restricted stock unit issuance agreement for daniel day in under equity incentive plan offer letter between registrant and johanna mercier dated may letter agreement between registrant and johanna mercier dated may global stock option agreement for johanna mercier in under equity incentive plan restricted stock unit issuance agreement for johanna mercier for performance objective in under equity incentive plan global restricted stock unit issuance agreement for johanna mercier in under equity incentive offer letter between registrant and merdad parsey dated september global stock option agreement for merdad parsey in under equity incentive plan global restricted stock unit issuance agreement for merdad parsey in under equity incentive plan form of indemnity agreement entered into between registrant and it director and executive officer form of employee proprietary information and invention agreement entered into between registrant and certain of it officer and key employee form of employee proprietary information and invention agreement entered into between registrant and certain of it officer and key employee revised september agreement dated october between registrant the institute of organic chemistry and biochemistry iocb and rega stichting rega together with the following exhibit the license agreement dated december between registrant iocb and rega the license agreement the license agreement dated october between registrant iocb and rega the october license agreement and the license agreement dated december between registrant iocb and rega the december license agreement agreement between registrant and iocb rega dated december amending the license agreement and the december license agreement amendment agreement to the license agreement between iocb rega and registrant dated august amending the october license agreement and the december license agreement amendment agreement to the license agreement between iocb rega and registrant dated july amending the october license agreement and the december license agreement license agreement by and between registrant successor to triangle pharmaceutical inc glaxo group limited the wellcome foundation limited glaxo wellcome inc and emory university dated may sale agreement by and among registrant emory university and investor trust custodial service ireland limited solely in it capacity trustee of royalty pharma dated july and restated license agreement by and between registrant emory university and investor trust custodial service ireland limited solely in it capacity trustee of royalty pharma dated july and restated evg license agreement by and between japan tobacco inc and registrant dated november agreement by and between registrant gilead science and japan tobacco inc dated november and restated collaboration agreement by and among registrant gilead science ireland uc formerly gilead science limited and janssen ireland dated december agreement by and among kite pharma inc cabaret biotech ltd and dr zelig eshhar dated december license and collaboration agreement by and between galapagos nv and registrant dated july subsidiary of consent of independent registered public accounting power of attorney included on the signature page of this report certification of chief executive officer required by rule or rule of the security exchange act of certification of chief financial officer required by rule or rule of the security exchange act of certification of chief executive officer and chief financial officer required by rule or rule and section of chapter of title of the united state code in xbrl instance document the instance document doe not appear in the interactive data file because it xbrl tag are embedded within the inline xbrl sch inline xbrl taxonomy extension schema cal inline xbrl taxonomy extension calculation linkbase def inline xbrl taxonomy extension definition linkbase lab inline xbrl taxonomy extension label linkbase pre inline xbrl taxonomy extension presentation linkbase page interactive data file formatted in inline xbrl included exhibit filed an exhibit to registrant current report on form filed on may and incorporated herein by reference filed an exhibit to registrant current report on form filed on april and incorporated herein by reference filed an exhibit to registrant current report on form filed on december and incorporated herein by reference filed an exhibit to registrant current report on form filed on march and incorporated herein by reference filed an exhibit to registrant current report on form filed on november and incorporated herein by reference filed an exhibit to registrant current report on form filed on september and incorporated herein by reference filed an exhibit to registrant current report on form filed on september and incorporated herein by reference filed an exhibit to registrant current report on form filed on september and incorporated herein by reference filed an exhibit to registrant annual report on form for the fiscal year ended december and incorporated herein by reference filed an exhibit to registrant current report on form filed on may and incorporated herein by reference filed an exhibit to registrant annual report on form for the fiscal year ended december and incorporated herein by reference filed an exhibit to registrant current report on form filed on may and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended march and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended june and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended september and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended march and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended march and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended march and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended june and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended june and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended june and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended june and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended june and incorporated herein by reference filed an exhibit to registrant current report on form filed on may and incorporated herein by reference filed an exhibit to registrant current report on form filed on december and incorporated herein by reference filed an exhibit to registrant registration statement on form no amended and incorporated herein by reference filed an exhibit to registrant annual report on form for the fiscal year ended december and incorporated herein by reference filed an exhibit to registrant annual report on form for the fiscal year ended march and incorporated herein by reference filed an exhibit to registrant annual report on form for the fiscal year ended december and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended september and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended september and incorporated herein by reference filed an exhibit to triangle pharmaceutical inc quarterly report on form filed on november and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended september and incorporated herein by reference filed an exhibit to registrant amendment no to annual report on form filed on april and incorporated herein by reference filed an exhibit to registrant annual report on form for the fiscal year ended december and incorporated herein by reference filed an exhibit to kite pharma inc registration statement on form no filed on june and incorporated herein by reference management contract or compensatory plan or arrangement filed herewith furnished herewith certain confidential portion of this exhibit were omitted by mean of marking such portion with an asterisk the mark this exhibit ha been filed separately with the secretary of the security and exchange commission without the mark pursuant to registrant application requesting confidential treatment under rule under the security exchange act of amended certain portion of this exhibit were omitted by mean of marking such portion with the mark because the identified portion are private or confidential and ii not material item form summarynone pursuant to the requirement of section or of the security exchange act of the registrant ha duly caused this report to be signed on it behalf by the undersigned thereunto duly authorized gilead science inc by daniel day daniel daychairman and chief executive officerpower of attorney know all person by these present that each person whose signature appears below constitutes and appoints daniel day and deborah telman and each of them true and lawful attorney in fact and agent with full power of substitution and resubstitution for or and in his or her name place and stead in any and all capacity to sign any and all amendment to this report and to file the same with all exhibit thereto and other document in connection therewith with the security and exchange commission granting unto said attorney in fact and agent and each of them full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith fully to all intent and purpose might or could do in person hereby ratifying and confirming that all said attorney in fact and agent or any of them or their or his substitute or substitute may lawfully do or cause to be done by virtue hereof pursuant to the requirement of the security exchange act of amended this report ha been signed below by the following person on behalf of the registrant and in the capacity and on the date indicated daniel daychairman and chief executive officerfebruary day principal executive officer andrew dickinsonchief financial officerfebruary dickinson principal financial officer diane wilfongsenior vice president and chief accounting officerfebruary wilfong principal accounting officer jacqueline bartondirectorfebruary barton ph jeffrey bluestonedirectorfebruary bluestone ph sandra horningdirectorfebruary horning kelly kramerdirectorfebruary kramer kevin loftondirectorfebruary lofton harish manwanidirectorfebruary manwani javier rodriguezdirectorfebruary rodriguez anthony weltersdirectorfebruary